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Abstract
Chemotherapeutic Drug Cytotoxicity Enhancement in Human Cells in 
Culture
Seamus Coyle
This thesis examined the effect of combinations of different drugs on toxicity to 
cancer cells in vitro. Combinations of a known anticancer agent with one of a series 
of coded non-toxic compounds known to be safe for human use were assayed. 
Significant enhancement of toxicity of adriamycin and vincristine but not 5- 
fluorouracil, was observed with three compounds from the series. Studies in a wide 
range of cellular models showed that this combination effect was not observed in cells 
overexpressing P-glycoprotein and that the mechanism involved was not inhibition of 
P-glycoprotein.
An assay was developed to analyse how synergy was affected when cells were 
exposed to the compounds at different times relative to chemotherapeutic drug pulse 
exposure. Activity of the active compounds was observed only during 24 hours 
subsequent to 2 hours drug exposure. Pre-treatment or treatment at later times was 
ineffective.
Flow cytometric analysis was used to determine the cell cycle distribution of these test 
compounds in DLKP-SQ, a human lung carcinoma clonal cell line. U-l (active in the 
combination assay) on its own was shown to induce a transient G /S  arrest. There was no 
apparent effect on the cell cycle distribution using A-l (inactive) or N-l (active). A 
combination of adriamycin and U-l caused an increased delay in the G, phase and the S 
phase compared to adriamycin alone. Vincristine in combination with U-l displayed an 
increased G2/M arrest compared to vincristine treated cells alone. DLKP-SQ treated with 
5-fluorouracil alone and in combination showed no effect on cell cycle distribution.
Time lapse videomicroscopic studies demonstrated that vincristine induced apoptosis 
within 24 hours and the rate of apoptosis increased in the combination. Cells underwent 
apoptosis 24 hours after treatment with adriamycin but surprisingly there was no 
significant difference in the rate of apoptosis between adriamycin alone and in 
combination.
To investigate if the combination effect was due to interference with proteins controlling 
cell cycle progress, the levels of cyclin E and CDK2 were determined using western 
blotting; Cyclin E/CDK2 kinase activity was also measured.
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ABC ATP binding cassette
ActD Actinomycin D
Adr Adriaraycin
AMSA Amsacrine
ATCC American Tissue Culture Collection
ATP Adenosine tri-phosphate
bp Base pair
BSA Bovine serum albumin
BSO DL-Buthionine-[S ,R]-sulfoximine
CaCl2 Calcium chloride
CAK Cdc2-activating kinase
CaP04 Calcium phosphate
CDI Cyclin dependent kinase inhibitor
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DTT DL-Dithiothreitol
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EDTA Ethylene glycol-bis(J3-aminoethylether)-N,N,N’,N’-tetraacetic acid
FCS Foetal calf serum
5-FU 5-Fluorouracil
GSH Glutathione
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PMSF Phenylmethylsulphonyl fluoride
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RNA Ribonucleic acid
rRNA Ribosomal ribonucleic acid
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SDS Sodium dodedecyl sulphate
TAP Transporter-related with antigen presentation
TBS Tris buffered saline
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Introduction
1.1 Introduction
The human body is a finely tuned organism. It has evolved defense mechanisms to the 
environmental stresses (radiation, UV light, chemicals) which it is exposed to in everyday 
life. Over 200 different types of cells act in synchrony so that the body can survive and 
function properly.
When something goes wrong in any one cell, it may die off or the altered cell may remain 
undetected by the body. In the latter case it might be allowed to survive until it evolved 
into a neoplastic cell in which some of the controls on the cell's proliferation would be 
abrogated.
The common human cancers are cancers that involve epithelial cells such as those lining 
the gastrointestinal tract (GIT), the lungs, cells in the breast and the outer surface layers of 
the body. Human skin is completely replaced every 6 weeks, 10,000 million epithelial 
cells are shed and replaced in the colon every day and 300,000 million blood and 
lymphatic cells are destroyed and replaced every 24 hours (Evans, 1993). These tissues 
comprise of and their function is dependent on, normal proliferating cells. The emergence 
of cancer is a consequence of the failure to control cell proliferation.
1.3 million new cases of cancer occur each year in Europe and there are 840,000 deaths. 
There are 7500 deaths in Ireland which is higher than the European per capita average.
At present the only way of treating cancer is by surgery, radiotherapy or chemotherapy or 
a combination of any of these.
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1.2 Chemotherapy
The idea of using drugs to treat cancer has been in existence for over 500 years when 
preparations of silver, zinc and mercury were used. The usefulness of drugs in the 
treatment of cancer was first documented in 1865 when Lissamer gave potassium arsenite 
to a patient with leukaemia and noticed a positive effect. However, successful systemic 
cancer chemotherapy was not developed until 1942 when Gilman, Goodman, Lindskog 
and Dougherty used nitrogen mustard in a patient with lymphosarcoma (Pratt et al., 
1994). Subsequently a number of chemotherapeutic drugs have been developed for clinical 
use. These drugs are members of a number of specific drug classes, including the 
anthracycline antibiotics, the Vinca alkaloids, epipodophyllotoxins, antimetabolites, 
covalent inhibitors of DNA and non-covalent inhibitors of DNA.
Chemotherapy is most useful against tumours with a high proportion of dividing cells. 
However, some normal tissues e.g. bone marrow and GIT, also have a high proportion of 
dividing cells. The clinical effectiveness of a chemotherapeutic drug necessitates that doses 
administered must allow enough cells in a patients normal tissues (bone marrow, GIT etc) 
to survive and allow the patient to recover, while killing malignant tumour cells in vivo .
Tumours with a high growth fraction rate e.g. leukaemia and lymphoma, can generally be 
effectively treated by chemotherapy. The more common malignant tumours, the solid 
tumours including colorectal, lung and breast tumours usually have a low proportion of 
dividing cells and are consequently less susceptible to treatment by chemotherapy alone.
1.2.1 Anthracyclines
The anthracyclines are antibiotics isolated from different Streptomvces species and include 
adriamycin (also called doxorubicin), daunorubicin and epirubicin. Adriamycin which has 
the most common clinical usage, is used for a variety of carcinomas including breast,
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bladder, endometrium, lung, ovaries, stomach and thyroid; bone and soft tissue sarcomas; 
paediatric solid tumours; lymphoid and myelogenous tumours.
It was first isolated in Italian soil samples from Streptomvces peucetium var caesius. It is 
generally administered by intravenous infusion at a dose of 60mg/m2, repeated after 21 
days. Clearance of the drug from the body follows a 2 phase pharmokinetic profile. The 
first Vi life (a tlA) lasts approximately 10 minutes. The second Vi life (ft tl/i) lasts 
approximately 30 hours. The longer B tVz represents the slow release of adriamycin from 
tissue depots in the body because of the ability of adriamycin to intercalate with DNA and 
perhaps elsewhere in cellular vesicles and membranes.
The metabolism of adriamycin is outlined in Figure 1.2.1. The major metabolic step is the 
reduction of adriamycin to doxorubicinol by cytoplasmic NADPH-dependent aldoketo 
reductases. Doxorubicinol, which is still an active cytotoxic agent, and doxorubicin are 
split into less active aglycones and the free amino sugar by microsomal glycosides. These 
aglycones are demethylated and conjugated to a sulphate or glucuronide ester, and 
excreted principally in the bile (Pratt et al., 1994).
As with all chemotherapeutic drugs, doxorubicin has serious side effects. A carcinogen 
and a mutagen, it also causes immunosuppression. The main limiting characteristic of 
adriamycin is that it can cause a cardiotoxic reaction. This cardiotoxicity is also a feature 
of other anthracycline drugs.
The primary mechanism of action of adriamycin is due to its ability to bind to DNA and 
RNA. Intercalation by the aglycone moiety between adjacent DNA base pairs in the 
double helix, results in the inhibition of replication, transcription, RNA and protein 
synthesis, stabilisation of topoisomerase II-DNA complex, which causes protein-associated 
DNA strand breaks, and free radical mediated cytotoxicity. Adriamycin and other 
anthracyclines are also metal chelators with high stability constants for transition metal 
ions such as iron. Ferric-adriamycin complexes have been shown to degrade deoxyribose 
and cleave DNA (DeGraff et a l, 1994) . The cytotoxicity induced by adriamycin can 
occur in the absence of significant DNA damage. When adriamycin is chemically altered
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so that its ability to bind to DNA and RNA is decreased, there is a corresponding decrease 
in cytotoxicity (Pratt et al., 1994). At high concentrations of adriamycin, synthesis of 
DNA and RNA is inhibited although this is not critical for cytotoxicity (Pratt et al., 
1994).
Active oxygen species induced by adriamycin can cause single strand DNA breaks, lipid 
peroxidation and disruption of cell membrane function and integrity (Skladanowski and 
Konopa, 1993) although the overall effect on cytotoxicity is thought to be minor. 
However, the active oxygen species play a major role in the ability of adriamycin to 
induce cardiotoxicity (Pratt et al., 1994).
Adriamycin has been shown to be active throughout the cell cycle, however the effect is 
greatest in exponential cells compared to plateau phase cells. Cells which have been 
synchronised in the S or the G2 phase are more sensitive to cytotoxicity than cells in Gi 
(Krishan and Frei, 1976). Low concentrations of adriamycin induce G2 arrest, higher 
concentrations or exposure to drug for longer periods of time induce a Gt arrest and a 
delay in S phase traverse (Barlogie et al., 1976).
1.2.2 Vinca Alkaloids
The Vinca alkaloids are extracted from the periwinkle plant Catharanthus rosea. The 
periwinkle plants have been used in folk medicine for centuries and a claim that extracts 
could cause hypoglycaemia led to the discovery of vincristine and vinblastine. The 
relatively low toxicity of vincristine for normal marrow cells makes it unusual compared 
to other chemotherapeutic agents. For this reason it is often included in combination 
chemotherapy with other myelosuppressive agents. It is used to treat acute leukaemia 
(adult and children), Hodgkin's lymphoma, aggressive non-Hodgkin's lymphoma, small 
cell lung cancer, Wilm's tumour, neuroblastoma, rhabdomyosarcoma and Ewing's 
sarcoma (Pratt et al., 1994).
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Given as a bolus intravenous injection, vincristine leaves the body's circulation by 
triexponential kinetics, having a  and B Vi lives of 2-5 minutes and 50-150 minutes 
respectively, the terminal lh  life lasts approximately 85 hours. It is primarily eliminated by 
a combination of hepatic metabolism and biliary excretion. Approximately 5-25 % of the 
parent drug and metabolites can be recovered in urine. Although there is relatively little 
toxicity to normal marrow cells, the dose-limiting toxicity of vincristine is predominantly 
peripheral neuropathy.
Vincristine is an antimitotic agent and acts by disrupting the mitotic spindle and as a 
consequence arrests cells in the mitotic phase. It binds to free tubulin dimers to form 
paracrystalline aggregates; this interrupts microtubule polymerisation and causes the 
dissolution of the microtubules (Pratt et a l, 1994). Some studies have shown that 
inhibition of cell proliferation by vincristine appears to be due to spindle microtubule 
perturbation rather than depolymerisation of the microtubules (Jordan et al., 1991; Jordan 
et al., 1992). Several other cellular processes unrelated to microtubule perturbation which 
are affected by the vinca alkaloids include RNA, DNA and lipid biosynthesis, cyclic 
nucleotide and glutathione metabolism and calmodulin-dependent ATPase activity (Jordan 
etal., 1991).
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Figure 1.2.1 The major metabolic pathway for doxorubicin in humans (Pratt et al., 
1994).
Deoxy doxoru bici n 
aglycone (II)
reductase
aldo-keto reductase, a soluble enzyme 
(carbonyl réduction)
o ,° — k CHjO O OM / H,C\j
V-rc
D o x o r u b ic in o l  (III)
OH
NH.
Deoxydoxorubicinol 
aglycone (IV)
(o-demethylatlon)
h o o OH
Demelhyldeoxydoxorubicmol 
aglycone (V) (glucutonidation)
Sulfate conjugate (VI) Glucoronide conjugate (VII)
12
1.2.3 Epipodophyllotoxms
These include etopside (VP-16) and tenopside (VM-26) which are semisynthetic 
derivatives of podophyllotoxin, a microtubule inhibitor found in extracts of the mandrake 
plant. Active against a number of cancers, VP-16 is used clinically in testicular and small­
cell lung cancer.
VP-16 can be administered orally or intravenously. Metabolism follows a biphasic kinetics 
with a terminal Vi-life of 4-8 hours. Approximately 30-50% of the drug can be recovered 
in urine and approximately 20% has been recovered as metabolites including hydroxy 
acids and glucuronide and sulphate conjugates. A portion of the administered drug (20- 
30%) is frequently unaccounted for, possibly due to tight binding to tissue proteins (Pratt 
etal., 1994).
Limitations in the use of VP-16 derive from its myelosuppressive actions, primarily 
leucopenia, other effects include nausea, diarrhoea mucositis and hypotension.
Initially VP-16 was thought to inhibit microtubule function but was subsequently shown to 
inhibit topoisomerase II. Topoisomerase II decatenates DNA. It binds to double stranded 
DNA making a transient double strand break. The enzyme is activated by sites on 
chromosomes where two double helices cross over each other. When the topoisomerase 
binds to such a crossing site, it; 1) breaks one double helix reversibly to create a DNA 
"gate"; 2) causes the second, nearby double helix to pass through this break; 3) reseals the 
break and dissociates from the DNA. In this way topoisomerase II efficiently separates 
two interlocked DNA circles (Alberts et al., 1994).
A schematic of drug induced topoisomerase II inhibition is given in Figure 1.2.3. 
Topoisomerase II-mediated cytotoxicity is achieved by drug stabilisation of the complex 
formed between cleaved DNA and the covalently bound enzyme (Liu, 1989). 
Stabilisation of the complex interferes with the cleavage / religation action of 
topoisomerase II resulting in double strand breaks.
13
1.2.4 Antipyrimidines
Antipyrimidines were developed during attempts to synthesise analogs that could inhibit 
uracil utilization by tumours. The rationale used was to substitute fluorine for the hydroxyl 
atom in the 5 position in the pyrimidine ring of uracil, since fluorine added to acetic acid 
(fluoroacetic acid) is a rat poison. From this, 5-fluorouracil was developed and this was 
the first antipyrimidine. 5-Fluorouracil is direct inhibitor of thymidylate synthase which is 
the key enzyme in thymidine nucleotide production. Because steady-state pools of 
thymidine nucleotides are small, DNA synthesis is inhibited until the drug is withdrawn 
and new thymidylate synthase can be made (Pratt et al., 1994). 5-Fluorouracil can also 
incorporate into RNA and DNA, inhibiting transcription, translation and the intracellular 
distribution of mRNA (Pratt et al., 1994). It is commonly used to treat common solid 
tumours including colorectal, breast, head and neck, gastric and pancreatic cancers. Other 
antipyrimidines have been developed including cytosine arabinoside, which is widely used 
in antileukaemic therapy.
Topoisomerase II
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Figure 1.2.3: DNA damage induced by inhibition of topoisomerase n. Temporary double-strand breaks are 
induced by topoisomerase II in the course of its normal catalytic cycle, by formation of a cleavable complex. 
Disruption of this complex, which results in a permanent double-strand break, occurs infrequently in the 
absence of drugs. Inhibitors of topoisomerase II cause the cleavable complex to persist, thereby increasing the 
probability that the cleavable complex will be converted to an irreversible double strand break (Pratt et al. , 
1994).
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1.3 The Cell Cycle
One o f the general findings of chemotherapy is that chemotherapeutic drugs work best on 
proliferating cells even if  the mode of action of the drug is not cell cycle specific. A lot of 
attention has now focused on the role of the cell cycle.
The cell cycle is the process that a cell must undergo in order to replicate. It is composed 
of four different phases; G! (Gap 1) which is a growth phase; the S phase, during which 
DNA is replicated; G2 (Gap 2) where the cell pauses as it prepares to divide; mitosis (M) 
(see Figure 1.3.1).
Figure 1.3.1
The four phases of the cell cycle are controlled by the actions of specific serine/threonine 
kinases, the cdc-2 related proteins. The cdc-2 related proteins all need to bind a protein 
called a cyclin in order to become active, thus they are called cyclin-dependent-kinases 
(CDKs). A t present there are 8 CDKs and more than 10 cyclins known.
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During various stages of the cell cycle different cyclins bind to different CDKs e.g., cyclin 
A  binds to CDK2 during the S phase and to CDK1 during G?. The cyclins can be broadly 
classed as being G^S cyclins or G2/M  cyclins (see Table 1.3.1).
Table 1.3.1
G./S cvclins Go/M cvclins
Cyclin A Cyclin A
Cyclin C Cyclin B1
Cyclin D (1-3) Cyclin B2
Cyclin E Cyclin H
A t present 8 different kinases have been identified that bind a cyclin. Several other 
structurally related proteins are known, and some o f these may be re-classified as CDKs if  
they are shown to bind a cyclin (Table 1.3.2).
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Cydin dependent kinases and related proteins (Pines, 1993)
Table 1.3.2
Name Identity to cdc2 
kinase domain (%)
Cydin bound
cdc2 (CDK1)
CDK2
CDK3
CDK4
CDK5
CDK6
100
65
66 
44
57
47
Cydin B (1-2) 
Cydin A, D(l-3), E 
?
Cydin D (1-3) 
Cydin D (1-3) 
Cydin D (1-3)
PICTAIRE (1-3) 
PIT AIRE 
p58GTA
p40Mo15 / CDK7
51-55
42
42
40 Cydin H
1.3.1 phase
After mitosis, most cells in the body enter a quiescent state called G0. Entry into the cell 
cycle can be stimulated by growth factors which regulate cell proliferation through a 
complex network of intracellular signalling cascades which ulitimately regulate gene 
transcription and the assembly and activation o f the cell cycle control system. As yet no 
direct evidence between the signalling pathways and the cell cycle proteins have been 
shown.
At a point called the restriction (R) during Gx, the cells become independent of serum and 
commit to initiating DNA replication (Pardee, 1989). The CDK complexes that have 
been most closely linked to regulating the R point are those regulated by the D-type 
cyclins. In different cell types the 3 D-type cyclins are differentially expressed (Lew et
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al., 1991; Matsushime et al., 1991). The D-type cyclins can bind to a number of CDKs 
(CDK2, CDK4, CDK5 and CDK6) although they appear to predominantly act with CDK4 
and CDK6. Although cyclin D and CDK4 levels are almost constant in cycling cells the 
cyclin D/CDK4 complex forms as the cells reach the R point and dissociate once the cells 
enter the S phase. Transcription of these cyclins is GF dependent e.g. CDK4 synthesis can 
be regulated by TGF-fl (Ewen et al., 1993), and because both D cyclins mRNAs and 
proteins turn over rapidly their levels quickly decrease when growth factors are withdrawn 
(Matsushime et al., 1991). This has led to the concept that the D-type cyclins act primarily 
as growth factor sensors integrating external cellular signals with cell cycle progression 
(Sherr, 1993).
Only two substrates are known for the cyclin D/CDK4 complexes:
(i) Retinoblastoma tumour suppressor protein Rb
(ii) Components of the E2F family of transcription factors
Rb is a tumour suppressor gene which acts as a cell brake. Rb is underphosphorylated 
throughout Gx and phosphorylated at the G^S transition. Once phosphorylated, Rb leaves 
the nucleus, thus removing its suppressing activity. As the cell progresses through the cell 
cycle Rb is phosphorylated (at multiple sites) by different CDK complexes, until the M/Gj 
transition, where it becomes dephosphorylated and returns to the nucleus (Weinberg, 
1995). The hypophosphorylated form of Rb is able to block cells in G! phase and it binds 
and potentially sequesters large numbers of proteins including the transcription factor E2F 
(Chellappan et al., 1991).
The D type cyclin/CDK complexes may phosphorylate and inactivate Rb in mid-G! phase 
and it has been suggested that cyclin-Dl and Rb form a negative feedback loop in late Gx 
phase because cells that lack Rb also have less cyclin D1 (Sherr, 1993). Thus 
hypophosphorylated Rb may stimulate Cyclin D1 transcription and subsequently cyclin D1 
- CDK4/6 would inactivate Rb allowing cells to progress into S phase and concomitantly 
down-regulate cyclin D1 synthesis (Weinberg, 1995).
18
During Gb E2F is bound to Rb. At the restriction point, Rb phosphorylation by the 
cyclin/CDK complexes, causes a conformational change, which releases E2F and allows it 
to bind to DNA and activate transcription (Ludlow et al., 1990). E2F transcription factors 
are thought to regulate the early response genes such as c-myc and B-myb, and the 
synthesis o f cell cycle dependent proteins required for S phase e.g. DNA polymerase a, 
thymidine kinase, ribonucleotide reductase and dihydrofolate reductase. E2F is a 
heterodimer composed of an E2F family member and a DP family member. There are at 
present 5 E2F proteins and 3 DP proteins are known but the most detailed analysis have 
been performed with E2F-1 and DP-1 (LaThangue, 1994; Muller, 1995).
1.3.2 S phase
Once cells pass the R point they must pass into S phase. The transition from Gx into S is 
controlled by the cyclin E/CDK2 complex and this is essential for the cell to begin DNA 
replication. Cyclin E mRNA and protein levels and the activity o f the cyclin E/CDK2 
complex all peak at the Gj/S transition, sharply decreasing as the cells progress through 
the mid and late S phase (Dulic et al., 1992). Thus the cyclin E/CDK2 complex has a 
role in the initiation of DNA replication (Knoblich et al., 1994). When cyclin E is 
overexpressed in cells, the cells progress through Gt and into the S phase at a faster rate . 
These cells also have a diminished requirement for growth factors, indicating that cyclin E 
may overlap with the D-type cyclins in integrating growth factor signal transduction into 
the cell cycle (Ohtsubo and Roberts, 1993). The activation of the cyclin E/CDK 2 
complex also appears to be the point at which radiation damage in the Gt phase can delay 
the cell cycle (Dulic et al., 1994).
Cyclin E/CDK2 associates with E2F and pl07 (Lees et al., 1992). Cyclin E and pl07 
bind to the E2F sub-unit E2F-4, while E2F-1, -2 or -3 may associate with Rb, DP-1 is 
common to both complexes (Lees et al., 1992). Very little is known about the substrates 
of cyclin E but it is thought to be a potential regulator o f Rb (Sherr, 1993) and to activate 
E2F and thus transcription of S phase genes.
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Once cells enter the S phase cyclin E is rapidly degraded. It is replaced by cyclin A which 
also forms a complex with CDK2 and this is required for continued DNA replication. 
E2F-4/DP-1 and pl07, which bind to cyclin E at the G^S transition, then form a complex 
with cyclin A/CDK2 (Lees et al., 1992). Cyclin A/CDK2 is also thought to 
phosphorylate E2F-1 and therefore inhibit E2F-1/DP-1 DNA-binding activity (Krek et 
al., 1994; Xu et al., 1994). Thus cyclin A/CDK2 might inactivate E2F and turn o ff Gj/S 
phase genes (Krek et al., 1994). The exact role of cyclin A/cdk2 in continued DNA 
replication is not known.
1.3 .3 . G2/M  phase
The most widely studied CDK is the p34cdc2 kinase. p34cdc2's regulation has been 
extensively studied and is important because it controls the G2/M  transition. This has 
immediate applications to chemotherapy since DNA-damaging chemotherapeutic drugs 
often cause a cell cycle arrest in G2 (Sorenson and Eastman, 1988; Tsao et al., 1992; 
Demarcq et al., 1994). p34cdc2 kinase is active during the G2 and M phase and binds the 
mitotic cyclins i.e. cyclin A, cyclin B1 or cyclin B2. Once activated p34cllc2 kinase 
catalyses the breakdown o f the nuclear envelope, the organisation of the mitotic spindle 
and the packaging of the chromatin (DNA) for mitosis. Because the actions of this kinase 
are so potent (i.e. dissociation of the nucleus) its regulation is tightly controlled (see 
Figure 1.3.2).
Activation of p34cdc2 is rapid and produces an all or nothing effect. Once cyclin B and 
cdc2 combine the complex is immediately phosphorylated on Thr-161, stabilising the 
complex. Phosphorylation on a homologous site appears to be required for activation of all 
CDKs. The kinase that phosphorylates this site is the cdc2-activating kinase (CAK). CAK 
is itself a CDK and is a complex between cyclin H and CDK7 and as such also needs to be 
phosphorylated at a similar site to become active (Fisher and Morgan, 1994). 
Phosphorylation at two sites overlapping the ATP-binding site (Tyr-15 and Thr-14), keeps
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p34cdca in a catalytically inactive state (Solomon et al., 1990; Krek and Nigg, 1991). One 
o f these inhibitory kinases is weel which phosphorylates Tyr-15 (Parker and Piwnica- 
Worms, 1992) and can itself be inactivated by another protein kinase nim l and can also be 
phosphorylated. Other unknown kinases also act on p34cde2 (Parker et al., 1993).
Since tyrosine phosphorylation plays an important role in restraining p34c4<a activity, the 
regulation of tyrosine déphosphorylation becomes a crucial step in p34cdc2 activation. 
Cdc25C is a tyrosine phosphatase which specifically removes the inhibitory tyrosine 
phosphate on p34cdcZ that is generated by weel. Cdc25C itself appears to be regulated by 
several complex pathways.
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Figure 1.3.2: Regulation of p34cdc2 activity during the cell cycle. Cyclin B association 
with p34cdc2 occurs during interphase, possibly regulated by Thr 161 phosphorylation of 
p34cdc2. Sufficient cyclin B can be accumulated early in the cell cycle for subsequent 
protein kinase activation. Phosphorylation of Thr 14 and Tyr 15 in the ATP-binding site 
of p34cdc2 prevents protein kinase activation for the remainder of interphase. 
Dephosphorylation o f Thr 14 and Tyrl5 by cdc25C brings about protein kinase activation, 
but this cannot usually occur unless DNA replication is completed (Norbury and Nurse,
1992).
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1.3.4 Cyclin Dependent Kinase Inhibitors
Cyclin dependent kinases inhibiters (CDIs) can bind and inhibit the function of CDKs and 
are an extra control mechanism by which CDKs can be regulated. Most CDIs inhibit the 
progression of the cell cycle, some respond to extracellular signals while others are 
involved in intrinsic steps of the cycle. CDIs (in vitro) act by binding to the cyclin, the 
kinase or to the cyclin-CDK complex and inhibiting the function of cyclin-CDK 
complexes while not covalently modifying either the cyclin or the CDK (Peter and 
Herskowitz, 1994).
A t present there are six mammalian CDIs identified, p l4 , p l5 , p l6, p21, p27 and p28. 
These CDIs can be roughly divided into two groups, one group which have a broad 
affinity for different cyclins (p21 and p27) and the other which have a more specific 
mechanism of action (p i5 and p i6) (see Table 1.3.4).
p21 and p27 can both bind to cyclins A, B, D (l-3) and E. p27 is produced in response to 
TGF-B and inhibits cyclin E/CDK2 kinase activity (Polyak et al., 1994). p21 is a protein 
whose gene expression can be induced by p53 (Dulic et al., 1994). p53 is necessary for a 
G, check-point control which senses DNA damage (fibroblasts lacking p53 do not respond 
to DNA damage induced by radiation). This w ill then lead to a transient arrest in G! since 
p21 inhibits the CDK complexes (Dulic et al., 1994). It is also possible that p21 inhibits 
proliferating cell nuclear antigen (PCNA; a small protein which binds to DNA polymerase 
8 during DNA replication) (Fotedar et al., 1996). Recent work has shown that p21 can 
(in vitro) inhibit DNA replication directly. This means that p21 has a dual role in response 
to DNA damage, by inhibiting CDK complexes it prevents transition from Gj to S and 
may also directly block DNA replication by inhibiting PCNA (Chen et al., 1995; Fotedar 
etal., 1996).
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Cell Cycle Phase Cvclin-CDK complex Inhibitors
p l5 p !6 p l8  p21
p27
Table 1.3.4 Mai or Cvclin-CDK Cell Cycle Complexes
Gi Cyclin D - CDK4/6 +  +  4- +
+
Gj/S Cyclin E - CDK2 +
+
S Cyclin A  - CDK2 +
G2/M  Cyclin B - cdc2 -I-
1.4 Chemotherapy and the Cell Cycle
1.4.1 G 2 arrest
The most common effect of DNA-damaging drugs is the accumulation of cells in the G2 
phase. These drugs include cisplatin (Sorenson and Eastman, 1988; Demarcq et al.,
1994), campothecin (Tsao et al., 1992), VP-16 (Wood et a l, 1995), adriamycin 
(Barlogie et al., 1976), bleomycin, X-rays and nitrosurea compounds (Rao, 1980). 
Active DNA synthesis is required before a cell w ill arrest in G2 (Tsao et al., 1992).
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Arrest in G2 is thought to allow time for the repair of DNA damage (Liicke-Huhle, 
1982). This idea is supported by the increased radiosensitivity of yeast mutants which are 
unable to arrest in G2 (Liicke-Huhle, 1982).
It is proposed that there are two distinct check-point mechanisms in mammalian G2 
(Downes et al., 1994); one sensitive to DNA damage and another which is sensitive to the 
catenation state of DNA (this includes the decatenatory activity of topoisomerase II) 
(Downes et al., 1994; Ishida et al., 1994). Downes et al showed that ICRF-193 (an 
epipodophyllotoxin analogue which selectively binds topoisomerase II but does not induce 
DNA strand breaks) blocks entry but not exit from mitosis. Compounds which are able to 
circumvent this G2 arrest e.g. caffeine, result in malformed condensed chromosomes 
(Downes et al., 1994). This also highlights the important role topoisomerase II has in 
mitosis.
1.4.2 G2 and p34cdc2
DNA damaging chemotherapeutic drugs often cause a cell cycle arrest in G2. Research 
investigating the role of the cell cycle and chemotherapeutic drugs has consistently shown 
that the activity of p34cdc2 kinase is inhibited (Lock and Ross, 1990; Lock and Ross, 
1990; Steinmann et al., 1991; Lock, 1992; Lock and Keeling, 1993; O'Connor et al., 
1993; Demarcq et al., 1994). Since activation of p34cdc2 kinase results in the transition of 
cells from G2 into mitosis inactivation o f this kinase induces a G2 arrest.
Studies using chemotherapeutic drugs and radiation have shown that they can exert their 
effect in different ways on p34cdc2 kinase activity. CA46 (human lymphoma) cells treated 
with nitrogen mustard, showed that the cyclin A/cdk2 complex remained active while the 
activity o f cyclin B/cdc2 and cyclin A/cdc2 decreased (O'Connor et al., 1993). Cyclin B 
accumulation was altered in HeLa cells treated with campothecin (Tsao et al., 1992). 
Studies using ionising radiation on HeLa cells which induced G2 arrest showed a decrease 
in cyclin B levels while cyclin A levels increased. In control cells the levels of cyclin A
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and cyclin B both increased (Muschel et a l, 1991; Muschel et al., 1993). This suggests 
that cells proceed through the S phase but are inhibited in G2.
Brief exposure of both CHO and HeLa cells to VP-16 inhibits mitotic progress. Cell cycle 
arrest in G2 showed a concomitant increase in cyclin B levels and accumulation of 
hyperphosphorylated p34cdc2. Inactivation o f p34cdc2 was due to the inhibition of 
déphosphorylation of a tyrosine residue (Lock and Ross, 1990; Lock and Ross, 1990) and 
a threonine residue, both in the active site (Lock, 1992).
p34cdc2 kinase is regulated by the complex interaction of a number of protein kinases and 
phosphatases. Since tyrosine phosphorylation plays an important role in restraining p34cdc2 
activity, the regulation of tyrosine dephosphorylation becomes a crucial step in p34cdc2 
activation. Cdc25C is a tyrosine phosphatase which specifically removes the inhibitory 
tyrosine phosphate on p34cdc2 that is generated by weel. When phosphorylated cdc25C 
becomes active and dephosphorylates p34cdc2 at the active site, thus activating it.
G2 arrested HeLa cells treated with campothecin have unaltered levels o f cdc25C (Tsao et 
al., 1992). No activation of cdc25C was found in nitrogen mustard treated G2 arrested 
CA46 cells (O'Connor et al., 1994). This suggests that the G2 check-points preventing 
entry into mitosis in the presence of unreplicated or damaged DNA, suppress the initiation 
of the cdc2-cdc25C autocatalytic feedback loop, which normally brings about the rapid 
activation of cdc2. Therefore p34cdc2 inhibition is a result of the inactivation of some 
unknown factor early in its control.
In drug resistant cells drug-induced G2 arrest depends on the amount of chemotherapeutic 
drugs getting into the cell. In a CHO/VpmR-5 drug resistant cell line, VP-16 
concentrations differing by a factor of 10 were needed to induce the equivalent inhibition 
of p34cdc2 kinase in the sensitive CHO parent. This is equivalent to the degree of 
resistance displayed by the VpmR-5 cell line (Lock and Ross, 1990). Thus for VP-16 
treated cells, damage caused to the cells' DNA appears a prerequisite for the cellular
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process resulting in the inhibition of p34cdc2 kinase activity and G2 arrest i.e. it is the 
DNA damage caused by chemotherapeutic drugs which causes inhibition of p34cdc2.
Despite the ability of chemotherapeutic agents to induce an arrest in G2, there are some 
compounds which have the ability to overcome this arrest. These include okadaic acid 
(which is a type 2A phosphatase inhibitor) (Symthe and Newport, 1992), 2-aminopurine 
(Bunch et al., 1994), 6-dimethyl-aminopurine (two protein kinase inhibitors) and the 
methylxanthines (MEX). The MEXs (which include caffeine and pentoxifylline) enhance 
the in vitro cytotoxicity of X-irradiation (Hain et al., 1994), UV light and alkylating 
agents (Byfield et al., 1981; Das et al., 1982).
Exposure to caffeine after a brief VP-16 exposure is known to release G2 arrest and 
increase mitotic death (Lock et al., 1994). Premature chromosome condensation, a 
feature of some G2 arrested cell lines when exposed to caffeine, needs cyclin B and 
p34cdc2 to be intact (Steinmann et al., 1991; Lock et al., 1994). Activation of p34cdc2 
kinase activity is a common response to caffeine exposure (Symthe and Newport, 1992; 
Hain et al., 1993; O'Connor et al., 1993; Bunch et al., 1994; Lock et al., 1994). 
Pentoxifylline reverts the activity of cyclin A/cdc2 and cyclin B/cdc2 kinases to control 
levels in CA46 cells treated with nitrogen mustard (O'Connor et al., 1993). However, 
Bunch et al (1994) demonstrated that dephosphorylation of p34cdc2 kinase is not enough 
to induce mitosis in all systems .
Not all cell lines showed enhanced cytotoxicity when exposed to caffeine. Caffeine did not 
circumvent cell cycle blocks induced by replication inhibitors or UV radiation in SVM 
Indian muntjac DM87 cells. Similarly, G2 arrest induced by T-irradiation or VP-16 in 
HeLa was caffeine insensitive (Musk et al., 1988; Downes et al., 1994).
MEXs are also reported to reduce the cytotoxicity of DNA damaging anti-topoisomerase 
drugs (including doxorubicin, mitoxantrone, VP-16 and ellipticine). Intercalation between 
the drug and the MEX can lead to a decrease in the effective drug concentration available
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(Traganos et al., 1991) (Traganos et al., 1993) while inhibition of RNA synthesis may 
also be a possible mechanism (Perez et al., 1994).
1.5 Apoptosis
Even though the mechanism of action of chemotherapeutic agents is known to the extent 
that some cellular targets have been identified, it is unknown how or why they are more 
toxic to cancer cells than normal cells. How these drugs cause a cell to die is at present a 
major focus of research worldwide.
Apoptosis is a mechanism of cell death whereby a cell actively dismantles itself. It is 
characterised by a detachment of the apoptotic cell from surrounding cells, a decrease in 
cell volume, membrane blebbing, condensation of the nucleus and endonucleolytic 
cleavage of DNA into nucleosomal-length fragments. Finally the cell content is packaged 
into numerous apoptotic bodies which can be phagocytosed by surrounding cells.
Under normal physiological conditions, the stimuli which induce apoptosis are diverse and 
vary from normal physiological signals, such as hormones that trigger selection of cells 
during differentiation, to the removal of cells that have sustained some form of damage. 
Cells can also be primed to undergo apoptosis by the removal of either some intracellular 
apoptosis inhibitory factor or the withdrawal o f important extracellular components such as 
serum or growth factors. Non-physiological conditions which induce apoptosis include 
radiation, hyperthermia, calcium influx, glucocorticoids and cytotoxic agents.
The regular and controlled nature of apoptosis implies that the process is under genetic 
control. Research into the nematode Caenorhabditis elegans has provided a detailed 
cascade of the genetic factors involved. Three genes (ced3, ced4, and ced9) are involved 
in the death o f the cell and two groups of genes (cedi, ced6, ced7 &  ced8 and ced2, ced5
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& cedlO) appear to be involved in parallel pathways implicated in the phagocytosis of 
apoptotic bodies. Another gene, nucl, which encodes for a nuclease, is involved in 
degrading the DNA of the apoptotic cell. Mutations in this gene still results in apoptosis 
but there is no degradation of DNA (Hall and Lane, 1994).
1.5.1 Bcl-2
The ced-9 gene is essential for development and protects cells from apoptosis. It exhibits 
partial homology to the mammalian proto-oncogene product bcl-2 (Hengartner and 
Horwitz, 1994) and expression of bcl-2 in C.eleeans blocks apoptosis (Vaux et al.,
1992).
The bcl-2 gene was first identified at the t(14:18) translocation in human follicular 
lymphoma and was subsequently shown to be expressed in all haematopoietic cell types 
having a renewing stem cell population (Korsmeyer, 1992). The gene is also expressed in 
other cell types that have an extended life span (Allsopp et al., 1993; Merry et al., 1994). 
The bcl-2 gene encodes a 26 kDa intracellular membrane associated protein which is 
localised to mitochondria, endoplasmic reticulum and nuclear membranes (Chen-Levy 
and Cleary, 1990; Nguyen et al., 1993).
Mice lacking bcl-2 complete embryonic development and appear normal during the first 
week after birth. Consequently, the mice begin to show growth retardation, and have 
small external ears and immature facial features. The mice die young. These mice show 
apoptosis in the embryonic kidney and hypoplastic renal development, which progresses to 
severe polycystic kidney disease. There is apoptotic involution of the thymus and spleen 
and an almost complete loss of lymphocytes (Veis etal., 1993).
Apart from its role in protecting against physiologic cell death, deregulation of bcl-2 in 
non-Hodgkin's lymphoma cells rendered the cells resistant to a range of drugs (including
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dexamethasone, methotrexate and VP-16) commonly used to treat the disease (Miyashita 
and Reed, 1993). However, the gene is not protective in all situations i.e. Fas/FasL. 
Monoclonal antibodies raised against the Fas (APO-1) cell curface protein have cell killing 
activity, reviewed in (Nagata and Suda, 1995). Therefore there is a bcl-2 independent 
mechanism of apoptosis. Protection by bcl-2 against the potentially lethal effects of 
exogenous and endogenous factors (including radiation, various peptides, heat, and other 
gene products) provides a basis for categorising bcl-2-dependent and bcl-2 independent 
pathways to cell death (Reed, 1994).
Bcl-2 is the original member of an increasing multigene family. Members of the family 
are in two functional categories, those that inhibit and those that promote apoptosis. The 
inhibitors of apoptosis include bcl-2 (Vaux et al., 1992), Bcl-xL (Boise et al., 1993), 
Mcl-1 (Kozopas et al., 1993), Adenovirus E1B 19K Epstein-Barr virus BHRF1 and Ced- 
9 (Hengartner and Horwitz, 1994). The promotors include Bax (Oltvai et al., 1993), Bak 
(Chittenden et al., 1995; Chittenden et al., 1995; Farrow et al., 1995), Nbk/Bikl (Boyd 
e ta l., 1995), Bad (Yang et al., 1995) and Bcl-xs (Boise et al., 1993) (see Table 1.5.1).
Bcl-2 family members interact with each other forming both homo and heterodimers. Bax 
counters bcl-2 activity, accelerating apoptotic cell death but only after a death-inducing 
signal. When bcl-2 is excess, bcl-2 homodimers and heterodimers predominate and cells 
are protected from apoptosis. When bax is in excess, bax homodimers predominate and 
cells are susceptible to apoptosis (Oltvai et al., 1993; Oltvai and Korsmeyer, 1994). A 
number of biological systems indicate that, during development, cells vary in their 
inherent sensitivity or resistance to a given death stimulus. The ratio of bcl-2:bax 
represents one cell-autonomous rheostat that predetermines a cell's life or death response 
to an apoptotic stimulus.
Other interactions between Bcl-2 family members include Bcl-2 and Bak (Chittenden et 
al., 1995; Chittenden et al., 1995), Bcl-xs (Boise et al., 1993) or Bad (Yang et al., 
1995); Bcl-xLand Bcl-xs (Boise et al., 1993); E1B 19K and Bak (Farrow et al., 1995),
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Bax or Nbk/Bikl (Han and White, 1995); Bcl-xL and Bak (Farrow et al., 1995) (see 
Table 1.5.2).
Three conserved regions within Bcl-2-related proteins have been identified, bcl-1 
homology 1 (BH1), homology 2 (BH2) (Yin et al., 1994) and homology 3 (BH3) 
(Chittenden et al., 1995; Chittenden et al., 1995). These conserved motifs control protein- 
protein interactions. Selected mutations within BH1 or BH2 of bcl-2 disrupt its 
heterodimerisation with bax, but not its homodimerisation, and destroy the ability o f bcl-2 
to counter apoptosis (Yin et al., 1994), demonstrating that bcl-2 must heterodimerise with 
bax to function.
The difference between Bcl-xL and Bcl-xs is that Bcl-xL contains the BH1 and BH2 
domains, which w ill inhibit apoptosis, while the short version, bcl-xs, lacks those motifs 
and favours death (Boise et al., 1993).
The ability of the bcl-2 family proteins to dimerise is not restricted to proteins within the 
family. Bcl-2 can dimerise with R-ras which accelerates apoptosis (Wang et al., 1995), 
while Bag-1 enhances the ability of bcl-2 to block apoptosis (Takayama et al., 1995) (see 
Table 1.5.3).
Another protein implicated in resistance to apoptosis is the bcr-abl oncoprotein. In chronic 
myelocytic leukeamia (CML) cells, translocation of the c-abl gene from chromosome 7 to 
chromosome 22 leads to the formation of a bcr-abl fusion protein. This results in the up- 
regulation of abl tyrosine kinase activity. Transfection of v-abl in HL-60 resulted in the 
acquisition of resistance to spontaneous and induced apoptosis (McGahon et al., 1994). 
CML cells isolated from newly diagnosed, untreated patients showed increased resistance 
to spontaneous or drug-induced apoptosis comared to normal granuolcytes. The CML cell 
line, K562, is more resistant to apoptosis compared to cell lines derived from other types 
o f leukaemias. Antisense strategies, which reduce the levels of fusion protein in K562 cells 
restored sensitivity to apoptosis (McGahon et al., 1994).
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Table 1.5.1
Apoptotic protectors Apoptotic inducers
Bax 
Bak
Nbk/Bikl 
Bcl-xs
Bad
Bcl-2 family members
Table 1.5.2
Bcl-2 family interactions
Bcl-2 +  Bax 
Bcl-2 +  Bak 
Bcl-2 +  Bcl-xs 
Bcl-2 +  Bad
Bcl-xL -I- Bcl-xs
E1B 19K +  Bak 
E1B 19K +  Bax 
E1B 19K +  Nbk/Bikl
Bcl-xL + Bak
Bcl-2
Bcl-xL
Mcl-1
E1B 19K
BHRF1
Ced-9
bcr-abl
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Proteins which interact w ith Bcl-2 fam ily members
Apoptotic protectors Apoptotic inducers
Bcl-2 + Bag-1 Bcl-2 4- R-ras
Table 1.5.3
1.5.2 ICE / Apoptotic proteases
The ced-3 protein may act as a cysteine protease which may have an important role in the 
execution pathway of apoptosis in both C.elegans and mammalian cells, ced-3 has close 
homology with the human interleukin-1 B-converting enzyme (ICE). ICE is a cysteine 
protease with a novel specificity for aspartic acid. ICE is comprised of two sub-units (p20 
and plO) both of which can be autocatalytically derived from an inactive 45 kDa 
proenzyme (Thornberry et al., 1992). Transient overproduction of ICE or CED-3 w ill 
cause Rat-1 fibroblast cells to die. This effect o f ICE can be countered by bcl-2 (Miura et 
al., 1993).
There is another protease with specificity for aspartic acid, a serine protease called 
Granzyme B, also known as fragmentin 2. Granzyme B is stored within the cytolytic 
granules o f cytotoxic T cells (CTL), and it is transferred upon CTL attack to recognised 
target cells (Heusel et al., 1994).
Other ICE-like genes have been identified; NEDD-l/ICH-1 demonstrates only 29% 
identity and 52% similarity with ICE but the sequence QACRG, which contains the active
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cysteine residue required for the proteolytic activity of ICE, is conserved. Overproduction 
of this protein w ill induce cell death that can be blocked by bcl-2 (Kumar et al., 1994; 
Wang et al., 1994). However, Wang et al (1994) also noted a truncated version of ICH-1 
generated by alternative RNA splicing. This truncated version (ICH-1S) begins to diverge 
immediately following the QACRG active site and terminates shortly downstream. When 
overproduced, ICH-1S countered the death-inducing effect of the fu ll length ICH-1L 
protein. This system provides another example of positive/negative regulation of apoptosis 
encoded within the same gene or gene family.
Transcription factors such as myc, fos, jun and p53 are intimately associated with cellular 
proliferation and are also important in apoptosis. The transcription factor c-rel w ill induce 
apoptosis in bone marrow cells when expressed at high levels (Abbadie et al., 1993). c- 
fos is expressed immediately prior to apoptosis in many cells in vivo (Smeyne et al., 
1993). Deregulated c-myc expression is a potent inducer of apoptosis. Overexpression of 
c-myc during cell cycle arrest, e.g. following deprivation of growth factors or forcible 
arrest with cytostatic drugs induces apoptosis (Evan et al., 1994). Expression of the c- 
myc gene is rapidly induced upon addition of serum to quiescent cells, and its expression 
is followed by mitosis. However, overexpression of c-myc in quiescent rat-1 fibroblasts 
maintained without serum leads to apoptosis (Evan et al., 1992). This is most likely due 
to regulation of gene transcription by the myc-max heterodimer (Evan et al., 1992). 
Thus, the induction of c-myc in cells grown in the presence of appropriate growth factors 
or co-expression of other 'survival genes' such as bcl-2, causes cell proliferation. In the 
absence of these factors, c-myc expression causes cell death.
The complexity o f pathways which induce apoptosis and the variety of unique proteins in 
the ICE and bcl-2 families argues for the existence of different pathways each using one or 
more family members to regulate induction of apoptosis within a given tissue or for a 
particular differentiation program (Martin et al., 1995).
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1.6 Apoptosis and Chemotherapy
Research into apoptosis from a cancer research perspective has focused on three main 
areas; oncogenesis i.e. the ability to acquire genes (e.g. bcl-2) which prevent apoptosis 
and therefore prolong the life of a cell; tumour homeostasis i.e. the growth of a tumour is 
now thought to be a balance between the rate of apoptosis and mitosis within the tumour 
mass (Staunton and Gaffney, 1995); and the mechanism of action of cytotoxic drugs.
The exact mechanisms by which chemotherapeutic agents are cytotoxic are unclear. 
Several chemotherapeutic agents commonly used in the treatment of both solid and 
haematologic malignancies have been shown to be able to induce apoptosis in a number of 
cell lines in vitro. These include cisplatin (Demarcq et a l, 1994), adriamycin (Ling et 
al., 1993; Skladanowski and Konopa, 1993; Smith et al., 1994), DNA alkylating agents 
(O'Connor et al., 1991; Gorczyca et al., 1993; O'Connor et al., 1993), macromolecular 
synthesis inhibitors (Gorczyca et al., 1993) and other topoisomerase I and II inhibitors 
(Solary et al., 1994; Dubrez et al., 1995). The kinetics of cell death by each of these 
agents varies depending upon the cells under study.
As discussed previously, chemotherapeutic drugs cause DNA damage, this damage 
disrupts the cell cycle, induces cell cycle perturbations and initiates cell death. Arrest of 
the cell cycle in Gi or G2 in response to DNA damage is the result of activation of p53. 
p53 mediated arrest leads to either the repair of the damaged DNA and cell recovery or 
the induction of apoptosis. In p53 negative cells, apoptosis can still occur by a p53- 
independent mechanism (Lowe et al., 1993). p53 has also been shown to have a direct 
effect on apoptosis by downregulating bcl-2 expression and upregulating bax expression 
(Miyashita et al., 1994).
p53 induction in response to DNA damage activates the expression of a number of genes 
p21WAF1/cn>1, GADD45, mdm2, bax and cyclin G, the function of which has yet to be 
determined (Enoch and Norbury, 1995; Miyashita and Reed, 1995).
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Induction of the p21 protein w ill lead to a transient arrest in and G2 since p21 inhibits 
the CDK complexes (Section 1.3.4). As an inhibitor of the CDKs, p21 contributes to Gj 
arrest by preventing the phosphorylation of Rb. Hypophosphorylated Rb binds to and 
inactivates the E2F family of transcription factors which control the expression of proteins 
important for entry into S-phase.
p53 acts as a specific transactivator of the GADD45 gene (Kastan et al., 1992; Zhan et 
al., 1994) though other types of DNA damage induce GADD45 by p53-independent 
mechanisms (Kastan et al., 1992; Zhan et al., 1993). Overexpression of GADD45 
inhibits colony formation in clonogenic assays (Zhan et a l, 1994), suggesting a role in 
cellular proliferation and/or cell survival. The mechanism of action of GADD45 is 
unknown although there is a physical association between gadd45 protein and PCNA ( 
(Smith et al., 1994). It is thought that gadd45 participates in the DNA repair process and 
that overexpression of gadd45 inhibits DNA synthesis (Smith et al., 1994).
The mdm2 oncoprotein is also transcriptionally activated by p53 following DNA damage 
(Perry et al., 1993; Chen et al., 1994; Price and Park, 1994) . mdm2 is a 54kDa nuclear 
phosphoprotein which forms complexes with both wild-type and mutant p53. This 
interaction inhibits wild-type p53-directed transcription of target genes (Oliner et al., 
1993; Chen et al., 1994). It has been suggested that the mdm2 may serve as an element of 
a feedback loop with p53 (Chen et al., 1994; Price and Park, 1994). p53 induces the 
expression of mdm2, which in turn binds to and inactivates p53. mdm2 may be involved 
in cellular recovery from the cell cycle arrest caused by p53 induction, allowing the cells 
to resume cycling after the DNA damage has been repaired (Kastan et al., 1995).
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1.7 Cell Cycle and Apoptosis
The role of cell cycle proteins in apoptosis is unclear. It has been proposed that apoptosis 
may be a result of aberrant cell cycle control, i.e. apoptosis may be a consequence of 
conflicting growth regulatory signals which lead to an unsuccessful attempt at traversing 
the cell cycle (Freeman et al., 1994; Kastan et al., 1995).
Apoptosis has a number of features i.e. cell rounding, nuclear envelope breakdown and 
chromatin condensation, which are also characteristic of mitosis. This has led researchers 
to investigate the role of cyclin B/cdk2 and cyclin B/cdc2 during apoptosis.
In YAC lymphoma cells, cyclin B/cdc2 was found to be essential during serine protease 
induced apoptosis (Shi et al., 1994). Overexpression of Weel has been found to inhibit 
this effect (Chen et al., 1995). Cyclin B/cdc2 kinase activity was also found to be 
elevated in HL-60 cells treated with camptothecin or etopside (Shimizu et al., 1995). In 
A 1.1 hybridoma cells induced to undergo apoptosis when the T receptor is cross-linked 
with anti-CD3 antibodies, apoptosis was blocked with cyclin antisense oligonucleotides 
(Fotedar et al., 1995). However, no cdc2 kinase activity was found during apoptosis in 
FT-210 cells (Martin et al., 1995), an embryonic fibroblast cell line during chromatin 
condensation (Oberhammer et al., 1994), thymocytes, which die during G0 (Norbury et 
al., 1994) and neurons (Freeman et al., 1994).
The role of cyclin A  is less clear. Rat fibroblasts undergoing apoptosis increase cyclin A 
mRNA levels while cyclins B, C, D1 and E remain unaffected, and deregulated 
expression of cyclin-A was found to be sufficient to induce apoptosis in cells exposed to 
low serum (Hoang et al., 1994). HeLa cells arrested in S phase have increased cyclin A  
kinase activity when induced to undergo S phase apoptosis by caffeine, okadaic acid, 
staurosporine, di-methylaminepurine or TNF-a (Meikrnatz et al., 1994). HIV-1 Tat 
protein induced apoptosis in CD4 T-lymphocytes has elevated levels of CDK2 and cdc2 
activity which can be inhibited by antisense oligonucleotides to cyclin A, B and E (Li et 
al., 1995). However, there has been no increase in cyclin A levels in HL-60 cells (Dou et
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al., 1995; Shimizu et al., 1995) and neurons (Freeman et al., 1994) undergoing 
apoptosis. HL-60 cells exposed to cytosine arabinoside increase cyclin E kinase activity 
(Dou etal., 1995).
Thus although CDK2/cdc2 activity is induced during apoptosis in some systems there is no 
evidence that it is necessary. Other studies have shown the involvement o f other cell cycle 
proteins. Cyclin D1 expression is selectively induced in post-mitotic neurons undergoing 
programmed cell death (Freeman et al., 1994; Kranenburg et al., 1996). Overexpression 
of p58 PITSLRE, a CDK-related kinase, was found to initiate apoptosis and the kinase 
activity of p58 was elevated during Fas induced apoptosis in human T cells (Lahti et al., 
1995).
Fotedar et al (1995) suggest that there are at least 2 apoptotic pathways in T cell death; 
one which is dependent on activation through surface receptors (e.g. anti-CD3) leading to 
cyclin B-dependent cell death during G2/M  and a second (e.g. dexamethasone-induced 
pathway) which is independent of cell activation and cyclin B.
While there is a single apoptotic pathway and a single effector molecule in Caenorhabditis 
elegans. this is not the case in higher eukaryotic cells. The variety of unique proteins in the 
ICE and bcl-2 families argues for the existence o f different pathways each using one or 
more family members to regulate induction of apoptosis. Cdc2, as a member of a larger 
family of CDK effectors, participates in some of these apoptotic pathways, although it is 
unknown whether all pathways would necessarily involve a CDK effector (Martin et al., 
1995).
1.8 Necrosis
Necrosis is a passive mode of cell death, characterised by an increase in cell volume which 
ultimately leads to cell lysis. Necrosis is not genetically influenced, does not appear to
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require expression of new mRNAs or proteins and would seem to be uncontrollable in 
terms of drug intervention (Dive and Hickman, 1991).
It is thought that necrosis is initiated by cellular damage that disrupts osmotic balance. 
Ions, especially Ca++, enter the cell passively and the cell swells with H20  because of 
ion influx. Increasing Ca++ can also inhibit some enzymatic pathways e.g. ATP 
production and stimulate others e.g. proteolysis. An early fall in ATP precedes a fatal 
disruption of the ionic gradients within the cell. The cell ruptures to spill out degradative 
lysosomal enzymes which mediate an inflammatory reaction in the immediate locality.
The choice to between dying actively by apoptosis or passively by necrosis, appears to 
depend on the severity o f the injury inflicted on the cell. Higher doses of cytotoxic drugs 
tend to cause necrosis rather than apoptosis, although this effect was not evident with VP- 
16 (Marks and Fox, 1991).
HL-60 cells exposed to melphalan or chlorambucil, showed that the mode of cell death 
depended on the levels of intracellular reduced glutathione (GSH). Reducing the levels of 
GSH induced necrosis at concentrations that would normally induce apoptosis. The 
monocytic cell line, U937 and the chronic myelogenous leukaemia line, K562, have been 
found to be more resistant to melphalan or chlorambucil and were found to contain higher 
levels of GSH as compared to the HL-60 line (Fernandes and Cotter, 1994). This 
suggests that intracellular levels of GSH might preset the injury-levels the cell can sustain 
before it becomes too damaged to undergo apoptosis and dies by necrosis.
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1.9 Multidrug Resistance
Successful systemic cancer chemotherapy was not developed until 1942 when Gilman, 
Goodman, Lindskog and Dougherty used nitrogen mustard in a patient with 
lymphosarcoma. However, the clinical course of this first patient treated is reflected in the 
use o f anticancer drugs today. He was administered nitrogen mustard for 10 days. Within 
that time there was a noticeable regression of the tumour. However, about 3V2 weeks after 
initiation of therapy the total white blood cell count decreased down to 200 cells/cubic 
millimeter. Subsequently, the bone marrow gradually recovered, but so did the tumour. A 
second, shorter course of treatment produced a transient improvement, and a third course 
had virtually no effect. Thus, the therapy-limiting effect of marrow toxicity and the 
development of drug resistance, both of which are still problems in cancer chemotherapy, 
were observed in the first patient.
Approximately 50% of patients with cancer can be cured by surgery and radiation therapy 
since their tumours have not spread. Of the remaining 50%, 10% are curable with 
systemic chemotherapy, including children with leukaemia and sarcomas and adults with 
testicular cancer and choriocarcinoma. However, the majority of metastatic cancers are not 
currently curable by chemotherapy or by any other kind of therapy. These cancers fall into 
two categories; cancers which are intrinsically resistant to chemotherapy (i.e. there is no 
significant response to chemotherapy); and those cancers which respond initially to 
chemotherapy but then acquire resistance during the course of therapy.
When a population resistant to an administered drug develops, this new population may 
also be resistant to a number of other chemotherapy drugs, even if  they are structurally 
dissimilar and have different modes of action. This is called Multidrug Resistance (MDR).
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1.9.1 P-glycoprotein
Currently the best understood mechanism of MDR is the resistance mediated by the 
MDR1 gene product, P-glycoprotein (P-170). P-glycoprotein is a 170 kDa glycoprotein, 
1280 amino acids in length and consists of 12 transmembrane domains and two nucleotide 
binding sites (see figure 1.9.1). It acts as an energy-dependent transmembrane efflux 
pump that actively transports chemotherapeutic agents out of the cell. Several structurally 
and functionally unrelated agents, including anthracyclines (doxorubicin, daunorubicin), 
vinca alkaloids (vincristine, vinblastine), epipodophyllotoxins (VP-16, VM-26), taxanes 
(paclitaxel, docetaxel), and actinomycin D are substrates for P-glycoprotein.
There are two human MDR genes, MDR1 and MDR3 (Roninson et al., 1986; Van der 
Bliek et al., 1986). However only fu ll cDNA from the MDR1 gene can confer the MDR 
phenotype (Gros et al., 1986; Ueda et al., 1987). Although P-glycoprotein is believed to 
be a pump that actively effluxes drugs from resistant cells (Dano, 1973; Safa et al., 
1987), the actual mechanism for this activity is not understood.
P-glycoprotein is a member of the ATP binding cassette (ABC) superfamily of transport 
systems which includes over 30 proteins that share extensive sequence similarity and 
domain organisation (Hyde et al., 1990). There are marked similarities in sequence and 
apparent structure between P-glycoprotein and a number of prokaryotic transport proteins 
(Chen et al., 1986; Higgins, 1989); including HLYB, the ATP-binding haemolysin export 
protein in Escherichia coli (Felmelee et al., 1985; Blight and Holland, 1990); pfMDR, 
the MDR gene in Malaria parasites Plasmodium falciparum (Foote et al., 1989); CFTR, 
the product of the cystic fibrosis (Riordan et al., 1989; Hyde et a l, 1990).
P-glycoprotein expression has been detected in a number of normal tissues; liver, adrenal 
gland, pancreas, kidney colon and jejunum (Fojo et al., 1987). Localisation within these 
tissues appears to be extremely specific; apical surface of epithelial cells in liver, kidney, 
colon, and jejunum; biliary canalicular front of hepatocytes; on small biliary and 
pancreatic ductules; on the adrenal cortex (Thiebaut et a l, 1987; Sugawara et al., 1988)
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human placenta (Sugawara et al., 1988) and is expressed in specialised endothelial cells in 
the brain and testis (Cordon-Cardo et al., 1990).
The localisation o f P-glycoprotein to specialised cells in human tissues indicates that it 
might be involved in transepithelial secretion of toxic substances or unknown cellular 
metabolites into the bile or the lumen of the GI tract. The fact that the MDR1 gene can be 
co-induced with the P450A1 gene probably supports this (Burt and Thorgeirsson, 1988).
Expression o f the MDR1 gene is in general, high in those tumours which derive from 
tissues that naturally express high levels of P-glycoprotein i.e. tumours derived from the 
colon, kidney, liver and pancreas. In poorly differentiated tumours of the kidney and 
colon the levels may often be lower because of the altered differentiation state of these 
tumours . Expression o f the MDR1 gene is sometimes high in leukaemias, lymphomas 
and some other tissues that do not normally express the MDR1 gene. Several tumour types 
have low levels o f the MDR1 gene and are known to be drug sensitive. These include 
Wilm 's tumour and cancer of the ovary and breast (see Table 1.9.1). However a number 
of tumours exhibit low levels of MDR1 expression but are resistant to chemotherapy, for 
example adenocarcinoma of the lung and non small cell lung cancer (Pastan and 
Gottesman, 1991).
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Table 1.9.1
MDR expression in untreated Human Cancers
High Sometimes High Low
Colon Acute Leukaemias SCLC
Kidney Lymphomas NSCLC
Liver NSCLC-NE Gastric
Adrenal CML Oesophageal
Pancreas Neuroblastoma Ovary
Wilm's
Head and Neck
Myeloma
Breast
Table 1.9.2
Cancers in which MDR1 expression has been found to increase after chemotherapy
Acute Leukaemias
Breast
Lymphomas
Multiple Myeloma
Neuroblastoma
Ovary
Pheochromocytoma
Rhabdomyosarcoma
Sarcomas
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1.9.2 Multidrug Resistance Related Protein
Despite the widespread occurence of drug resistance in human lung tumours, 
overexpression of P-glycoprotein is infrequent. This implies that alternative mechanisms 
of resistance exist (Cole et al., 1992).
Overexpression of the Multidrug Resistance Related Protein (MRP) is sufficient to 
confer multidrug resistance (Cole et al., 1992). MRP is a 1531-amino acid, 190-kDa 
glycoprotein, that is overexpressed in a number of non-P-glycoprotein MDR cell lines 
(Krishnamachary and Center, 1993; Zaman et al., 1993). MRP has been detected in a 
number of normal human tissues, including lung, stomach, colon, peripheral blood 
macrophages, thyroid, testis, nerve, bladder, adrenal, ovary, pancreas, gall-bladder, 
duodenum, heart, muscle, placenta, brain, kidney, liver and spleen (Cole et al., 1992; 
Zaman etal., 1993).
MRP has minor sequence homology to P-glycoprotein but it is most related to the 
ABC-transporter encoded by the pgpA gene of Leishmania tarentolae. This protein is 
involved in low level oxyanion (arsenite) resistance, rather than resistance to hydrophobic 
drugs (Zamanetal., 1993).
MRP functions as an ATP dependent export pump for endogenous as well as 
exogenous glutathione, glucuronidated and sulfated conjugates (Jedlitschky et al., 1996).
MRP-transfected cell lines demonstrated a 5-15 fold more resistant profile to 
adriamycin, daunorubicin, epirubicin, vincristine and VP-16, <3 fold resistance to taxol, 
vinblastine and colchicine and no cross resistance was observed to 9-alkyl anthracyclines, 
mitoxantrone or cisplatin. There was also cross resistance to some heavy metal anions 
including arsenite, arsenate, and trivalent and pentavalent antimonials but not to cadmium 
chloride. Thus, the MDR phenotype conferred by MRP is similar but not identical to that 
conferred by P-glycoprotein (Cole et al., 1994).
MRP is predominantly located in the endoplasmic reticulum of resistant cells but 
lower levels are also contained in the plasma membrane (Krishnamachary and Center,
1993).
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Because the cellular accumulation of chemotherapeutic drugs appears unchanged in 
MRP overexpressing cell lines it is thought that MRP may participate directly in the active 
transport of drugs into subcellular organelles or influence drug distribution indirectly 
(Cole et al., 1992; Krishnamachary and Center, 1993)
Immunohistochemical examination of 61 human cell lines demonstrated that some 
of the most sensitive cell lines had a relatively high expression of MRP suggesting that 
resistance may not be a simple function of the level of MRP (Izquierdo et al., 1996).
1.9.3 Transporter-related with Antigen Presentation
Another member o f the ABC-transporter superfamily which has been found to be 
overexpressed in a number of MDR cell lines of different histogenic origin is the 
Transporter-related with Antigen Presentation (TAP) (Izquierdo, 1996). TAP is a 
heterodimer formed by the TAPI and TAP2 gene products and a plays a role in MHC 
class I restricted antigen presentation by mediating peptide translocation over the 
endoplasmic reticulum membrane (Neefjes et al., 1993).
Transfection o f the TAP genes into mutant lymphoblastoid cells lacking TAP 
genes, showed a 2-3 fold increase in resistance to VP-16, vincristine and adriamycin. 
High concentrations o f VP-16 or vincristine were able to inhibit the TAP-mediated 
transport of a model peptide into the endoplasmic reticulum (Izquierdo, 1996).
1.9.4 Lung Resistance-related Protein
Lung resistance-related protein (LRP) was first identified as a 110 kDa vesicular protein 
overexpressed in a non-P-glycoprotein MDR lung cell line (Scheper et al., 1993). LRP 
expression was seen in bronchus, digestive tract, renal proximal tubules, keratinocytes, 
macrophages, and the adrenal cortex, varying levels were observed in other organs. 
Expression of LRP in normal tissues parallels that of other drug-resistance related proteins
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such as P-glycoprotein and MRP (Izquierdo et al., 1996). The LRP gene was found to be 
located on chromosome 16pll.2, 27 cM, proximal to the MRP gene (16pl3.1) 
(Izquierdo, 1996). When it was cloned and sequenced it was found to be the major 
component of vaults (Scheffer etal., 1995).
Vaults were first identified by negative staining and transmission EM in 1986, as 
contaminant particles o f clathrin-coated vesicle preparations derived from rat liver 
(Kedersha and Rome, 1986). Vaults were subsequently isolated from various species 
including a lower eukaryote Dictvostelium discoideum. amphibians, avians, and mammals 
and are highly conserved among different species supporting the notion that their function 
is essential to eukaryotic cells (Kedersha et al., 1990).
As found with LRP in normal human tissues, the expression of vaults in other 
species is most abundant in epithelial cells (i.e. rat intestine) and macrophages (rat alveolar 
macrophages) (Kedersha et al., 1990). In rats, vaults are ribonucleoprotein particles 
composed of a major vault protein of 104kDa (accounting for >70% of the mass and is 
equivalent to LRP), three minor proteins of 210, 192 and 54kDa and a small RNA 
molecule. These are assembled in a barrel-like structure o f approx. 57 x 32 nm with a 
molecular mass of about 13MDa, which is 3 times the size of a ribosome. The vault 
particle has 2-fold symmetry, and each half can be opened into a flower-like structure 
which contains eight petals surrounding a central ring (Kedersha et al., 1991). These 
dynamic structural variations are likely to play a role in vault function. Most vaults are 
present in the cytoplasm and most cells contain thousands of vaults although there precise 
function is unknown (Chugani et al., 1993).
Vaults structure and localisation support a transport function for this particle which 
could involve a variety o f substances. It is thought that vaults may play a role in drug 
resistance by regulating the nucleocytoplasmic transport of drugs.
Low levels o f LRP positivity were seen in testicular cancer, neuroblastoma and 
acute myeloid leukaemia, intermediate levels in ovarian cancer and high levels in colon, 
renal and pancreatic carcinomas (Izquierdo et al., 1996). MRP and LRP were found to be 
widely expressed in a panel o f 61 human cancer cell lines as opposed to the low frequency 
of expression of P-glycoprotein. LRP was also found to be a superior marker of in vitro 
drug resistance compared to P-glycoprotein and MRP (Izquierdo et al., 1996). Positivity
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of LRP in primary ovarian cancer was significantly associated with a worse response to 
chemotherapy, a shorter progression-free interval and shorter overall survival (Izquierdo 
etal., 1995).
1.10 Alternative Mechanisms o f Resistance
The above mechanisms do not account for all the types of resistance observed.
1.10.1 Topoisomerase II
Alterations in topoisomerase II can lead to resistance to anthracyclines and the 
epipodophyllotoxins (De Isabella et al., 1990) but not to the vinca alkaloids. 
Changes in topoisomerase-II can occur via a number o f mechanisms;
i) Quantitative changes
A  number of cell lines selected for resistance to VP-16 have decreased topoisomerase-II 
content (Ferguson et al., 1988; Liu et al., 1989; Heenan, 1994). A decrease in cellular 
content of topoisomerase-II in many instances contributes to MDR. This results in a 
decreased number of drug-induced topoisomerase-II DNA strands breaks and thus confers 
resistance to topoisomerase-II drugs. The decrease in topoisomerase-II content can be 
caused by gene inactivation e.g. gene rearrangement and/or hypermethylation (Tan et a l, 
1989), leading diminished transcription, or possibly post-translational events (Deffie et 
al., 1992).
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Hi Decreased drug-induced DNA cleavage
In a CHO cell line selected for resistance to VM-26, the cellular amounts and catalytic 
activity of topoisomerase-II were equal in resistant and wild-type cells. The 
topoisomerase-II cleaved DNA normally but was insensitive to drug inhibition of 
religation (Glisson et al., 1986; Sullivan et al., 1989). Subsequendy the normal allele of 
topoisomerase-II was found to be lost and a point mutation was found (Chan et al.,
1993). Further mutations in the gene which confer decreased cleavage and religation 
activity due to alterations in ATP binding has been described (Danks et al., 1989).
iii) Differential expression of topoisomerase-II isoforms
In various resistant cell lines there can be alterations in isoform expression compared to 
the parent cell line. For example, an m-AMSA-resistant P388 cell line, in which the 
content of the pl70 topoisomerase-II isoform was reduced, whereas there was no 
difference in expression of the p i80 isoform (Drake et al., 1987).
iv) Altered subcellular distribution of topoisomerase-II
In a VM-26-resistant CCRF-CEM cell line less topoisomerase-II was detected in the 
nuclear matrix, whereas the amount o f total nuclear topoisomerase-II was equal in resistant 
and sensitive cells. The catalytic activity of topoisomerase-II in nuclear matrix preparations 
were reduced 6-7 fold in the resistant cell lines. It is thought that a mutation in the enzyme 
may impair its incorporation into the nuclear matrix (Fernandes et al., 1990).
v l Changes in extrinsic factors modulating topoisomerase-II activity
Cytosolic proteins may modulate the activity of topoisomerase-II. A  VP-16-resistant 
human melanoma cell line, where drug uptake was unchanged and the catalytic activity 
and drug-induced DNA strand breaks mediated by isolated topoisomerase-II were similar
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from resistant and sensitive cells had decreased drug-induced cleavage in whole cells 
although it was unchanged in isolated nuclei (Campain et al., 1993).
The formation of an m-AMSA-induced topoisomerase-II-DNA complex in isolated nuclei 
was reduced compared to whole cells from the murine mastocytoma cell line K21 (Darkin 
and Ralph, 1989). When protein from cytoplasmic extracts was added, complex formation 
was increased to the same level as in whole cells. This protein was tentatively identified as 
a type of casein kinase (Darkin-Rattray and Ralph, 1991). Thus, the resistance of 
quiescent cells to topoisomerase-II-active drugs may be explained by decreased activation 
of topoisomerase-II.
v il Phosphorylation of Topoisomerase-II
Stimulation o f topoisomerase-II activity has been shown by phosphorylation in vivo 
(Ackerman et al., 1988). Casein kinase II (Ackerman et al., 1985), protein kinase C 
(Rottmann et al., 1987) and a cAMP-independent protein kinase (Sander et al., 1984) 
have been shown to phosphorylate topoisomerase-II in vitro. Changes in phosphorylation 
o f topoisomerase-II caused by mutations in protein kinases or phosphorylation sites on 
topoisomerase-II could result in drug resistance. Although this has yet to be proven, it has 
been shown that phosphorylation of topoisomerase-II decreases its sensitivity to drug- 
induced DNA cleavage, while increasing the overall catalytic activity (DeVore et al., 
1992).
1.10.2 Glutathione S-transferases
Many active chemotherapeutic agents are electrophiles and are subject to conjugation with 
molecules such as glutathione and glucuronic acid to facilitate transport, metabolism and 
ultimately excretion. In almost all animal models of carcinogenesis there is overexpression
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of conjugation enzymes, amongst which the glutathione S-transferases (GSTs) have been 
most extensively studied. Many human cancers show overexpression of GSTs, although a 
significant proportion of liver and breast carcinomas may show no expression at all, 
despite being resistant to drugs metabolised by these enzymes (Harrison, 1995).
GSTs are a family of multifunctional enzymes which play an important role in the 
detoxification of cytotoxic compounds and mediate the conjugation of cytotoxic drugs and 
carcinogens with reduced glutathione. GSTs are a widely distributed family of enzymes, 
expressed in most normal tissues. In general, the enzymes are rather low in catalytic 
activity but present in high abundance, accounting for approximately 6% of liver cytosolic 
protein. Overexpression of GSTs (GST-71 is the most commonly elevated isoenzyme) is 
commonly associated with increased P-glycoprotein expression in leukaemias (Gekeler et 
al., 1992) leading to the hypothesis that GSTs may serve the drug efflux pump with its 
substrate, thereby increasing the efficiency of drug exclusion from the cell. However, 
clear evidence for a direct metabolic role of GSTs in tumour cell resistance is still lacking.
1.10.3 BcI-2 / p53
Alterations in levels of proteins involved in the apoptotic pathway may prevent drug- 
induced cell death. The tumour suppressor gene p53 acts as a sensor in cells detecting 
DNA strand breakage and preventing a cell from proliferating whilst bearing damaged or 
mutated DNA (Kastan et al., 1991). In some systems p53 causes cell cycle arrest at the 
Gr S interface, but in other situations p53 commits a cell to die by apoptosis (Clarke et 
al., 1993). Thus, in mouse thymocytes, absence of p53 confers resistance to the 
topoisomerase II inhibitor VP-16, even though this drug can k ill lymphoid cells in and out 
of the cell cycle (Dive and Wyllie, ).
Overexpression of bcl-2 oncogene in lymphoma cell lines (Miyashita and Reed, 1993), 
murine FL5.12 (Walton et al., 1993) and neuroblastoma cells (Dole et al., 1994) confers 
drug resistance and is of proven clinical significance.
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Increased levels of bcl-2 and decreased levels of bax may elevate drug resistance and 
thereby cause a broad spectrum of drug resistance (R. NicAmhlaoibh, personal 
communication).
Elevations o f the bcl-2 : bax ratio do not prevent drug-induced apoptosis but rather shifts 
the dose response curve so that an increased concentration of drug is required to achieve 
an equivalent tumour cell kill.
Overexpression of bcl-xs in MCF-7 cells induces sensitisation to apoptosis induced by low 
concentrations of VP-16 and Taxol (Sumantran et al., 1995). Overexpression of bcl-xL 
inhibited both cisplatin and cyclophosphamide induced cell death in the shep-1 cell line 
(Dole et al., 1995) and decreased the cytotoxicity of bleomycin, cisplatin, VP-16 and 
vincristine in FL5.12 murine cells. Overexpression of bcl-xL did not prevent cells from 
undergoing cell cycle arrest in response to these drugs rather it prevented the treated cells 
from undergoing apoptosis (Minn et al., 1995).
1.10.4 Metallothioneins
Metallothioneins (MT) are intracellular proteins of low molecular weight (6-7 kDa) that 
are characterised by a high content o f cysteine and the ability to bind heavy metals. Most 
tissues have a basel level of MT although their physiological function is not well 
understood. MT have been demonstrated in a variety of malignancies including colorectal, 
testicular germ cell, ovarian and lung tumours. The synthesis of MT by tumour cells has 
been proposed as a possible mechanism for the intracellular inactivation of metal- 
containing chemotherapeutic agents such as cisplatin. Cells transfected with MT were 
found to be resistant to cisplatin, chlorobucil, melphalan and doxorubicin. Cells of various 
origins selected for cisplatin resistance often, but not always show an increased MT
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expression. In human NSCLC a significant relationship was found between MT expression 
and doxorubicin resistance in vitro (Mattern and Volm, 1995).
1.10.5 DNA repair mechanisms
The DNA repair protein, 06-alkylguanine DNA alkyltransferase is a major contributor to 
the resistance to nitrosurea, triazine class of alkylating agents (Gerson and Wilson 1995). 
DNA repair is a vast subject, directly involving up to 200 different genes (Harrison,
1995) reviewed in Friedburg (Friedberg, 1985). In general, two fundamental reactions 
are involved in cellular responses to DNA damage; (i) repair of the damage and (ii) 
tolerance of the damage. Different DNA repair mechanisms are shown in Table 1.10.1.
Table 1.10.1
Mechanisms o f drug repair, modulations of which may be important in altering tumour 
sensitivity to drugs
Mechanism Function Drugs affected
Mismatch repair 
Excision repair 
Recombination 
Other
Removal of mismatched bases 
Removal of drug/DNA adducts 
Double-strand break repair 
Dealkylation and deamination
cisp latin
Alkylating agents 
Bleomycin, irradiation 
Nitrosoureas
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The reality of MDR is not as simple as just explained and may involve more than one 
mechanism coexpressed in the same cell. Resistant cells in situ are usually not more than 5 
to 10 fold resistant compared to in vitro models whereby resistance may increase 100- or 
1000-fold (Simon and Schindler, 1994).
1.11 M DR circumvention:
The best understood mechanism of MDR is the resistance mediated by P-glycoprotein. 
Should this protein be inhibited then there is a restoration of cytotoxic drug accumulation 
in MDR cells. This is the present rational for the circumvention of MDR and two 
approaches are being taken; pharmacological intervention and genetic antisense 
technology.
1.11.1 Pharmacological circumvention
A number o f compounds have been identified which inhibit the efflux of chemotherapeutic 
drugs by P-glycoprotein and reverse cellular resistance in eperimental systems. These 
chemosensitisers may block cytotoxic drug efflux by acting as competive or noncompetive 
inhibitors, perhaps by binding to similar drug substrate binding sites, or to other 
chemosensitiser binding sites that cause allosteric changes resulting in inhibition of 
cytotoxic drug binding (Ford, 1995). The majority of chemosensitisers described to date 
may be grouped into six broad categories, based on their primary pharmacologic activity; 
calcium channel blockers; calmodulin antagonists; steroids and hormonal analogues; 
cyclosporines; dipyridamole; miscellaneous other compounds (see Table 1.11.1).
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Table 1.11.1 Selected pharmacologic agents with ability to reverse multidrug resistance (Ford, 1995)
Calcium channel blockers 
Verapamil 
Nifedipine 
Niguldipine 
Bepridil 
PAK-200 
Roll-2933
Calmodulin Antagonists 
Trifluoperazine 
Prochlorperazine 
Fluphenazine 
Tram'-Flupenthixol
Vinca Alkaloid Analogs 
Vindoline 
Thaliblasdne
Steroidal Agents
Progesterone 
Tamoxifen 
Toremifene 
Megestrol acetate 
17ß-Estradiol glucuronide
Immunosuppressive Drugs 
Cyclosporin A 
SDZ PSC 833 
SDZ 280-446 
FK506 
Rapamycin
Antibiotics
Cefoperazone
Ceftriaxone
Erythromycin
Miscellaneous Compounds 
Dipyridamol 
BIBW22 
Quinidine 
Chloroquine 
Terfenadine 
Reserpine 
Amiodarone 
Methodone 
S 9788 
GF 120918 
Tolyphorphin
A number of these compounds demonstrate circumvention ability in vitro but are too toxic 
for use in vivo. Verapamil, cyclosporin A  and quinine have been used in early clinical 
trials, but the results have been disappointing so far.
Verapamil inhibits the P-glycoprotein-associated, energy-dependent drug efflux and is 
a potent and effective antagonist o f resistance to a number o f drugs in most MDR cell 
lines in vitro. Verapamil inhibits the binding of many chemotherapeutic drugs as well 
as other chemosensitisers to P-glycoprotein suggesting that the mechanism o f action of 
verapamil is through blocking the binding of drugs to P-glycoprotein (Ford, 1995). 
Spoelstra et al demonstrated that verapamil was actively transported by P-glycoprotein
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and that verapamil and daunorubicin were non-competing substrates for P-glycoprotein. 
Therefore the effectiveness of verapamil as a MDR antagonist may be compromised 
because it may be extruded by P-glycoprotein (Spoelstra et al., 1994). The use of 
verapamil in humans is limited by its cardiovascular effects at plasma concentrations 
in the 2 to 6/xM range, which are needed for the antagonism of MDR in vitro. 
Therefore more potent and less toxic chemosensitising agents other than verapamil 
have been investigated e.g. Roll-2933, which is ten fold more potent than verapamil 
with plasma levels in vivo o f less than 2fj.M effective in vitro (Ford, 1995).
Cyclosporin A, a hydrophobic cyclic peptide of 11 amino acids that is widely used in 
human organ transplantation, has been found to reverse resistance in MDR cells but not 
sensitive cells. Interestingly, cyclosporin A apparently does not inhibit the function of 
MRP in combination with doxorubicin, vincristine or mitoxantrone (van der Graaf et al.,
1994). Cyclosporin A  has been found to act as a P-glycoprotein substrate and antagonise 
P-glycoprotein at least in part through competitive inhibition of cytotoxic drugs efflux 
(Ford, 1995). However because of the profound pharmacologic effects of cyclosporin A  in 
vivo (Erlichman et al., 1993), there has been an interest in developing the anti-MDR 
activity of other, less immunosuppressive or nephrotoxic cyclosporine analogues e.g. PSC 
833 and PSC 280-446.
Attempts at chemomodulation of P-glycoprotein has been investigated using various P- 
glycoprotein antagonists. A lack of specificity (calcium antagonists) or toxic effects 
(cyclosporin A) however, result in a limited clinical application of these chemomodulators. 
Therefore a more specific modulation of MDR is necessary for an improved reduction in 
drug resistance.
55
1.11.2 Genetic circumvention
The results of circumvention compounds in clinical trials have been disappointing due to 
non-specific or toxic effects of the circumvention agent. Other alternatives such as 
molecular approaches may improve attempts at the reversal of MDR. A more specific 
interference with P-glycoprotein expression achieved by modern antisense technology may 
be more promising approach..
Ribozymes are RNA molecules which have catalytic activity. They were first discovered 
when the large ribosomal RNA (rRNA) precursor of Tetrahymena thermophila could self­
splice the intron and as the RNA component of the E.coli RNase P, an RNA-protein 
which could cleave the leader segment from precursor transfer RNA molecules. 
Subsequently the hammerhead ribozyme and hairpin ribozyme were discovered in viroids 
(helper viruses found in plants) and the hepatitis delta virus ribozyme was found in the 
hepatitis delta virus. These latter ribozymes cleave RNA which is synthesised in a rolling 
circle into individual RNA transcripts. Further research demonstrated that these RNA 
molecules with self-splicing activity could be manipulated to target specific RNA 
molecules. Once paired to a target site, the manipulated ribozymes can cleave single 
stranded RNA and thus functionally destroy the RNA target and several substrate 
molecules can be turned over by one molecule of catalytic RNA. The high specificity of 
ribozymes in RNA cleavage reactions has provided a new method in controlling gene 
expression artificially and this makes ribozymes potentially useful therapeutic agents.
The hammerhead ribozyme is the smallest of the ribozymes. Figure 1.11.2.1 shows the 
hammerhead ribozyme bound to a substrate. The non-based paired nucleotides of stem II 
make up the catalytic core. The substrate and the ribozyme hybridise to form stem I and 
stem III, orienting the -UH- nucleotides of the substrate over the catalytic core. The GUC 
nucleotide triplet is thought to yield the highest rate of cleavage compared to other 
cleavage triplet sequences. The hammerhead ribozyme has been the best characterised 
ribozyme with respect to optimised target sequence, conserved nucleotides sequences 
within the catalytic core, and the kinetic parameters. The target RNA cleavage sites have
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the least constraints with respect to sequence and therefore are the most abundant sites 
compared to the other ribozyme types (Sullivan, 1994).
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Figure 1.11.2.1 Structure of the hammerhead ribozyme.
The hammerhead ribozyme is in bold. Stem I and stem ID are the binding arms and stem n  is a part of the 
catalytic core. The H represents the cleaveage site of the the substrate RNA and may be an adenine, cytosine 
or uridine (Sullivan, 1994).
A  hammerhead ribozyme which cleaves the 3’-end of the GUC sequence in codon 880 of 
mdrl RNA was transfected into the pancreatic carcinoma cell line EPP85-181RDB , 
which is 1,600 fold-more resistant to daunorubicin than the parental cell line. Ribozyme 
decreased the level of mdrl mRNA expression, inhibited the formation of P-glycoprotein 
and reduced the cell’s resistance to daunorubicin. Cell clones that showed ribozyme
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expression were only 5.3-fold more resistant than the parental cell line (Holm et al.,
1994). This ribozyme was also effective in two adriamycin resistant human lung 
carcinoma cell lines DLKP-A and SK-MES-l/Adr (Daly et a l, 1996).
Other researchers with different ribozymes have successfully reduced P-glycoprotein 
expression in the human colon adenocarcinoma cell line LoVo, a mouse sarcoma cell line 
S-180, a human oral epidermoid carcinoma cell line KB (Bertram et al., 1995) and a 
human plueral mesothelioma cell line (Kiehntopf et al., 1994). Interestingly, the 
expression of the c-fos ribozyme in A2780S human ovarian carcinoma cells, not only 
decreased the expression of c-fos but also the expression of the mdrl gene, c-jun and 
mutant p53. Reversal o f the MDR phenotype by an anti-MDR ribozyme occured one- 
fourth as rapidly as that induced by the anti-fos ribozyme (Scanlon et al., 1994).
1.12 Non-M DR chemosensitisers
There are a number of other non-chemotherapeutic drugs which enhance chemotherapeutic 
cytotoxicity by mechanisms other than reversal of drug resistance (reviewed in Stewart 
and Evans, 1989). These include buthionine sulfoximine (BSO) and other glutathionine 
depletors, the nitroimidazoles and the methylxanthines.
Glutathione helps to protect cells both by reacting with cytotoxic electrophile drug 
derivatives and by reacting with drug generated reactive oxygen compounds such as 
peroxides (Pratt et al., 1994). High glutathione levels were found to be associated with 
decreased DNA cross-link formation by some chemotherapy drugs. This reduction in 
DNA cross-link formation was probably due to intracellular drug inactivation by the 
glutathione rather than an increased rate of DNA repair (Stewart and Evans, 1989). BSO 
is structural analogue o f y-glutamylcysteine, which reduces cellular glutathione levels, by 
irreversibly inhibiting y-glutamylcysteine synthetase, the first enzyme involved in de novo 
glutathione synthesis (Pratt et al., 1994). BSO also inhibits glutahtione transferase 
activity, and inhibits the uptake of cystine, a precursor of glutathione (Stewart and Evans,
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1989). While BSO decreased glutathione concentrations in most normal tissues, the degree 
o f glutathione reduction in these normal tissues has not been as great as in tumour tissues. 
Chemotherapy toxicity to normal tissues (including bone marrow) was generally not 
augmented at BSO doses that enhanced chemotherapy efficacy against tumours (Lee et 
al., 1987; Stewart and Evans, 1989; Siemann and Beyers, 1993).
The nitroimidazoles also potentiate the effect o f numerous chemotherapeutic drugs against 
hypoxic tumour cells. Although their mechanism of action is not well understood they are 
thought to act by decreasing tumour cell thiols, increasing DNA damage (in part from 
inhibition of repair processes) and possibly alterating tumour vasculature (Stewart and 
Evans, 1989).
The methylxanthines, which include caffeine and pentoxifylline, have also been found to 
potentiate the cytotoxic effect of chemotherapeutic drugs (Das et al., 1982; Hain et al., 
1993; Hain et al., 1994). The actual mechansim of action of methylxanthines is unclear 
although they are thought to act by interfering with the repair of DNA, preventing G2 
arrest and prematurely inducung mitosis (Fingert et al., 1986; Schlegel and Pardee, 1986; 
Lock et al., 1994) or inhibiting the induction of, or indirectly inhibiting with post­
replication repair mechanisms (Schiano et al., 1991). Methylxanthines are also reported 
to reduce the cytotoxicity of DNA damaging anti-topoisomerase drugs (including 
adriamycin, mitoxantrone, VP-16 and ellipticine). Intercalation between the drug and 
methylxanthine can lead to a decrease in the effective drug concentration available 
(Traganos et al., 1991; Traganos et al., 1993), while inhibition of RNA synthesis may 
also be a possible mechanism (Perez et al., 1994).
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1.13 Aims of this thesis
The aims of this thesis were to examine the effect of combinations of different drugs on 
toxicity to sensitive and multidrug resistant cancer cells in vitro. Combinations of 
existing anticancer agents were analysed. Combinations o f anticancer drugs and a 
variety of chemosensitivity drugs used at nontoxic levels were then studied. Cellular 
models transfected with the MDR1 gene and an anti-MDRl ribozyme were also 
developed. Combinations o f a known anticancer agent with one of a series of coded 
non-toxic compounds known to be safe for human use were examined in a number of 
cell lines. The effects o f adding these compounds at different times after 
chemotherapeutic drug treatment were investigated. The rate and timing of apoptosis, 
progress through the cell cycle and levels of cell cycle-related proteins then were 
examined.
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Materials and Methods
2.1 WATER
Ultrapure water was used in the preparation of all media and solutions. This water was 
purified by a reverse osmosis system (Millipore M illi-RO 10 Plus, Elgastat UHP) to a 
standard o f 12 - 18 MQ/cm resistance.
2.2 GLASSWARE
Solutions pertaining to cell culture and maintenance were prepared and stored in sterile 
glass bottles. Bottles (and lids) and all other glassware used for any cell-related work were 
prepared as follows:- all glassware and lids were soaked in a 2% (v/v) solution of RBS-25 
(AGB Scientific) for at least 1 hour, after which they were scrubbed and rinsed several 
times in tap water. They were then washed by machine using Neodisher detergent which is 
an organic, phosphate-based acid detergent, rinsed twice with distilled water, once with 
ultrapure water and sterilised by autoclaving.
2.3 STERILISATION
Water, glassware and all thermostable solutions were sterilised by autoclaving at 120°C 
for 20 min. under pressure of lbar. Thermolabile solutions were filtered through a
0.22(im sterile filter (Millipore, millex-gv). Low protein-binding filters were used for all 
protein-containing solutions.
2.4  MEDIA PREPARATION
The basal media used during routine cell culture were prepared according to the 
formulations shown in Table 2.4.1. 10X media were added to sterile ultrapure water, 
buffered with HEPES and NaHC03 and adjusted to a pH o f 7.45 - 7.55 using sterile 1.5M
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NaOH and 1.5M HC1. The media were then filtered through sterile 0.22|im bell filters 
(Gelman; G.1423S) and stored in 500ml sterile bottles at 4°C. Sterility checks were 
carried out on each 500ml bottle of medium as described in Section 2.5.5.
The basal media were stored at 4°C up to their expiry dates as specified on each individual 
10X medium container. Prior to use, 100ml aliquots of basal media were supplemented 
with 2mM L-glutamine (Gibco; 043-05030) and 5% foetal calf serum (Sigma; F7524, 
Batch #13H 3389) and this was used as routine culture medium. This was stored for up to 
2 weeks at 4°C, after which time, fresh culture medium was prepared.
Table 2.4.1 Preparation of basal media
DM EM
(Gibco 042-02501M)
Hams F12
(Gibco 042-01430M)
MEM 
(Gibco 074-01700N)
10X Medium 500ml Powder 500ml
Ultrapure H20 4300ml 4700ml 4300ml
1M HEPES*
i Sigma H9136
100ml 100ml 100ml
7.5% NaHCOj 
BDH 30151
45ml 45ml 45ml
* HEPES = N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
2 .5  CELL LINES
A ll cell culture work was carried out in a class II down-flow re-circulating laminar flow 
cabinet (Nuaire Biological Cabinet) and any work which involved toxic compounds was 
carried out in a cytoguard (Gelman). Strict aseptic techniques were adhered to at all times. 
The laminar flow cabinet was swabbed with 70% industrial methylated spirits (IMS) 
before and after use, as were all items used in the cabinet. Each cell line was assigned
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specific media and waste bottles and only one cell line was worked with at a time in the 
cabinet which was allowed to clear for 15min between different cell lines. The cabinet 
itself was cleaned each week with industrial detergents (Virkon; Antec. International, 
TEGO; TH.Goldschmidt Ltd.), as were the incubators.
The cell lines used during the course of this study, their sources and their basal media 
requirements are listed in Table 2.5.1. Basal medium was supplemented with 5-10% 
serum and 2mM L-glutamine. Lines were maintained in 25cm2 flasks (Costar; 3050) or 
75cm2 flasks (Costar; 3075) at 37°C and fed every two to three days.
2.5 .1  Subculture of Adherent Lines
During routine subculturing or harvesting of adherent lines, cells were removed from their 
flasks by enzymatic detachment.
1. Waste medium was removed from the flasks and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (TV) solution (0.25% trypsin (Gibco; 043-05090), 0.01% EDTA 
(Sigma; EDS) solution in PBS A (Oxoid; BR14a)). The purpose of this was to 
sequester naturally occurring trypsin inhibitor which would be present in any 
residual serum.
2. Fresh TV was then placed on the cells (2ml/25cm2 flask or 4ml/75cm2 flask) and 
the flasks incubated at 37°C until the cells were seen to have detached (5 - 10 
min).
3. The trypsin was deactivated by addition of a equal volume of growth medium (i.e. 
containing 5% serum).
4. The entire solution was transferred to a 30ml sterile universal tube (Sterilin; 128a) 
and centrifuged at 1,000 r.p.m. for 5 min.
5. The resulting cell pellet was resuspended in pre-warmed (37°C) fresh growth 
medium, counted (Section 2.5.2) and used to re-seed a flask at the required cell 
density or to set up an assay.
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Table 2.5.1 Cell lines used during the course of this study
Cell line Basal medium Cell type Source
DLKP
(and all its
derivatives)
ATCC1 Human lung squamous carcinoma Dr. Grant 
NCTCC
SK-MES-1
(and all its 
derivatives
MEM Human lung squamous carcinoma ATCC
\ATCC consists of a 1:1 mixture of DMEM and Hams F12.
2MEM medium was supplemented with 1 % (v/v) MEM Non-essential amino acids (NEAA) (Gibco; 
043-01140) and ImM sodium pyruvate for all lines 
3ATCC = American Type Culture Collection
2.5.2 Cell Counting
Cell counting and viability determinations were carried out using a trypan blue (Gibco;
525) dye exclusion technique.
1. An aliquot of trypan blue was added to a sample from a single cell suspension in a 
ratio o f 1:5.
2. After 3 min. incubation at room temperature, a sample of this mixture was applied 
to the chamber o f a haemocytometer over which a glass coverslip had been placed.
3. Cells in the 16 squares of the four outer corner grids of the chamber were counted 
microscopically, an average per corner grid was calculated with the dilution factor 
being taken into account and final cell numbers were multiplied by 104 to 
determine the number of cells per ml (volume occupied by sample in chamber is
0.1cm x 0.1cm x 0.01cm i.e. 0.0001cm3 therefore cell number x 104 is equivalent 
to cells per ml).
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4. Non-viable cells were those which stained blue while viable cells excluded the
trypan blue dye and remained unstained.
2.5.3 Cell Freezing
To allow long term storage of cell stocks, cells were frozen and cryo-preserved in liquid
nitrogen at temperatures below -180°C. Once frozen properly, such stocks should last
indefinitely.
1. Cells to be frozen were harvested in the log phase of growth (i.e. actively growing 
and approximately 50-70% confluent) and counted as described in Sections 
2.5.2.
2. Pelleted cells were re-suspended in serum and an equal volume of a DMSO/serum 
(1:9, v/v). This solution was slowly added dropwise to the cell suspension to give
a final concentration of at least 5xl06 cells/ml.
3. 1.5ml aliquots of this suspension was placed in cryovials (Greiner; 122 278) which 
were then quickly placed in the vapour phase of liquid nitrogen containers 
(approximately -80°C).
4 After 2.5 - 3.5 hours, the cryovials were lowered down into the liquid nitrogen
where they were stored until required.
2.5.4 Cell Thawing
1. Immediately prior to the removal of a cryovial from the liquid nitrogen stores for 
thawing, a sterile universal tube containing growth medium was prepared for the 
rapid transfer and dilution of thawed cells to reduce their exposure time to the 
DMSO freezing solution which is toxic at room temperature.
2. The suspension was centrifuged at 1,000 r.p.m. for 5 min., the DMSO-containing 
supernatant removed and the pellet re-suspended in fresh growth medium.
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3. A viability count was carried out (Section 2.5.2) to determine the efficacy of the 
freezing/ thawing procedures
4. Thawed cells were placed into tissue culture flasks with the appropriate volume of 
medium (10ml/25cm2 flask and 15ml/75cm2 flask) and allowed to attach 
overnight.
5. After 24 hours, the cells were re-fed with fresh medium to remove any residual 
traces of DMSO.
2.5.5 Sterility Checks
Sterility checks were routinely carried out on all media, supplements and trypsin used for 
cell culture. Samples of basal media were inoculated into Columbia (Oxoid; CM331) 
blood agar plates, Sabauraud (Oxoid; CM217) dextrose and Thioglycollate (Oxoid; 
CM173) broths which should between them detect most contaminants including bacteria, 
fungus and yeast. Growth media (i.e. supplemented with serum and L-glutamine) were 
sterility checked at least 2 days prior to use by incubating samples at 37°C which were 
subsequently examined for turbidity and other indications of contamination.
2.6 MYCOPLASMA ANALYSIS
Mycoplasma examinations were carried out routinely (at least every 3 months) on all cell 
lines used in this study. These analyses were performed by Mary Heenan and William 
Nugent.
2.6.1 Indirect Staining Procedure
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast line) 
were used as indicator cells. As such, these cells were incubated with supernatant from test 
cell lines and then examined for Mycoplasma contamination. NRK cells were used for this
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procedure because cell integrity is well maintained during fixation. A fluorescent Hoechst 
stain was utilised which binds specifically to DNA and so will stain the nucleus of the cell 
in addition to any Mycoplasma DNA present. A Mycoplasma infection would thus be seen 
as small fluorescent bodies in the cytoplasm of the NRK cells and sometimes outside the 
cells.
1. NRK cells were seeded onto sterile coverslips in sterile Petri dishes at a cell 
density of 2xl03 cells per ml and allowed to attach over night at 37°C in a 5 %
C 02, humidified incubator.
2. 1ml of cell-free (cleared by centrifugation at 1,000 r.p.m. for 5 min) supernatant 
from each test cell line was then inoculated onto a NRK Petri dish and incubated as 
before until the cells reached 20-50%  confluency (4 -5  days).
3. After this time, the waste medium was removed from the Petri dishes, the 
coverslips washed twice with sterile PBS A, once with a cold PBS/Carnoys 
(50/50) solution and fixed with 2ml of Carnoys solution (acetic acid: methanol-1:3) 
for 10 min.
4. The fixative was then removed and after air drying, the coverslips were washed 
twice in deionised water and stained with 2ml of Hoechst 33258 stain (BDH) 
(50ng/ml) for 10 min.
From this point on, work proceeded in the dark to limit quenching of the fluorescent stain.
5. The coverslips were rinsed three times in PBS.
6. They were then mounted in 50% (v/v) glycerol in 0.05M citric acid and 0 .1M 
disodium phosphate and examined using a fluorescent microscope with a UV 
filter.
2 .6 .2  Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid; CM403) - supplemented 
with 16% serum. 0.002% DNA (BDH; 42026), 2(Xg/ml fungizone (Gibco; 042 05920),
2xl03 units penicillin (Sigma; Pen-3) and 10ml of a 25 % (w/v) yeast extract solution - to 
optimise growth of any contaminants and incubated at 37°C for 48 hours. Sample of this 
broth were then streaked onto plates of Mycoplasma agar base (Oxoid; CM401) which had 
also been supplemented as above and the plates were incubated for 3 weeks at 37°C in a 
C02 environment. The plates were viewed microscopically at least every 7 days and the 
appearance of small, “fried egg” -shaped colonies would be indicative of a mycoplasma 
infection.
2.7 Toxicity assay
Due to the nature of the compounds tested in the assays, precautions were taken to limit 
the risks involved in their handling and disposal. All work involving toxic compounds was 
carried out in a Gelman “Cytoguard” laminar air flow cabinet (CG Series). All 
chemotherapeutic drugs were stored and disposed of as described in table 2.7.1.
Table 2.7.1 
Cytotoxic Drug
Adriamycin
Carboplatinum
Supplier
Farmitalia
Bristol Myers 
Pharmaceuticals
Inactivation
Hyperchlorite inactivation 
followed by autoclaving 
Incineration
Storage
Stock at 4°C
Store at room 
temperature
5-Fluorouracil
Vincristine
VP-16
Farmitalia
David Bull 
Laboratories Ltd 
Bristol Myers 
Pharmaceuticals
NaOH inactivation followed 
by autoclaving 
Autoclave
Incineration
Store at room 
temperature 
Store at 4°C
Store at room 
temperature
All drugs were stored in the dark
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2.7.1 Toxicity assay
Before setting up any assay, a cell line was pretreated so that it would be in the
exponential phase of growth. Two days prior to the assay, the cells were subcultured into
75cm2 flasks at a density of 2 x 105 cells/flask. The cell were allowed to attach overnight
and the next day were fed with fresh medium.
1. Cells were harvested from a flask in the exponential phase of growth.
2. A cell suspension of lxlO4 cells/ml was made up in growth medium and 100(0.1 
added into 96-well plates (Costar; 3599) and allowed to attach overnight at 37°C, 
5% C02.
3. Drug dilutions (including a control with no drug) were prepared at 2X their final 
concentration in growth medium and lOOjil added to each well in replicas of eight, 
giving final a concentration of IX drug.
4. The plates were incubated for 6 days at 37°C and 5 % C02 or until the control 
wells reached 80% confluency.
5. Cell survival was determined by acid phosphatase assay (Section 2.7.2).
6. The concentration of drug which causes 50% cell kill (the IC50 value) was 
calculated using the Chou and Talalay computer package (Section 2.7.5).
2.7.2 Acid Phosphatase Assay
1. After incubation for 6 days or until 80% confluency was reached in the control 
wells the plates were removed from the incubator and the medium discarded.
2. The wells were washed twice with PBS (100|J.l) and the PBS discarded. 100|il of
phosphatase substrate (lOmM p-nitrophenolphosphate (Sigma; 104-0), 0.1M 
sodium acetate (Sigma; S8625), 0.1% triton X-100 (BDH; 30632) pH 5.5) was 
added to each well.
3. Plates were then wrapped in aluminium foil and left in the dark at 37°C for 2 
hours.
4. The enzyme reaction was stopped by the addition of 50|il of 1.0M NaOH.
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5. The plate was read in a dual beam plate reader at 405nm (reference wavelength 
620nm).
2.7.3 Circumvention assays
1. Cells were harvested from a flask in the exponential phase of growth.
2. A cell suspension of lxlO4 cells/ml was made up in growth medium and lOOjxl 
added into 96-well plates (Costar; 3599) and allowed to attach overnight at 37°C 
and 5 % C02.
3. Drug dilutions (including a control with no drug) were prepared at 4X their final 
concentration in growth medium and 50|xl added to each appropriate well, giving a 
final concentration of IX drug.
All circumvention agents (DL-buthionine-[S,R]-sulphoximine (Sigma; B2640), cyclosporin 
A (Sandoz; Sandimmune), verapamil (Sigma; V4629) and the test compounds) were 
dissolved in media. A 2mg/ml stock solution of the test compounds U-l or N-l, was 
prepared by dissolving 20mg in 250¡x\ of DMSO, the volume made up to 10 mis with 
media and the resulting solution filter sterilised using a 0.22/xm filter.
In assays where more than 2 drug were used in combination, 8X drug dilutions were 
prepared and 25|J,1 added to the appropriate wells. The final volume in each well was 
always 200|il.
4. The plates were incubated for 6 days at 37°C and 5 % C02 or until the control
wells reached 80% confluency.
5. Cell survival was determined by the acid phosphatase assay (Section 2.7.2).
6. The combination index (Cl value), which quantifies the synergistic, additive or 
antagonistic effect of a combination of drugs, was calculated using the Chou and 
Talalay computer package.
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2.7.4 Chemotherapeutic drug pulse assays
1. Cells were harvested from a flask in the exponential phase of growth.
2. A cell suspension of lxlO4 cells/ml was made up in growth medium and lOOpl 
added into 96-well plates (Costar; 3599) and allowed to attach overnight at 37°C 
and 5 % C02.
3. Drug dilutions (including a control with no drug) were prepared at 2X their final 
concentration in growth medium and 100|il added to each well in replicas of eight, 
giving a final concentration of IX drug for 2 hours.
4. Drug was removed from the wells by inverting and tapping the plates over an open 
vessel which had been swabbed with IMS. The wells were then washed twice with 
preheated sterile PBS, ensuring to remove as much PBS as possible after the final 
rinse.
5. Circumvention agent was prepared at IX final concentration and added 
immediately after drug exposure, 24 hours, 48 hours or 72 hours after drug 
exposure as appropriate. Each time the circumvention agent was removed the cells 
were washed once with preheated sterile PBS.
6. The plates were incubated for a total of 6 days at 37°C and 5 % C02 or until the 
control wells reached 80% confluency.
7. Cell survival was determined by acid phosphatase assay (Section 2.7.2).
2.7.5 IC50 calculation
The multiple drug effect analysis of Chou and was used to calculate the IC50 value of
drugs on their own and the effects of combinations of drugs (Chou and Talalay, 1983;
Chou and Talalay, 1984). This involved plotting of dose-effect curves for a drug or
combination of drugs, at different concentrations using the median-effect equation
[Equation 1].
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fa /fu  =  ( D /D m f [Equation 1]
Where:
fa  represents the fraction of cells affected by D.
fu represents the fraction of cells unaffected by D  (i.e. fa =  1 -fu).
D  represents the dose of drug used.
Dm is the dose required for 50% inhibition of cell growth and is the IC50 value. 
m is the coefficient of the sigmoidicity of the dose-effect curve; m =  1, m < 1 and m > 
1 indicate hyperbolic, sigmoidal and negative sigmoidal dose-effect curves respectively for 
the inhibitory drug.
The above equation can be rearranged to give:
D =  Dm lfal(l-fa)]1/m [Equation 2]
The values of Dm and m can be calculated by the median-effect plot of*  =  log (D) versus
y  =  log (fa/(l-fa)). In the median-effect plot, m is the slope and log (Dm) is the x-
intercept. The conformity of the data to the median-effect principle was checked by the 
linear correlation coefficient (r) of the median effect plot. Values of drug concentrations 
and their corresponding percentage inhibition (expressed as a fraction) were entered for 
computer analysis by the computer package, Dose effect analysis with microcomputers 
(Chou and Chou, 1987).
2.7.6 Combination Index calculation
The Combination Index value was calculated for a combination of two drugs using 
Equation 3:
Where,
Cl = (D)i / (Dx)i +  (D)2 / (Dx)2 [Equation 3]
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(D)t is the concentration of drug 1 used in a combination with drug 2, (D)2, that causes 
x% inhibition.
(D)2 is the concentration of drug 2 used in a combination with drug 1, (D)1; that causes 
x% inhibition.
(Dx)j is the concentration of drug 1 alone that causes x% inhibition.
(Djc)2 is the concentration of drug 2 alone that causes x% inhibition.
Synergy is indicated by a Cl value < 1 , an additive effect is indicated by a Cl value equal 
to 1 and antagonism is indicated by a Cl value > 1. Analysis was carried out using Dose 
effect analysis with microcomputers (Chou and Chou, 1987).
Two examples are given below:
Example 1:
(a) drug 1 inhibits cell growth by 50% at 5/xg/ml (Dx)[
(b) drug 2 inhibits cell growth by 50% at 1/xg/ml (Djc)2
(c) a combination of the two drugs at 5^g/ml in a e.g. 4:1 ratio (i.e. 4 /xg/ml drug 1 (D)j 
and 1/xg/ml drug 2 (D)^ inhibits cell growth by 50%.
Cl =  (D \ / (Dx), +  (D)2 / {Dx)2
Then,
Cl =  4/5 +  1/1
0.8 + 1 
1.8
=  Antagonistic
Example 2:
(a) drug 1 inhibits cell growth by 50% at 5/xg/ml (Dx)L
(b) drug 2 inhibits cell growth by 50% at 1/xg/ml (D;t)2
(c) a combination of the two drugs at 1/xg/ml in a e.g. 4:1 ratio (i.e. 0.8 /xg/ml drug 1 
(D)( and 0.2/xg/ml drug 2 (D)2) inhibits cell growth by 50%.
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Cl =  0.8/5 +  0.2/1
0.16 +  .2
0.36
= Synergistic
2.8 Flow cytometry
1. Cells were seeded at 5 x 104cells/25cm2 flask four days before experiments.
2. Drug dilutions (including a control with no drug) were prepared at 2X their final 
concentration in growth medium and added to each flask giving a final 
concentration of IX drug for 2 hours.
3. Drug was removed from the flasks by pouring the drug into a sterile bottle. The 
flasks were then washed twice with preheated sterile PBS, removing as much 
PBS as possible after the final rinse.
4. Circumvention agent was prepared at IX final concentration and added 
immediately after drug exposure.
5. Samples were collected for flow cytometry at various time points; media from the 
flasks were poured into labelled universals, the flasks were trypsinised into single 
cell suspensions and the trypsinised cells added to the labelled universals (this 
ensured that any floating cells were collected), pelleted and resuspended in 70% 
ethanol 30% PBS and kept at 4°C. The samples could be stored for up to 1 month.
6. On the day samples were analysed, cells were harvested and resuspended in PBS 
with 100(Xg/ml RNase (DNase free) (Boeringher Mannheim; 1 119 915) and 
40(ig/ml propidium iodide (Sigma; P4170).
7. Samples were analysed on a Becton Dickenson (FACScan) using an argon-ion 
laser tuned to 488nm measuring forward and orthogonal light scatter and red 
fluorescence. Cell cycle analysis was performed on the Lysis program.
C l =  (D)y / (Dx)i +  (D)2 / (Dx)2
Then,
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2.9 Time-lapse videomicroscopy
Time-lapse videomicroscopy was carried out on a Nikon Diaphot inverted microscope 
(Micron Optical, Bray, Ireland) equipped with phase-contrast optics, linked to a 
Mitsubishi CCD-100 colour video camera. Images were recorded in S-VHS onto a 
Mitsubishi HS-S5600 video recorder with time lapse capabilities. Recording speed was set 
at 3.22 sec/field (480 hour mode), which at normal playback speed resulted in an 
acceleration factor of 160.
The temperature of the culture vessel was controlled by a Linkam CO 102 warm stage 
controller. This controller was adjusted to keep the culture medium inside the vessel at 
37°C, as measured using a TB3301 probe. All time-lapse video equipment was obtained 
from Laboratory Instruments (Ashbourne, Ireland).
Cells were seeded at 5 x 106cells/25cm2 flask four days before experiments. Recording 
was started after cells were exposed to chemotherapeutic drug for two hours and washed 
twice with PBS.
Cell death was classified as apoptotic on the basis of morphological events starting with 
rounding up of adherent cells, subsequent cell shrinkage and/or breakup into apoptotic 
bodies. These cell death events were scored at the time when rounding up first occurred. 
Cell division was classified as mitotic on the basis of morphological events starting with 
rounding up of adherent cells, subsequent cytokinesis and readherance of daughter cells to 
the surface. Mitotic events were scored at the time when rounding up first occurred. 
Typically 100 cells in the microscope field were followed.
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2.10 Western blot analysis
2.10.1 Sample preparation
1. Cells were seeded at 5 x 106cells/25cm2 flask two days before experiments.
2. Drug dilutions (including a control with no drug) were prepared at 2X their final
concentration in growth medium and added to each flask giving a final 
concentration of IX drug for 2 hours.
3. Drug was removed from the flasks by pouring the drug into a sterile bottle. The 
flasks were then washed twice with preheated sterile PBS, removing as much PBS 
as possible after the final rinse.
4. Circumvention agent was prepared at IX final concentration and added 
immediately after drug exposure.
5. Samples were collected at various time points i.e. the media from the flasks were
poured into labelled universals, the flasks were trypsinised into single cell 
suspensions and the trypsinised cells added to the labelled universals (this ensured 
that any floating cells were collected), pelleted and stored at -80°C.
6. Cells were lysed by sonication (7 pulses at 50% power) in SDS-
radioimmunoprecipitation assay (RIPA) buffer (50mM Tris (pH 7.5), 150mM 
NaCl, 1 % nonidet P-40 (Sigma; N6507), 0.1% sodium dodecyl sulphate (SDS) 
(Riedel-de Hain; 62862), 1% sodium deoxycholate (Sigma; D5670)) containing 
protease inhibitors (ImM sodium orthovanadate (Sigma; S6508), ImM DTT 
(Sigma; D5545), ImM phenylmethylsulphonyl fluoride (PMSF) (Sigma; P7626), 
25(ig/ml leupeptin (Sigma; L2884), 25|Xg/ml aprotinin (Sigma; A1153), ImM 
benzamidine (Sigma; B6506), lOmg/ml trypsin inhibitor (Sigma; T9003)).
7. Samples were centrifuged at 4,000rpm for 10 minutes.
8. The supernatant was collected and centrifuged for 1 hour at 13,000rpm.
9. Samples were collected, aliquoted and stored at -80°C.
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2.10.2 Protein Quantitation
The protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500- 
0006).
1. Standard concentrations of bovine serum albumin (BSA) (Sigma; A9543) were 
prepared fresh.
2. 20(0.1 of protein standard or unknown protein sample was added to an Eppendorf.
3. 1ml of diluted (1:5) dye reagent was added and the mixture vortexed.
4. The OD570 was measured against a reagent blank after 5 mins to 1 hour.
5. The concentration of the protein samples was determined from the plot of the 
OD595 of the BSA standards.
2.10.3 Gel electrophoresis
Proteins for western blot analysis were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Resolving and stacking gels were prepared as outlined in 
Table 2.17.1 and poured into clean 10cm x 8cm gel cassettes which consisted of 1 glass 
and 1 aluminium plate, separated by 0.75cm plastic spacers. The resolving gel was poured 
first and allowed to set. The stacking gel was then poured and a comb was placed into the 
stacking gel in order to create wells for sample loading. Once set, the gels could be used 
immediately or wrapped in aluminium foil and stored at 4°C for 24 hours.
Table 2.10.1 Preparation of electrophoresis gels
Resolving gel (15%) Stacking gel
Acrylamide stock* 10ml 0.8ml
Distilled HzO 5.7ml 3.6ml
1.875M-Tris/HCl, pH 8.8 4ml
1.25M-Tris/HCL, pH 6.8 - 0.5ml
10% SDS
(Sigma; L4509) 150jxl 50|il
10% Ammonium persulphate
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(Sigma; A1433) 
TEMED 
(Sigma; T8133) 9jxl 6)xl
5 0 p l 17JÜ
Acrylamide stock = 29.lg acrylamide (Sigma; A8887) and 0.9g NN'-methylene bis-acrylamide 
(Sigma; N7256) made up to 100ml with distilled water.
Before samples were loaded onto the stacking gels, 10[ig of protein was diluted in 5X 
loading buffer (2.5ml 1.25M-Tris/HCl, l.Og SDS, 2.5ml mercaptoethanol (Sigma; 
M6250), 5.8ml glycerol and 0.1% bromophenol blue (Sigma; B8026) made up to 10ml 
with distilled water). The samples were then loaded including 5|xl of molecular weight 
protein markers (Sigma; P1677). The gels were run at 250V, 45mA for approximately 1.5 
hours. When the bromophenol blue dye front was seen to have reached the end of the 
gels, electrophoresis was stopped.
2.10.4 Western blotting
1. Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer 
(25mM Tris, 192mM glycine (Sigma; G7126) pH 8.3 - 8.5 unadjusted) for 20 
mins.
2. Protein in gels were transferred onto Hybond ECL nitrocellulose membranes 
(Amersham; RPN 2020D) by semi-dry electroblotting; Four sheets of Whatman 
3mm filter paper were soaked in transfer buffer and placed on the cathode plate of 
the semi-dry blotting apparatus. Excess air was removed from between the filters 
by moving a glass pipette over the filter paper. Nitrocellulose, cut to the same size 
of the gel, was soaked in transfer buffer and placed over the filter paper, making 
sure there were no air bubbles.The acrylamide gel was placed over the 
nitrocellulose and four more sheets of presoaked filter paper were placed on top of 
the gel. Excess air was again removed by rolling the pipette over the filter paper. 
The proteins were transferred from the gel to the nitrocellulose at a current of 
34mA at 15V for 30 mins.
All incubation steps from now on, including the blocking step, were carried out on a
revolving apparatus to ensure even exposure of the nitrocellulose blot to all reagents.
3. The nitrocellulose membranes were blocked for 2 hours with fresh filtered 5 % 
milk (Cadburys; Marvel skimmed milk) in TBS (125mM NaCl, 20mM Tris pH 
7.5).
4. Membranes were probed overnight with cyclin-E antiserum (HE12) (Santa Cruz 
Biotechnology Inc; sc-247) diluted 1:1000 or CDK2 antiserum (M2) (Santa Cruz 
Biotechnology Inc.; sc-163) diluted 1:1000.
5. The primary antibody was removed and the membranes rinsed 3 times with TBS. 
The membranes were washed for 15 mins, and then twice for 5 mins in TBS.
6. Bound antibody was detected using enhanced chemiluminescence (ECL).
2.10.5 Enhanced chemiluminescence detection
Protein bands were developed using the Enhanced Chemiluminescence Kit (ECL)
(Amersham; RPN2109) according to the manufacturers instructions.
1. Membranes were rinsed 3 times with TBS. The membranes were first washed for 
15 mins and then washed twice for 5 mins.
2. Secondary antibody (1/1,000 dilution of anti-mouse IgG peroxidase conjugate 
(Sigma; A-6782) in TBS or a 1/1000 dilution of anti-rabbit IgG (Sigma; A-4914) 
in TBS) was added for lhour.
3. The secondary antibody was removed and the membranes rinsed 3 times with 
TBS. The membranes were washed for 15 mins first, and then twice for 5 mins.
4. A sheet of parafilm was flattened over a smooth surface e.g. a glass plate, making 
sure all air bubbles were removed. The membrane was then placed on the 
parafilm, and excess fluid removed.
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5. 1.5ml of ECL detection reagent 1 and 1.5 ml of reagent 2 were mixed and covered 
over the membrane. Charges on the parafilm ensured the fluid stayed on the 
membrane.
6. The reagent was removed after one minute and the membrane wrapped in cling 
film.
7. The membrane was then exposed to autoradiographic film (Kodak; X-OMAT S) in 
an autoradiographic cassette for various times, depending on the signal.
9. The autoradiographic film was then developed.
2.10.6 Autoradiograph film processing
1. The exposed film was developed for 5mins in developer (Kodak; LX24), 1;6.5
dilution in water.
2. The film was briefly immersed in water and transferred to a Fixer solution 
(Kodak; FX-40) a 1:5 dilution in water, for 5mins.
3. The film was transferred to water for 5 mins and then air-dried.
2.11 Immunoprécipitation
Samples for all immunoprécipitation experiments were prepared as for western blotting 
(Section 2.10.1)
1. 100|Xg of total protein were centrifuged at 3000rpm at 4°C for 15 minutes.
2. The supernatant was transferred to another Eppendorf with ljxg of normal mouse 
IgG (Sigma; 1-5381) and 20|xl of agarose conjugate (Santa Cruz Biotechnology 
Inc.; sc-2001).
3. This was then centrifuged at l,500rpm at 4°C for 5 minutes.
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4. The supernatant was transferred to another Eppendorf with 10|il of mouse anti-
cyclin E (H E(lll)) (Santa Cruz Biotechnology Inc.; sc-248) for 1 hour at 4°C.
5. The solution was then incubated overnight at 4°C with 20|il of agarose conjugate.
6. The agarose beads were collected by centrifugation at 2,500rpm for 5 mins at 4°C.
7. The resulting pellet was washed 4 times with RIPA buffer.
8. After the final wash the supernatant was discarded and the pellet was resuspended 
in 50|Xl kinase buffer for kinase assays (see protein kinase assay, Section 2.12).
2.12 Protein kinase assay
1. 100/ig of protein was immunoprecipitated and resuspended in 50/xl kinase buffer 
(20mM Tris pH 7.5, lOmM MgCl2 and ImM DTT) see Section 2.11.
2. The agarose beads were collected by centrifugation at 2,500rpm for 5 mins at 4°C.
3. The resulting pellet was washed 2 times with kinase buffer.
4. The pellet was resuspended in 50/d of 100/xg/ml histone HI (Boehringer 
Mannheim; 223 549), 5/xM adenosine-5'-triphosphate (ATP) (Boehringer 
Mannheim; 127 523) and 0 .1/xCi/ml [32-P] ATP in kinase buffer for 30 mins at 
30°C.
5. The reaction was stopped by adding 5X loading buffer and boiled for 4 mins.
20/xl of the reaction mixture was run on a 15 % SDS gel for 1 hour at 200mA and 
1000V.
6. The gel was placed on three sheets of blotting paper and dried on a gel dryer 
(GS200, Savent, USA) for 3 hours at 70°C.
7. The sheet of blotting paper with the dried gel was placed in an autoradiographic 
cassette with autoradiography film and left at -80°C.
8. After 1 -3  days the film was developed as in Section 2.10.6.
9. The levels of kinase activity was quantified by using a densitometer (Bio-Rad GS- 
670, imaging densitometer).
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2.13 Plasmid DNA Isolation
2.13.1 Preparation of competent cells for transformation
1, 20ml of sterile LB-broth (10(ig/ml tryptone (Oxoid; L42), 5|ig/ml yeast extract
(Oxoid; L21), 10[ig/ml NaCl) was inoculated with JM 109 Escherichia coli in a 
50ml universal and grown overnight at 37°C in a shaking incubator at 250rpm. 
2.4mls of this overnight culture was inoculated in 400ml sterile LB-broth in a 
sterile 21 baffled flask and placed at 37°C at 250rpm until the absorbance at 590nm 
was exactly 0.375.
3. This culture was then aliquoted into pre-chilled 50ml universals and left on ice for 
5-10 mins.
4. The cells were then centrifuged at 3000rpm at 4°C for 7 mins.
5. The supernatant was removed and the pellet resuspended in 10 mis of ice-cold
sterile CaCl2 (60mM CaCl2 (Sigma; C7902), 15% glycerol, lOmM PIPES (Sigma; 
P9291) pH 7.0).
6. Cells were centrifuged again for 5 mins at 2500rpm at 4°C.
7. The resulting pellet was resuspended in 2mls of ice-cold CaCl2 and left on ice for
12-24  hours.
8. The suspension was then aliquoted into -80°C pre-chilled sterile Eppendorfs and
stored at -80°C.
2.13.2 Transformation of Escherichia coli
1. lOng of plasmid DNA to be transformed was placed in a sterile Eppendorf.
2 . 100|xl of competent cells were taken directly from the freezer, thawed and added 
to the DNA.
3. The mixture was left on ice for 30 mins.
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4. 1ml of LB-broth was added to this suspension, mixed gently by inversion and 
incubated at 37°C and 250rpm for 1 hour.
5. The cells were then pelleted for 1 - 2 mins at 13,000rpm and resuspended in 200[il 
LB-broth.
6. 200|il of this culture was spread on LB Agar plates (LB-broth and 25|ig/ml agar 
(Sigma; A5054)) containing 100(ig/ml ampicillin (Sigma; A9393) (ampicillin 
resistance was encoded for on the transformed plasmid).
7. The plates were incubated at 37°C overnight.
8. The resulting colonies were checked for the plasmid using a plasmid Miniprep.
2.13.3 Plasmid Miniprep
1. One colony (from a transformed plate) was removed and added to 10 ml of LB- 
broth containing ampicillin and incubated overnight at 37°C and 250 rpm.
2. 1.5mls of the overnight culture was placed in a sterile Eppendorf and the cells 
pelleted at 12,000rpm for 30 secs at 4°C.
3. The supernatant was removed and the pellet resuspended in 300(il STET (8 % 
glucose (Riedel-de Hain; 16325), 5% triton X-100, 50mM Tris-HCl, 50mM 
EDTA).
4. 25(il of fresh lOmg/ml lysozyme (Sigma; L7001) solution was added to the cell 
suspension. This was then vortexed and boiled for 45 secs. The suspension was 
pelleted at 13,000rpm for 15 mins.
5. Approximately 210(11 of the supernatant was removed.
6. 230|il of isopropanol (Riedel-de Hain; 33539) was mixed with the pellet and left
for 10 mins at 4°C.
7. This was centrifuged at 13,000rpm for 5 mins.
8. The pellet was washed twice with 70% ethanol and then resuspended in 25(0.1 of
TE (lOmM Tris-HCl, ImM EDTA, pH 8.0) .
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9. l|il boiled RNase (lOmg/ml) was added and left at 37°C for 15mins to remove 
RNA.
2.14 Transfection procedures
2.14.1 Electroporation
1. Cells were pretreated so that they were in the exponential phase of growth.
2. They were trypsinised at 4°C, spun down and resuspended in half the original 
volume using ice cold PBS (sterile and without Mg or Ca).
3. A cell count was performed and the cells were centrifuged at lOOOrpm for 5mins 
resuspended at 1 x 106 cells/600|xl in PBS at 0°C.
4. 600(0,1 of the cell suspension was transferred to 200|il of TE in an electroporation 
cuvette (Bio-Rad; 165-2088) at 0°C.
5. 10|ig of plasmid was added. The plasmid/cell suspension was mixed by holding 
the cuvette on the two “window sides” and flicking the bottom of the cuvette and 
then left for 5 minutes.
6. The dried cuvettes were placed in the holder of the electroporation apparatus at
room temperature and one pulse delivered at the desired setting;
Cell line Settings
DLKP 600V 25 (iF °oQ
SK-MES-l/Adr 250V 25|xF °oQ
7. The electroporated cells were returned to ice for 10 minutes and then diluted 20- 
fold in non-selective medium. The cuvette was rinsed with the same medium to 
get all the transfected cells.
8. (i) The cells were plated out in 10cm diameter sterile petri dishes at 37°C and
5% C 02.
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(ii) The cells were plated out in 96-well plates at a density of 100 cells per well 
and incubated at 37°C and 5 % C02.
2.14.2 Calcium phosphate co-precipitation
1. Cells were pretreated so that they were in the exponential phase of growth.
2. Cells were set up at 5 x 105 cells per 10cm petri dish and incubated at 37°C and
5 % C02 overnight.
3. 10|Xg of pCHl 10 plasmid was added to 410(i.l of sterile H20  and left overnight at 
4°C.
4. The following day the plasmid was incubated at 37°C for 1 hour.
5. 60(xl of 2M CaCl2 was added dropwise into the plasmid using continuous 
vortexing.
6. This was immediately added dropwise to 480(xl of 2X hepes buffer saline (HBS) 
(280mM NaCl, 50mM hepes, 1.5mM Na^PC^, pH 7.12) with continuous 
vortexing and left for 30mins at room temperature.
7. The plasmid-CaP04 mixture was added dropwise to a petri dish of cells which had 
been set up the previous day. The plates were gently shaken to ensure even mixing 
and left for 4 hours at 37°C and 5 % C 02.
8. After 4 hours the media was removed and 5mls of 10% glycerol was added for 3 
mins (this is critical).
9. The glycerol was then removed and the cells washed twice with 5mls of serum- 
free media.
10. lOmls of fresh growth media was then added and the cells incubated at 37°C.
86
2.15 Assay for B-Galactosidase activity
This assay was used to optimise the transfection protocol for various cell lines. pCHllO,
which encodes for B-galactosidase, was used as a marker plasmid. Its activity was detected
as follows;
2.15.1 Preparation of cell extract
1. 24 hours after cells were transfected, they were rinsed twice with lOmls PBS.
2. 1ml of TEN (40mM Tris, ImM EDTA, 150mM NaCl) was added and the cells 
were harvested using a cell scraper.
3. The harvested cells were centrifuged at 13,000rpm for 5mins.
4. The supernatant was removed with a pipette.
5. The pellet was resuspended in 60|il of 0.25M Tris-HCl pH 7.8. This cell
suspension was left at -80°C for 5mins and then at 37°C for 5mins.
6. This freeze/thaw cycle was repeated 3 times.
7. The lysate was centrifuged at 13,000rpm for 5 mins and then the supernatant was 
transfered to a separate Eppendorf.
2.15.2 Assay
1. 100(0,1 of fresh 15mg/ml chlorophenol red fl-D-galactopyranoside (CPRG) 
(Boehringer Mannheim; 884 308) was added to 400jxl of buffer A (lOOmM 
NaH2P 0 4 adjusted to pH 7.2 with NaOH, lOmM KC1, ImM MgCl2, lOmM 15- 
mercaptoethanol added just before use) in an Eppendorf.
2. 50(il of cell extract was then added (one tube was left as a control) and left for 2 
hours in a water bath at 37°C.
3. If there was no difference in colour between the control and the samples with the 
extract then the samples were incubated overnight (8 -1 6  hours) at 37°C.
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4. After a colour change the samples were diluted with 1. lmls (2 volumes) of buffer 
A without B-mercaptoethanol.
5. The absorbance was read at 574nm using the control sample as a blank. The 
higher the absorbance value, the higher the fl-galactosidase activity. The activity of 
fi-galactosidase correlates to the efficiency of transfection of pCHllO into the cells.
2.16 Selection of Transfectants
Cells transfected with pHaMDRl/A (a kind gift from M. Gottesman, National Institutes of
Health, Bethesda) were allowed to grow for 3 days in nonselective media and selected
with 50(ig/ml Adriamycin. MDR1 ribozyme (received as a gift from Dr.Kevin Scanlon,
City of Hope Medical Centre, Los Angeles) transfected cells were allowed to grow for 24
hours in nonselective medium and selected with 400|ig/ml geneticin (Sigma, G418).
Untransfected cells were treated in the same way as a control.
2.16.1 Isolation of clonal transfectants
1. 5 days after transfection, each well was examined microscopically and those wells 
identified as containing a single colony were marked. The remaining wells 
contained no cells, had more than one colony or contained cells lying close to each 
other but it was not clear if they were clones or not. All such wells were 
disregarded.
2. The marked wells were fed every 6 - 7  days until they became confluent.
3. The cells were then removed from their wells by trypsinisation. This involved 
removing the waste medium from each well and adding 50|il trypsin.
4. The plates were then incubated at 37°C for approximately 5 min. After this time, 
cells which had not completely detached from the well surface were resuspended 
with a micropipette.
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5. Each clonal population was then transferred to an individual well in a 24-well plate 
(Greiner; 662160) without centrifugation. Each well contained 1ml of growth 
medium which was sufficient to inactivate the trypsin.
6. When these wells were confluent (after 6 - 7  days), the clones were transferred
into 6-well plates (Costar; 3516) in a similar manner to that of the previous 
transfer.
7. When these wells became confluent, the cells were transferred to 25cm2 flasks and
then to 75cm2 flasks.
8. Frozen stocks were then prepared (Section 2.5.3).
2.17 RNA Extraction
The labile nature of RNA required that strict procedures were followed in the course of
work involving RNA. This procedures included the wearing of gloves at all times that
RNA-containing vessels were being used, the baking of all glassware and foil used to
make up solutions and weigh compounds and most solutions and plastics were treated with
0.1.% diethyl pyrocarbonate (DEPC) which is a strong inhibitor of RNases.
RNA was then extracted from cells as follows:-
1. Cells were grown in 175cm2 flasks to approximately 80% confluency.
2. Waste medium was removed and the cells washed twice with DEPC-PBS
3. The cells were lysed in 25ml of 4M-guanidinium thiocyanate (GnSCn) solution 
(50g guanidinium thiocyanate (Sigma; G6639), 0.5g N-lauroyl sarcosine (Sigma; 
L5125) and 5ml of lM-sodium citrate (RDH; 32320), pH 7.0 - brought up to 
100ml with DEPC-water, filtered through a 0.45|im filter and supplemented with 
700|Xl/ml P-mercaptoethanol and 330(il/ 100ml antifoam A (Sigma; A5758) prior 
to use).
4. 5.5ml of a 5.7M-cesium chloride solution (95.8g CsCl (Sigma; C3032) and 2.5ml 
of lM-sodium citrate, pH 7.0 in 100ml water, filtered through a 0.22(im filter, 
treated with 0.1 % DEPC and autoclaved) was placed into polyallomer
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ultracentrifuge tubes and the cell lysates were then layered onto tiiese CsCl 
cushions.
5. The lysates were centrifuged at 26,000 r.p.m. for 21 - 24 hours at 15°C in a 
swinging bucket centrifuge.
6. The tubes were then brought into a laminar flow cabinet and the supernatant 
removed from the tubes using a pasteur pipette, leaving approximately 1ml of 
CsCl in the bottom of the tube, below which lay the RNA pellet.
7. The tube was inverted and the bottom of the tube was cut away using a heated 
scalpel blade.
8. The pellet was rinsed with 95 % ethanol and resuspended in 200|il DEPC-water. 
The solution was transferred to an Eppendorf and the bottom of the tube was 
rinsed with a further 200|il water which was added to the Eppendorf.
9. 40|xl of 3M-sodium acetate was added to the RNA solution to give a final 
concentration of 0.3M-sodium acetate, and 2 volumes of ice-cold absolute ethanol 
were also added.
10. The Eppendorfs were stored at -80°C overnight and the RNA was then pelleted at 
4°C at maximum speed in a microfuge.
11. The resulting pellet was washed with 70% ethanol, the supernatant removed and 
the pellet resuspended in 20(4,1 DEPC-water.
RNA concentration was calculated by determining its OD at 260nm and using the
following formula:-
O D 260nm x Dilution factor x 40 = ¿ig/jd RNA
The purity of the RNA extraction was calculated by determining its OD at 260nm and
280nm. An A260 : A280 ratio of 2 is indicative of pure RNA and only those samples with
ratios between 1.8 and 2.1 were used.
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2.18 Reverse transcriptase reaction
Reverse transcriptase (RT) reactions were carried out in laminar flow cabinets using 
micropipettes which were specifically allocated to this work.
cDNA was formed using the following procedure:- 
l|il oligo (dT)12'18 primers (ljig/(il) (Promega; C l 101) 
l\il total RNA (l(ig/(xl)
3(il water
were mixed in an Eppendorf, heated to 70°C for 10 min and then chilled on ice. To this, 
the following were added:-
4|ol of a 5x buffer (250mM-Tris/HCl pH 8.3, 375mM-KCl and 15mM-MgCl2)
2JJ.1 DTT (lOOmM) (Gibco; 510-8025 SA) 
l(il RNasin (40U/[il) (Promega; N2511)
1(0.1 dNTPs (lOmM of each dNTP)
6(0,1 water
1(0.1 Moloney murine leukemia virus-reverse transcriptase (MMLV-RT) (40,000u/(ol) 
(Gibco; 510-8025 SA).
The solutions were mixed and the RT reaction was carried out by incubating the 
Eppendorfs at 37°C for 1 hour. The MMLV-RT enzyme was then inactivated by heating 
to 95 °C for 2 min. The cDNA was stored at -20°C until required for use in PCR reactions 
as outlined in Section 2.18.
2.19 Polymerase chain reaction
A standardised polymerase chain reaction (PCR) procedure was followed in this study. 
The Eppendorf tubes used (Eppendorf; 0030 121 023) and the sterile water were DEPC- 
treated. All reagents had been aliquoted and were stored at -20°C and all reactions were 
carried out in a laminar flow cabinet.
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Each PCR tube contained the following:- 
24.5(0.1 water
5|Ol lOx buffer* (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1 % Triton X-100)
3|Ol 25mM-MgCl2*
8(0,1 dNTPs (1.25mM each of dATP, dCTP, dGTP and gTTP) (Promega; U1240)
1(0,1 each of first and second strand target primers (250ng/(ol)
l|ol each of first and second strand endogenous control primer (250ng/(o,l)
0.5(ol of 5U/|0,1 Taq DNA polymerase enzyme*
5(0,1 DNA or cDNA 
*(Promega; N1862)
A drop of autoclaved mineral oil was placed in each reaction tube to prevent evaporation 
and the DNA was amplified by PCR (Techne; PHC-3) as follows:- 
95 °C for 1.5 min - to denature double-stranded DNA 
30 cycles: 95°C for 1.5 min. - denature
55 °C for 1 min - anneal 
72°C for 3 min. - extend 
72°C for 7 min. - extend 
The reaction tubes were then stored at 4°C until analysed by gel electrophoresis as 
described in Section 2.19.
2.20 Electrophoresis of PCR products
1. A 3% agarose gel (NuSieve;GTG) was prepared in TBE buffer (5.4g Tris, 2.75g 
boric acid, 2ml 0.5M-EDTA pH 8.0 in 500ml water) and melted in a microwave 
oven.
2. After allowing to cool, 0.003 % of a lOmg/ml ethidium bromide solution was 
added to the gel which was then poured into an electrophoresis apparatus
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(BioRad). Combs were placed in the gel to form wells and the gel was allowed to 
set.
3. 10/d loading buffer (50% glycerol, lmg/ml xylene cyanol, lmg/ml bromophenol 
blue, ImM EDTA) was added to each 50^1 PCR sample and 10 - 20|xl was run on 
the gel at 80mV for approximately 1 hour.
4. When the dye front was seen to have migrated the required distance, the gel was 
removed from the apparatus and examined on a transilluminator.
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3.0 RESULT
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3.1 Chemotherapeutic drug combinations
The use of multiple drugs in combination is standard in treating a patient with cancer. 
Clinical studies have shown that drug combinations generally produce higher response 
rates in treated populations than those produced by single agents alone. However, it is 
possible that some drug combinations may be antagonistic. This series of experiments 
investigated the use of common chemotherapeutic drugs in combination at three different 
ratios. Assays were performed as described in Section 2.7 and the combination index (Cl) 
values were calculated as described in Section 2.7.6. These values indicate if a drug 
combination in synergistic, additive or antagonistic.
Three different ratios of adriamycin and carboplatin were used in combination in DLKP 
(Table 3.1.1). The results show that the ratios of adriamycin to carboplatin at 1:10 and 
1:100 were antagonistic with the lowest Cl value being 3. The ratio of adriamycin to 
carboplatin at 1:40 displayed some additive effects and a synergistic effect at high 
concentrations of the combination.
Combinations of adriamycin and carboplatin were assayed in DLKP-A (Table 3.1.2). The 
combination of adriamycin and carboplatin in a 1:40 ratio was additive although some 
concentrations did show synergy. The combination at ratios of 1:10 and 1:100 were 
antagonistic.
A combination of vincristine and carboplatin at ratios of 1:10, 1:40 and 1:100 were 
assayed in DLKP-A (Table 3.1.3). The combination at a ratio of 1:10 and 1:100 were 
antagonistic. The combination at a 1:40 ratio did show slight synergy at 5 and 7.5 /xg/ml 
and an additive effects at higher concentrations.
A combination of adriamycin and vincristine at a ratios of 1:4 was assayed in DLKP 
(Table 3.1.4). Vincristine and adriamycin were antagonistic initially but then showed some
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synergism at higher concentrations. Vincristine and adriamycin were assayed at ratios of 
1:1, 4:1 and 1:4 in DLKP-A (Table 3.1.5). At each combination the Cl values were 
antagonistic at lower concentrations but then showed some synergy at higher 
concentrations.
Vincristine and VP-16 were assayed at 1:1, 1:5 and 5:1 combination in DLKP (Table 
3.1.6). The combinations were antagonistic initially but were synergistic at higher 
concentrations of the combinations. However, the percentage growth at the higher 
concentrations was very low (<  10%).
At ratios of 1:1, 1:5 and 5:1, vincristine and VP-16 were assayed in combination in 
DLKP-A (Table 3.1.7). This combination in DLKP-A did show synergy in each 
combination at all concentrations used.
The above results demonstrated that a combination of carboplatin and 
adriamycin/vincristine was additive in DLKP-A. The combinations of adriamycin plus 
vincristine were antagonistic in DLKP and DLKP-A. Vincristine plus VP-16 were 
antagonistic in DLKP but did show synergism in DLKP-A.
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Table 3.1.1: Combination Index (Cl) values for carboplatin and adriamycin at different 
ratios in combination in DLKP. Survival was calculated as percentage growth relative to 
that measured in a drug-free control and is the mean of eight replicates. The values also 
include the standard deviations. The Combination Index (Cl) was calculated as outlined as 
in Section 2.7.6. Cl value <1  represents synergistic toxicity, Cl value =1 represents 
additive toxicity and Cl value >  1 antagonistic toxicity.
Combination 1 (adriamycin 1: carboplatin 10).
Concentration (ng/ml) % Growth Cl values
Control 100±6 -
2.5 100±7 13
5 98 ±10 3
10 100±4 5
15 95 ±9 4.5
20 95 ± 9 6
50 91 ± 9 9
100 64 ±8 3
Combination 2 (adriamycin 1 : carboplatin 40)
Concentration (ng/ml) % Growth Cl value
Control 100±10 -
0.05 102 ± 7 >100
0.1 75 ±13 1.5
0.25 69 ±15 3
0.5 37±8 1.6
0.75 20±3 1
1 13 ±2 .81
2.5 7± 2 1.13
5 7±1 2.7
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Combination 3 (adriamycin 1: carboplatin 100).
Concentration (ng/ml) % Growth Cl values
Control 100±4 -
0.05 100 ±8 -
0.1 104 ±12 >100
0.25 93 ±7 14
0.5 89±4 21
0.75 80±4 13.8
1 73±3 12
2.5 34±2 4.8
5 18±1 4.5
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Table 3.1.2: Combination Index (Cl) values for carboplatin and adriamycin in at 
different ratios in DLKP-A. Survival was calculated as percentage growth relative to that 
measured in a drug-free control and is the mean of eight replicates. The values also 
include the standard deviations. The Combination Index (Cl) was calculated as outlined as 
in Section 2.7.6. Cl value <1 represents synergistic toxicity, Cl value =1 represents 
additive toxicity and Cl value >  1 antagonistic toxicity.
Combination 1 (adriamycin 1: carboplatin 10)
Concentration (¿ig/ml) % Growth Cl values
Control 100±5 -
0.5 103±6 >100
0.75 103 ±8 >100
1 97±4 4.3
2.5 96±8 9
5 59±8 1.5
7.5 40±8 1.2
10 34±7 1.3
Combination 2 (adriamycin 1: carboplatin 40).
Concentration (¿ig/inl) % Growth Cl values
Control 100±7 -
0.75 102 ±3 >100
1 99±8 16
2.5 90±6 3.5
5 47±6 0.92
7.5 36±3 0.94
10 30±3 1.01
15 30±4 1.56
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Combination3 (adriamycin 1: carboplatin 100).
Concentration (¿ig/ml) % Growth Cl values
Control 100±11 -
0.5 99±4 5
0.75 104 ±6 >100
1 100±10 77
2.5 98±5 16
5 66±3 1.78
7.5 48±3 1.42
10 41±2 1.47
15 40±3 2.8
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Table 3.1.3: Combination Index (Cl) values for Carboplatin and Vincristine in 
DLKP-A. Survival was calculated as percentage growth relative to that measured in a 
drug-free control and is the mean of eight replicates. The values also include the standard 
deviations. The Combination Index (Cl) was calculated as outlined as in Section 2.7.6. Cl 
value < 1 represents synergistic toxicity, Cl value =1 represents additive toxicity and Cl 
value > 1 antagonistic toxicity.
Combination 1 (vincristine 1: carboplatin 10)
Concentration (fig/m\) % Growth Cl values
Control 100 ±7 -
0.5 85 ±7 88
0.75 89±7 -
1 86±3 10
2.5 66±8 26
5 44±4 4.7
7.5 25 ±5 4
10 17±4 4.6
Combination 2 (vincristine 1: carboplatin 40)
Concentration (jig/ml) % Growth Cl values
Control 100±7 -
0.75 102 ±3 >100
1 99±8 16
2.5 90±6 3.5
5 47±6 0.92
7.5 36±3 0.94
10 30±3 1.01
15 30±4 1.56
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Combinations (vincristine 1: carboplatin 100)
Concentration (jtg/ml) % Growth Cl values
Control 100±11 -
0.75 102±7 -
1 106±12 >100
2.5 88±9 5.6
5 56±8 3
7.5 37±7 2.5
10 26±4 2.3
15 17 ± 2 2.2
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Table 3.1.4: Combination Index (Cl) values for adriamycin and vincristine at a ratio of 
1:4 in DLKP. Survival was calculated as percentage growth relative to that measured in a 
drug-free control and is the mean of eight replicates. The values also include the standard 
deviations. The Combination Index (Cl) was calculated as outlined as in Section 2.7.6. Cl 
value < 1 represents synergistic toxicity, Cl value =  1 represents additive toxicity and Cl 
value > 1 antagonistic toxicity.
Concentration (n/ml) % Growth Cl values
Control 100± 5 -
10 94 ±5 2.79
20 57±4 1.31
40 13±1 0.75
80 5 0.53
150 3 0.76
300 3 1.08
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Table 3.1.5: Combination Index (Cl) values for adriamycin and vincristine in DLKP-A. 
Survival was calculated as percentage growth relative to that measured in a drug-free 
control and is the mean of eight replicates. The values also include the standard deviations. 
The Combination Index (Cl) was calculated as outlined as in Section 2.7.6. Cl value < 1 
represents synergistic toxicity, Cl value =1 represents additive toxicity and Cl value > 1 
antagonistic toxicity.
Combination 1 (1 adriamycin : vincristine 1).
Concentration (jig/ml) % Growth Cl values
Control 100±10 -
0.312 88±10 2.58
.625 56±8 1.28
1.25 30±4 1.06
2.5 9 ± 2 0.67
5 7± 1 1.14
7.5 7±1 1.59
Combination 2 (4 adriamycin : 1 Vincristine).
Concentration (/¿g/ml) % Growth Cl values
Control 100±5 -
0.312 80±6 1.5
0.625 66 ± 7 1.6
1.25 40±6 1.22
2.5 21 ±4 1.08
5 7 ± 2 0.69
7.5 6±1 0.99
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Combination 3 (1 adriamycin : 4 vincristine).
Concentration (/tg/ml) % Growth Cl values
Control 100±6 -
0.312 88±10 2.79
0.625 52±5 1.31
1.25 17±3 0.75
2.5 5±1 0.53
5 3±1 0.76
7.5 3±1 1.08
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Table 3.1.7: Combination Index (Cl) values for vincristine and VP-16 in DLKP-A. 
Survival was calculated as percentage growth relative to that measured in a drug-free 
control and is the mean of eight replicates. The values also include the standard deviations. 
The Combination Index (Cl) was calculated as outlined as in Section 2.7.6. Cl value < 1 
represents synergistic toxicity, Cl value =  1 represents additive toxicity and Cl value > 1 
antagonistic toxicity.
Combination 1 (vincristine 1: VP-16 1)
Concentration (mg/ml) % Growth Cl values
Control 100 ±8 -
0.05 97±8 0.2
0.125 97 ± 4 0.48
0.25 95 ± 8 0.79
0.5 68±11 0.535
1.25 8±2 0.31
2.5 6±1 0.55
3.75 8±2 0.95
5 9 ± 2 1.3
Combination 2 (vincristine 1: VP-16 5)
Concentration (/xg/ml) % Growth Cl values
Control 100±9 -
0.05 94±7 -
0.125 95 ± 9 0.22
0.25 95 ±14 0.45
0.5 92±9 0.72
1.25 19±4 0.48
2.5 7±1 0.56
3.75 7±1 0.88
5 7±1 1.13
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Combination 3 (vincristine 5 : VP -16 1)
Concentration (¿ig/ml) % Growth Cl values
Control 100±6 -
0.05 95 ± 9 -
0.125 96±6 0.63
0.25 91 ±  8 0.82
0.5 25 ±10 0.26
1.25 13 ±2 0.41
2.5 6±1 0.53
3.75 7± 1 0.91
5 7± 1 1.2
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Table 3.1.6: Combination Index (Cl) values for vincristine and VP-16 in DLKP. Survival 
was calculated as percentage growth relative to that measured in a drug-free control and is 
the mean of eight replicates. The values also include the standard deviations. The 
Combination Index (Cl) was calculated as outlined as in Section 2.7.6. Cl value < 1 
represents synergistic toxicity, Cl value = 1 represents additive toxicity and Cl value >  1 
antagonistic toxicity.
Combination 1 (vincristine 1: VP-16 1)
Concentration (ng/ml) % Growth Cl values
Control 100±4 -
0.5 56±7 8.38
1.25 12 zh 1 0.53
2.5 5 0.21
5 4 0.32
12.5 3 0.41
25 2 0.38
37.5 2 0.41
50 2 0.60
Combination 2 (vincristine 1 : VP-16 5)
Concentration (ng/ml) % Growth Cl values
Control 100 ±6 -
0.5 83±6 26.7
1.25 80±5 44.8
2.5 55 ±5 12.6
5 15±2 1.08
12.5 5 0.32
25 3 0.35
37.5 3 0.36
50 3 0.47
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Combination 3 (vincristine 5: VP-16 1).
Concentration (ng/ml) % Growth Cl values
Control 100±4 -
0.5 81 ±5 99
1.25 29±3 4.98
2.5 9±1 0.97
5 5 0.68
12.5 3 0.68
25 2 0.92
37.5 2 0.82
50 2 1.21
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3.2 MDR circumvention
A number of compounds have been identified which inhibit the efflux of chemotherapeutic 
drugs by P-glycoprotein and reverse cellular resistance in experimental systems including 
verapamil, a calcium antagonist.
However, there are a number of non-chemotherapeutic drugs which enhance 
chemotherapeutic cytotoxicity by mechanisms other than the reversal of drug resistance. 
One of these drugs, buthionine sulfoximine (BSO), reduces cellular glutathione levels, by 
irreversibly inhibiting y-glutamylcysteine synthetase, the first enzyme involved in de novo 
glutathione synthesis. Glutathione helps to protect cells both by reacting with cytotoxic 
drug derivatives and by reacting with drug generated reactive oxygen compounds.
This series of experiments was performed to investigate the efficacy of BSO plus a P- 
glycoprotein inhibitor (verapamil) in combination with adriamycin in DLKP and DLKP-A 
cell lines. DLKP is a human lung carcinoma cell line which is sensitive to 
chemotherapeutic drugs and DLKP-A is a MDR derivative of DLKP which overexpresses 
P-glycoprotein. Each experiment was performed twice as described in Section 2.7.3 and 
the combination Index (Cl) value calculated as outlined in Section 2.7.6.
The cytotoxicity of BSO in combination with adriamycin in DLKP is given in Table 3.2.1 
and the Combination Index (Cl) values are given in Table 3.2.2. These results show that 
at higher concentrations of BSO, the Cl value was approximately 1. This implies that 
there was an additive cytotoxic effect. A synergistic cytotoxic effect (i.e. Cl value < 1) 
was observed at lOng/ml adriamycin when ljug/ml of BSO was used.
The cytotoxicity of BSO in combination with adriamycin in DLKP-A is given in Table
3.2.3 and the Combination Index (Cl) values are given in Table 3.2.4. These results show 
that at the lowest concentration of BSO (1/xg/ml), the Cl values were less than 1. Thus
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there was a synergistic toxic effect with all the concentrations adriamycin used. At higher 
concentrations of BSO, the Cl values were in general antagonistic.
Verapamil in combination with adriamycin showed little enhanced cytotoxic effect in 
DLKP (Table 3.2.5), at the lower concentrations of BSO (0.125/xg/ml and 0.25/tg/ml), 
there was synergism in toxicity (Table 3.2.6). However, BSO plus verapamil in 
combination with adriamycin did not significantly enhance the toxicity of adriamycin alone 
compared to BSO alone with adriamycin (Table 3.2.7).
Verapamil did show enhanced cytotoxicity in combination with adriamycin in DLKP-A 
(Table 3.2.8). However, BSO did not significantly affect adriamycin toxicity (Table 
3.2.9). The combination of BSO plus verapamil in combination was synergistic with 
adriamycin (Table 3.2.10), however it is not clear if this effect is to verapamil alone or the 
combination of BSO and verapamil. A more detailed experiment using a number of 
combinations of BSO and verapamil with adriamycin was then performed in DLKP-A 
(Table 3.2.11). This showed that the combination of BSO plus verapamil with adriamycin 
did seem to be synergistic. For example, when one concentration of verapamil was used 
and the concentration of BSO was increased then the toxicity of adriamycin was enhanced. 
Conversely, when one concentration of BSO was used and the concentration of verapamil 
was increased then the toxicity of adriamycin was also enhanced
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Table 3.2.1: Effect o f BSO on adriamycin toxicity to DLKP. Survival was calculated as
percentage growth relative to that measured in a drug-free control and is the mean o f eight
replicates. The values also include the standard deviations.
Control 5ng/ml
Adriamycin
lOng/ml 15ng/ml 20ng/ml
BSO Oftg/ml 100 57±5 29±3 24 ±4 15 ±2
BSO 0.25jig/ml 44 ±7 20±3 16±3 14±2
BSO 0.5/tg/inl 77±8 44±5 20±2 17±1 14±1
BSO 1/ig/ml 26±4 15 ±2 14±2 12±2
Table 3.2.2: Effect of BSO on adriamycin toxicity to DLKP. The Combination Index 
(Cl) was calculated as oudined in Section 2.7.6. Cl value <  1 represents synergistic 
toxicity, Cl value »1 represents additive toxicity and Cl value >  1 antagonistic toxicity.
Adriamycin
5ng/ml lOng/ml 15ng/ml 20ng/ml
BSO ljig/ml 1.09 0.789 0.928 1.06
BSO 2.5/ig/ml 1.49 0.971 1.14 1.26
BSO 5/tg/ml 1.16 1.02 1.23 1.33
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Table 3.2.3: Effect o f BSO on adriamycin toxicity to DLKP-A. Survival was calculated
as percentage growth relative to that measured in a drug-free control and is the mean o f
eight replicates. The values also include the standard.
0/ig/ml 0.5/tg/ml
Adriamycin
1/tg/rnl 2/tg/ml 3/ig/ml
BSO 0/tg/ml 100±7 71 ±11 48± 15 18±4 12±3
BSO 1/ig/ml - 45 ±10 29±8 11 ±3 6±1
BSO 2.5/ig/ml 56±13 82±6 55 ±5 26±3 15 ±2
BSO 5/tg/ml 34±13 66±9 39±6 16±4 8±1
Table 3.2.4: Effect of BSO on adriamycin toxicity to DLKP-A. The Combination Index 
(Cl) was calculated as outlined as in Section 2.7.6. Cl value <  1 represents synergistic 
toxicity, Cl value »1 represents additive toxicity and Cl value > 1 antagonistic toxicity.
Adriamycin
0.5/tg/ml 1/ig/ml 2/tg/ml 3/ig/ml
BSO 1/ig/ml 0.975 0.868 0.691 0.688
BSO 2.5/ig/ml 16 4 1.76 1.5
BSO 5/ig/ml 8.8 3 1.3 0.95
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Table 3.2.5: Effect o f verapamil (Ver) on 15ng/ml adriamycin toxicity to DLKP.
Survival was calculated as percentage growth relative to that measured in a drug-free
control and is the mean o f eight replicates. The values also include the standard deviations.
Control Adriamycin
Ver 0/ig/ml 100±4 36±3
Ver 0.125/ig/ml 104 ±5 34±2
Ver 0.25ftg/ml 100 ±6 27 ±2
Ver 0.5/tg/ml 114 ±8 28±3
Table 3.2.6: Effect of BSO on 15ng/ml adriamycin toxicity to DLKP. Survival was 
calculated as percentage growth relative to that measured in a drug-free control and is the 
mean of eight replicates. The values also include the standard deviations.
Control Adriamycin
BSO 0/ig/ml 100 ±6 30±3
BSO 0.125/tg/ml 97 ±5 12 ± 1
BSO 0.25pg/ml 98±5 18±2
BSO 0.5fig/ml 100 ±5 20±5
Table 3.2.7: Effect of BSO plus verapamil (Ver) on 15ng/ml adriamycin toxicity to 
DLKP. Survival was calculated as percentage growth relative to that measured in a drug- 
free control and is the mean of eight replicates. The values also include the standard 
deviations.
0
Verl + BSOl 
0
Ver2 + BS02
Control Adrl Adr2
100 ±2 
90±5 
100 
94 ±24
30±2 
20±1 
36 ±9 
13±2
7±1
8±1
7±1
7±1
Where:
Verl = 0.5^ g/ml BSOl = 0.5/Ag/ml Adrl = 15ng/ml
Ver2 = 0.25/xg/ml BS02 = 0.25/ig/ml Adr2 = 30ng/ml
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Table 3.2.8: Effect o f verapamil (Ver) on 2.5/xg/ml adriamycin toxicity to DLKP-A.
Survival was calculated as percentage growth relative to that measured in a drug-free
control and is the mean o f eight replicates. The values also include the standard deviations.
Control Adriamycin
Ver 0^g/ml 100 ±5 75±6
Ver 0.125/xg/ml 100 ±8 26±2
Ver 0.25/tg/ml 98±6 44±4
Ver 0.5/xg/ml 101+7 62±4
Table 3.2.9: Effect of BSO on 2.5/xg/ml adriamycin toxicity to DLKP-A. Survival was 
calculated as percentage growth relative to that measured in a drug-free control and is the 
mean of eight replicates. The values also include the standard deviations.
Control Adriamycin
BSO 0/tg/ml 100 ±6 69±5
BSO 0.125Aig/ml 100±6 63 ±4
BSO 0.25/tg/ml 96±5 59±6
BSO 0.5/tg/ml 97±5 56±5
Table 3.2.10: Effect of BSO plus verapamil (Ver) on adriamycin toxicity to DLKP-A. 
Survival was calculated as percentage growth relative to that measured in a drug-free 
control and is the mean of eight replicates. The values also include the standard deviations.
0
Verl + BSOl 
0
Ver2 + BS02
Control Adrl Adr2
100 ±5 
99±5 
100±10 
91±8
67 ±5 
20±1 
56±5 
26±4
32±4 
8±1 
21±4 
12 ±2
Where:
Verl = 0.5/ig/ml BSOl = 0.5/tg/ml Adrl = 2.5/ig/ml
Vei2 = 0.25/xg/ml BS02 = 0.25/ig/ml Adr2 - 5/tg/ml
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Table 3.2.11: Effect of BSO plus verapamil (Ver) on adriamycin toxicity to DLKP-A. Survival
was calculated as percentage growth relative to that measured in a drug-free control and is the
mean of eight replicates. The values also include the standard deviations.
Control Adrl Adr2 Adr3
0 100±20 84±3 51+5 22±3
BSOl + Verl 100±7 80+6 42+5 14±2
0 100+14 88±20 59+5 27±3
BSOl + Ver2 101+23 75±6 37+5 17+1
0 100±12 90±6 58±4 28±3
BSOl + Ver3 99±12 63±6 31±3 17+1
0 100±7 90±5 51±4 21±2
BS02 + Verl 98+8 73±6 40+3 15±1
0 100+8 88±5 56±2 27±3
BS02 + Ver2 95±7 75+6 44±2 21±1
0 100±4 9G±6 52±6 26±4
BS02 + Ver3 98±8 44±7 22±5 14±2
0 100±9 86+6 52+5 23+4
BS03 + Verl 101+9 75±6 43+4 16±2
0 100+5 80±4 46±3 20±3
BS03 + Ver2 96±11 66±6 36±12 14+2
0 100±8 90±7 58±5 28±4
BS03 + Ver3 99±7 63 ±6 31±4 17±3
Where:
Verl = 0.125ptg/ml 
Vei2 = 0.25/xg/ml 
Ver3 = 0.5/ig/ml
BSOl
BS02
BS03
= 0.125/xg/ml 
= 0.25/ig/ml 
= 0.5/tg/ml
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Adrl = 1.25/xg/inl 
Adr2 = 2.5/xg/ml 
Adr3 = 5/tg/ml
3.3 MDR1 ribozyme transfection
Currently the best understood mechanism of MDR is the resistance mediated by the 
MDR1 gene product, P-glycoprotein (P-170) (see Section 1.9 and 1.10).
Attempts at chemomodulation of P-glycoprotein have been investigated using various P- 
glycoprotein antagonists. The results of circumvention compounds in clinical trials have 
been disappointing due to the non-specific effects (calcium antagonists) or toxic effects 
(cyclosporin A) of the circumvention agent. Therefore a more specific modulation of 
MDR is necessary for an improved reduction in drug resistance. At present, one 
alternative is to use antisense techniques to interfere with P-glycoprotein expression.
To test the efficacy of antisense in vitro, an anti-MDRl hammerhead ribozyme was 
transfected into the adriamycin resistant human lung carcinoma cell line SK-MES-l/Adr. 
SK-MES-l/Adr is a derivative of the chemotherapeutic drug sensitive cell line SK-MES-1 
(see Table 2.5.1), which was exposed to increasing concentrations of adriamycin. Its 
mechanism of drug resistance is primarily thought to be due to P-glycoprotein 
overexpression.
Before transfection of SK-MES-l/Adr with the MDR1 ribozyme, SK-MES-l/Adr was 
electroporated with the pCHllO fl-galactosidase reporter plasmid at various voltages in 
order to optimise transfection efficiency (see Section 2.14.4). fl-Galactosidase activity was 
assayed 24 hours after electroporation (see Section 2.15) and the results are given in Table
3.3.1 These show that increasing the voltage of electroporation beyond 250V decreased 
electroporation efficiency into SK-MES-l/Adr, as shown by highest OD570 value. Thus, 
the optimum voltage to electroporate SK-MES-l/Adr was determined to be 250V.
Three clones were isolated when SK-MES-l/Adr was electroporated with the anti-MDRl 
ribozyme plasmid (see Section 2.14.4). These clones were selected in 96-well plates by 
continuous exposure to 200/tg/ml geneticin in ATCC media (see Section 2.16).
117
Toxicity assays (see Section 2.7) were performed on each clone to adriamycin, vincristine 
and VP-16 and compared to SK-MES-1 and SK-MES-l/Adr (Figures 3.3.1 - 3.3.3). 
These graphs demonstrate that each clone displays a decreased resistance to adriamycin, 
vincristine and VP-16 compared to the resistant parent cell line, SK-MES-l/Adr. Clone 
#2 shows the least amount of chemosensitisation for each drug tested compared to clone 
#3 and clone #4. Clone #3 and clone #4 show a similar profile.
The IC50 values for adriamycin, vincristine and VP-16 of SK-MES-1, SK-MES-l/Adr 
and each ribozyme clone are given in Table 3.3.2. These values were calculated as 
described in Section 2.7.5. These values confirm Figures 3.3.1 - 3.3.3 and show that the 
IC50 values of the ribozyme clones were less than the resistant parent SK-MES-l/Adr.
The levels of resistance towards adriamycin, vincristine and VP-16 of SK-MES-l/Adr and 
each ribozyme clone was calculated from the IC50 values and are compared in Table 
3.3.3. These fold resistance values show that the ribozyme transfectant clones had an 
approximately 50% decrease in resistance to adriamycin. Their resistance to vincristine 
and VP-16 varied with clone #2 demonstrating the least amount of chemosensitivity while 
clone #4 displayed the most.
RT-PCR analysis of RNA isolated from SK-MES-1, SK-MES-l/Adr and each ribozyme 
clone as described in Section 2.16 - 2.18, was performed (Figure 3.3.4). No MDR1 
mRNA expression was detected in SK-MES-1. An increased expression of MDR1 mRNA 
was detected in SK-MES-l/Adr but the three MDR1 ribozyme transfectants expressed less 
than the resistant parent. Of the ribozyme transfectants, clone #4 expressed the least 
amount of MDR1 mRNA while clone #2 expressed the greatest amount MDR1 mRNA.
This experiment demonstrates the use of an anti-MDRl ribozyme in a MDR cell line. 
Three clones were selected when SK-MES-l/Adr was transfected with the ribozyme 
plasmid. These clones were assayed for their resistance to adriamycin, vincristine and VP- 
16. All the clones displayed increased chemosensitivity to each drug with clone #4 being 
the most sensitive. RT-PCR analysis demonstrated that MDR1 mRNA expression was
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decreased in the clones compared to the resistant parent SK-MES-l/Adr although there 
was no clone isolated in which MDR1 expression was completely abrogated. No MDR1 
mRNA expression was observed in the sensitive parent SK-MES-1.
Table 3.3.1: Effect of various voltages on the electroporation efficiency of pCHllO, a 
B-galactosidase reporter plasmid, into SK-MES-l/Adr. The O.D. at 570nm represents fl- 
galactosidase activity (Section 2.14).
Voltage (V) O.D. @ 570nm
0 0
250 0.031
500 0.002
750 0.007
1000 0.002
1250 0.002
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Figure 3.3.1: Adriamycin toxicity profiles o f SK-MES-l/Adr and the three MDR1
ribozyme clones. The error bars represent the standard deviation on the mean o f eight
replicates.
Adriamycin concentration (ng/ml)
\
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Figure 3.3.2: Vincristine toxicity profiles o f SK-MES-l/Adr and the three MDR1
ribozyme clones. The error bars represent the standard deviation on the mean o f eight
replicates.
Vincristine concentration (ng/ml)
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Figure 3.3.3: VP-16 toxicity profile o f SK-MES-l/Adr and the three MDR1 ribozyme
clones. The error bars represent the standard deviation on the mean o f eight replicates.
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Table 3.3.2: The IC50 values of adriamycin, vincristine and VP-16 in SK-MES-1, SK- 
MES-l/Adr and three MDR1 ribozyme transfectant clones. IC50 values were calculated as 
described in Section 2.7.5. The values also include the standard deviations.
Adriamycin (ng/ml) Vincristine (ng/ml) VP-16 (ng/ml)
SK-MES-1 24±16 2±1 333± 117
SK-MES-l/Adr 274 ±109 220 ±28 2273 ±631
Clone #2 120 ±73 130±80 1624 ±897
Clone #3 108±71 150±91 1284 ±1054
Clone M 117±36 91 ±27 1215 ±781
Table 3.3.3: Fold increase in resistance towards adriamycin, vincristine and VP-16 of 
SK-MES-1, SK-MES-l/Adr and three MDR1 ribozyme transfectant clones compared to 
SK-MES-1. The fold resistance was determined by dividing the average IC50 value for the 
cell line of interest by the corresponding average IC50 value for SK-MES-1. The values 
also include the standard deviations.
Adriamycin Vincristine VP-16
SK-MES-1 1±0.7 1±0.5 1±0.4
SK-MES-l/Adr 11.5 ±4.5 104.5±13.4 6.8±1.9
Clone #2 5±3 61.9±38.2 4.9±2.7
Clone #3 4.5±3 71.3±43.4 3.9±3.3
Clone M 4.9±1.5 43.3± 13 3.7±2.4
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Figure 3.3.4: Gel electrophoresis of the products of RT-PCR analysis of the
MDR1 mRNA levels in SK-MES-l/Adr and the three MDR1 ribo2yme clones. Two lanes 
were run per sample.
b.p. 1 2 3  4  5
1 SK-MES-1
2 SK-MES-l/Adr MDR1 ribozyme #2
3 SK-MES-l/Adr MDR1 ribozyme #3
4 SK-MES-l/Adr MDR1 ribozyme #4
5 SK-MES-l/Adr
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3.4 MDR1 gene transfection
MDR is a multifactorial phenomen with a number of resistance mechanisms co-expressed 
within a cell (see Section 1.9 and Section 1.10). DLKP-A is a MDR cell line derived from 
DLKP by sequential exposure to increasing concentrations of adriamycin. Nine clones 
were isolated from DLKP-A, each with different levels of resistance and a combination of 
resistance mechanisms (Heenan, 1994). However no clone solely expressed P- 
glycoprotein. Therefore DLKP was electroporated with the pHaMDRl/A plasmid, which 
encodes the full cDNA for the human MDR1 gene (Pastan et al., 1988), to develop a low 
level resistance DLKP clone whose only mechanism of resistance was the expression of P- 
glycoprotein. These clones could then be investigated to determine their relative resistance 
profiles to different chemotherapeutic drugs and determine if they correlate with each 
other. They could also be compared to the resistance profiles to the resistant clones 
derived from DLKP-A.
Before transfection of DLKP with the MDR1 gene, DLKP was electroporated with the 
pCHllO 8-galactosidase reporter plasmid at various voltages in order to optimise 
transfection efficiency (see Section 2.14.4). fl-Galactosidase activity was assayed 24 hours 
after electroporation (see Section 2.15) and the results are given in Table 3.4.1. These 
show that increasing the voltage of electroporation up to 800V increased electroporation 
efficiency into DLKP, as shown by highest O D ^ value. Thus, the optimum voltage to 
electroporate DLKP was determined to be 800V. Increasing the voltage further caused 
increased cell death and a decrease in transfection efficiency (results not shown).
Two clones were isolated when DLKP was transfected with the pHaMDRl/A plasmid (see 
Section 2.14.4). These clones were selected in 96-well plates by continuous exposure to 
50ng/ml adriamycin in ATCC media (see Section 2.16). The adriamycin concentration 
represents approximately 3 times the IC50 value for DLKP, thus control cells did not 
survive when exposed to this concentration and clones selected were resistant to 
adriamycin. The concentration of adriamycin in the selection medium was not increased to 
a higher concentration because a relatively low resistant clone was preferred.
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Toxicity assays (see Section 2.7) were performed on each clone to adriamycin, vincristine 
and VP-16 (Figures 3.4.1 - 3.4.3). These graphs demonstrate that each clone had an 
increased resistance to adriamycin, vincristine and VP-16 compared to the sensitive parent 
cell line, DLKP. Clone #1 demonstrated an increased resistance to adriamycin and 
vincristine compared to clone #2. In contrast clone #2 showed a greater resistance to VP- 
16. The IC50 values for adriamycin, vincristine and VP-16 of each clone are given in 
Table 3.4.2. These values were calculated as outlined in Section 2.7.5. The IC50 values 
determined for the clones are compared to the IC50 values of DLKP and DLKP-A as 
calculated by Dr. M. Heenan (Heenan, 1994). The values show that the MDR1 
transfectants were more resistant to each chemotherapeutic drug tested compared to DLKP 
but were not as resistant as DLKP-A. The fold increase in resistance towards adriamycin, 
vincristine and VP-16 of DLKP-A and the MDR1 transfectants was calculated from the 
IC50 values (Table 3.4.3). These fold resistance values showed that clone #1 was over 2 
fold as resistant as clone ti2 to adriamycin and 1.5 fold more resistant to vincristine but 
that clone ti2 was 1.7 fold more resistant to VP-16 than clone til.
RT-PCR analysis of RNA isolated from DLKP, the two MDR1 transfectants and DLKP- 
A as described in Section 2.16 - 2.18, was performed (Figure 3.4.44). No MDR1 
expression was detected in DLKP. An increased expression of MDR1 mRNA was 
detected in DLKP-A and the two MDR1 transfectants and the expression of MDR1 in 
DLKP-A was much greater than the two transfectant clones.
These results show that DLKP was successfully transfected with the MDR1 gene with two 
transfectant clones isolated. Toxicity assays were performed on each clone to determine 
their resistance profiles to adriamycin, vincristine and VP-16. These showed that the 
clones were more resistant to these chemotherapeutic drugs compared to the sensitive 
parent cell line DLKP. The toxicity data also demonstrated that clone til was more 
resistant to adriamycin and vincristine than clone ti2 but that clone #2 was more resistant 
to VP-16 than clone til. Thus even though these clones were derived from the same parent 
cell line and were transfected with the same plasmid, they displayed different resistance
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profiles to the chemotherapeutic drugs tested. RT-PCR analysis confirmed increased 
expression of MDR1 mRNA in each clone.
Table 3.4.1: Effect of various voltages on the electroporation efficiency of pCHllO, a 
B-galactosidase reporter plasmid, into DLKP. The O.D. at 570nm represents fi- 
galactosidase activity (Section 2.15).
Voltage (V) O.D. @ 
570nm
0 0
200 0.017
400 0.046
600 0.055
800 0.077
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Figure 3.4.1: Adriamycin toxicity profiles o f DLKP pHaM DR l/A  #\ and #2. The error
bars represent the standard deviation on the mean o f eight replicates.
Adriamycin ( M g / m l )
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Figure 3.4.2: Vincristine toxicity profiles o f DLKP pHaM DR l/A  ttl and #2. The error
bars represent the standard deviation on the mean o f eight replicates.
Vincristine (ng/ml)
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Figure 3.4.3: VP-16 toxicity profile o f DLKP pHaM DR l/A #1 and #2. The error bars
represent the standard deviation on the mean o f eight replicates.
0 2 4 6 e 10
VP-16 (Mg/ml)
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Table 3.4.2: The IC50 values of adriamycin, vincristine and VP-16 in DLKP 
pHaMDRl/A #1 and #2. IC50 values were calculated as outlined in Section 2.7.5. The 
IC50 values for DLKP and DLKP-A were calculated by Dr. M. Heenan (Heenan, 1994). 
The values also include the standard deviations.
DLKP DLKP-A DLKP
pHaMDRl/A
#1
DLKP
pHaMDRl/A
#2
Adriamycin 14±8ng/ml 3660±1720ng/ml 520±212ng/ml 215±7ng/ml
Vincristine l.l±0.3ng/m l 1680±790ng/ml 51±21ng/ml 33±15ng/ml
VP-16 86±40ng/ml 5230± 690ng/ml 690+0ng/ml 1170±47ng/ml
Table 3.4.3: Fold increase in resistance towards adriamycin, vincristine and VP-16 of 
DLKP-A and the MDR1 transfectants. The fold resistance was determined by dividing the 
average IC50 value for the cell line of interest by the corresponding average IC50 value 
for DLKP. The IC50 values of DLKP and DLKP-A were calculated by Dr. M. Heenan 
(Heenan, 1994). The values also include the standard deviations.
DLKP-A DLKP 
pHaMDRl/A #1
DLKP 
pHaMDRl/A #2
Adriamycin 254 ±  119 37 ±  14.7 15 ±  0.5
Vincristine 1500 ±  705 45.5 ±  18.8 29.5 ±  13.1
VP-16 61 ±  8 8 ±  0 13.6 ±  0.5
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Figure 3.4.4: Gel electrophoresis of the products of RT-PCR analysis of the MDR1 
mRNA levels in DLKP, DLKP-A and the two MDR1 transfectant clones. Two lanes were 
run per sample.
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1 DLKP
2 DLKP pHaMDRl/A #\
3 DLKP pHaMDRl/A #2
4 DLKP-A
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3.5 Test Compound Screening
There are a number of non-chemotherapeutic drugs which enhance chemotherapeutic 
cytotoxicity by mechanisms other than the reversal of drug resistance (reviewed in 
Stewart and Evans, 1989). These include buthionine sulfoximine (BSO) and other 
glutathione depletors, the nitroimidazoles and the methylxanthines. However none of these 
are in common clinical use. Thus, the need to test new non-chemotherapeutic drugs which 
enhances the cytotoxicity of chemotherapeutic drugs is needed more than ever. This series 
of experiments investigated possible cytotoxic synergy between adriamycin, a commonly 
used chemotherapeutic drug, and five selected non-chemotherapeutic test compounds. Two 
concentrations of adriamycin and three non-toxic concentrations of test compound were 
used in combination, and assays was performed as described in Section 2.7.3.. Seven cell 
lines were tested; DLKP (Table 3.5.1); DLKP pHaMDRl/A #2 (Table 3.5.2); DLKP-A- 
2B (Table 3.5.3); DLKP-A-2B IC7 (Table 3.5.4); SK-MES-1 (Table 3.5.5); SK-MES- 
1/Adr (Table 3.5.6); SK-MES-l/Adr mdrl ribozyme #4 (Table 3.5.7).
The effect of two concentrations of adriamycin (lOnM and 20 nM) was assayed in 
combination with five test compounds in DLKP, a chemotherapy drug sensitive human 
lung carcinoma cell line (Table 3.5.1). The test compounds N-l, 0-1 and U-l at non­
toxic concentrations, each enhanced the cytotoxicity of adriamycin at lOnM and 20nM 
concentrations. The largest effect was observed at the highest concentration of test 
compound used. None of the concentrations of the test compounds A-l or U-2 enhanced 
the cytotoxicity of adriamycin.
The five test compounds were also assayed in combination with adriamycin in DLKP 
pHaMDRl/A #2, a MDR1 transfectant of DLKP which is resistant to adriamycin (see 
Section 3.4). At the three concentrations of test compounds tested, none of the test 
compounds demonstrated any enhanced toxicity of adriamycin (Table 3.5.2).
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From the results of testing DLKP and DLKP pHaMDRl/A #2, three test compounds were 
further assayed in five other cell lines. These were N-l and U-l, both of which enhanced 
the toxicity of adriamycin in DLKP and A-l which did not enhance adriamycin toxicity 
and was therefore used as a negative control.
DLKP-A-2B is a low level resistant clone derived from the MDR cell line DLKP-A 
(Heenan, 1994). DLKP-A-2B was tested to observe the effect of the test compounds in a 
cell line which expresses a number of MDR mechanisms including overexpression of P- 
glycoprotein. None of the test compounds assayed enhanced the toxicity of adriamycin 
(Table 3.3.3).
In order to further investigate the effect of the test compounds in MDR cell lines, DLKP- 
A-2B IC7 was also assayed. DLKP-A-2B IC7 is a MDR1 ribozyme transfectant of DLKP- 
A-2B, in which the expression of P-glycoprotein mRNA is inhibited (McBride, 1995). 
The test compounds N-l and U-l at non-toxic concentrations, each enhanced the 
cytotoxicity of adriamycin at 40nM and 80nM concentrations (Table 3.5.4). The largest 
effect was observed at the highest concentration of test compound used. None of the 
concentrations of the test compound A-l significantly enhanced the cytotoxicity of 
adriamycin.
The test compounds N-l and U-l enhanced the toxicity of adriamycin at 5nM and lOnM 
in SK-MES-1, a chemotherapeutic drug sensitive cell line (Table 3.5.5). A-l did not 
enhance the toxicity of adriamycin.
SK-MES-l/Adr is a MDR derivative of SK-MES-1, which was exposed to increasing 
concentrations of adriamycin. When this cell line was assayed with the test compounds in 
combination with adriamycin (Table 3.5.6), no enhancement of toxicity was observed.
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A MDR1 ribozyme transfectant of SK-MES-l/Adr was then assayed with the test 
compounds. SK-MES-l/Adr MDR1 ribozyme clone M  was the most sensitive clone 
obtained after transfection of SK-MES-l/Adr with a MDR1 ribozyme, although P- 
glycoprotein mRNA expression was not completely inhibited (see Section 3.3). No 
enhancement of toxicity was observed when this cell line was assayed with the test 
compounds in combination with adriamycin (Table 3.5.7).
The above results demonstrated that the test compounds N -l, 0-1 and U-l were shown to 
be synergistic at non-toxic levels in combination with adriamycin in DLKP but not DLKP 
pHaMDRl/A #2, whereas A-l and U-2 exhibited no synergy. N-l and U-l exhibited 
synergy in DLKP-A-2B IC7 and SK-MES-1 but not in DLKP-A-2B, SK-MES-l/Adr and 
SK-MES-l/Adr mdrl ribozyme #4. A-l had no synergistic effect in any cell line assayed.
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Table 3.5.1: Adriamycin in combination w ith the test compounds in DLKP. Survival was
calculated as percentage growth relative to that measured in a drug-free control and is the
mean o f eight replicates. The values also include the standard deviations.
[1] [2] [3] Adr
(lOnM)
Adr + 
[1]
Adr +  
[2]
Adr +  
[3]
A-l 102 ±9 102 ±9 104+8 97 ±5 90±4 94 ±7 98±7
N -l 98±11 92±11 95±11 90±9 61 ±5 67±5 80±6
0-1 98±9 98±8 98±8 84 ±10 64± 11 63 ±13 56± 11
U-l 104 ±6 104 ±6 106±6 79±5 40±4 50±4 62±6
U-2 102 ±6 99±5 99±6 75 ±5 91 ±7 88 ±8 82±6
[1] [2] [3] Adr
(20nM)
Adr + 
[1]
Adr + 
[2]
Adr + 
[3]
A-l 96±7 100±6 106±5 35 ±3 26±3 28±2 33±5
N-l 97± 11 98±9 96±9 62 ±4 15 ±1 16±1 20±2
0-1 99±5 101 ±5 106 ±7 82 ±3 51±6 60±6 59±7
U-l 110±5 107±8 110±8 40±3 12±1 15 ±2 22 ±2
U-2 103 ±10 100±8 99±8 67 ±7 71 ±8 64±9 58± 10
Test compound concentrations
[A-l] 1 = 140/xM 
[A-l] 2 = 70/tM 
[A-l] 3 = 35/iM
[U-l] 1 =  17/iM 
[U-l] 2 =  8.5/xM 
[U-l] 3 =  4.25/iM
[N-l] 1 =  8/xM 
[N-l] 2 = 4j*M 
[N-l] 3 =  2/iM
[U-2] 1 = 5/xM 
[U-2] 2 =  2.5/*M 
[U-2] 3 = 1.25/tM
[0-1] 1 =  240/xM 
[0-1] 2 =  120/iM 
[0-1] 3 =  60/tM
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Table 3.5.2: Adriamycin in combination with the test compounds in DLKP pHaMDRl/A
#2. Survival was calculated as percentage growth relative to that measured in a drug-free
control and is the mean of eight replicates. The values also include the standard deviations.
[1] [2] [3] Adr
(180nM)
Adr + 
[1]
Adr + 
[2]
Adr + 
[3]
A-l 89±7 98±6 100±8 72 ±5 68±5 71±7 68±5
N-l 72±4 87±4 95±8 93 ±5 72±4 87 ±4 95 ±8
0-1 96 ±4 97 ± 7 96±5 72±8 70±8 67±6 62 ±7
U-l 98±11 102±6 100±8 72 ±5 69±5 67±3 68±6
U-2 98±6 101±6 101±6 64±5 63 ± 6 60±5 50±6
[1] [2] [3] Adr
(360nM)
Adr + 
[1]
Adr + 
[2]
Adr + 
[3]
A-l 94 ±7 97 ±5 98±7 41±4 48±6 44±5 40±4
N-l 79±5 94±5 101 ±8 69±8 47±5 58±5 65 ±5
0-1 97±5 99 ±5 102 ±5 47±3 48±5 44±4 36±5
U-l 105 ±9 96±4 100±8 37±3 39±4 37±5 37±3
U-2 97±3 91 ± 6 98±6 46±3 43 ±4 41±4 38±4
Test compound concentrations
[A-l] 1 = 140/xM 
[A-l] 2 = 7(VM 
[A-l] 3 = 35/xM
[U-l] 1 = 17/iM 
[U-l] 2 = 8.5/iM 
[U-l] 3 = 4.25piM
[N-l] 1 = 8/xM 
[N-l] 2 = 4/iM 
[N-l] 3 = 2/iM
[U-2] 1 = 5/xM 
[U-2] 2 = 2.5/iM 
[U-2] 3 = 1.25/iM
[0-1] 1 = 240/iM 
[0-1] 2 = 120/iM 
[0-1] 3 = 60/aM
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Table 3.5.3: Adriamycin in combination with the test compounds in DLKP-A-2B.
Survival was calculated as percentage growth relative to that measured in a drug-free
control and is the mean of eight replicates. The values also include the standard deviations.
[1] [2] [3] Adr
(lOOnM)
Adr +  
[1]
Adr + 
[2]
Adr + 
[3]
A-l 98±9 101±14 99± 11 96±9 104±10 102±7 95 ±7
N -l 150±15 120±12 99±10 96±8 116±9 101 ±8 88±8
U -l 120±19 93 ±12 92± 13 57±9 66±12 53±9 54± 11
[1] [2] [3] Adr
(200nM)
Adr +  
[1]
Adr +  
[2]
Adr + 
[3]
A-l 88± 12 112±13 110± 15 47 ±5 58±7 66± 11 97±9
N -l 130± 13 130± 11 99±10 84±8 108±5 91 ±7 85±8
U -l 120 ±20 95 ±20 91 ±  14 50±12 60±10 56±12 48±5
Test compound concentrations
[A-l] 1 = UOfiM 
[A-l] 2 =  IQfM 
[A-l] 3 =  35fM
[N-l] 1 =  SfiM 
[N-l] 2 =  4/*M 
[N-l] 3 =  2ixM
[U-l] 1 =  17/xM 
[U-l] 2 = 8.5/xM 
[U-l] 3 =  4.25/tM
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Table 3.5.4: Adriamycin in combination with the test compounds in DLKP-A-2B IC7.
Survival was calculated as percentage growth relative to that measured in a drug-free
control and is the mean of eight replicates. The values also include the standard deviations.
[1] [2] [3] Adr
(40nM)
Adr +  
[1]
Adr + 
[2]
Adr + 
[3]
A-l 90±7 99 ±7 125 ±6 76±4 58±4 63 ±5 93±6
N-l 72 ±4 104±7 102 ±6 81 ±7 18±1 26±2 32±2
U-l 105 ±6 107 ±7 103 ±6 79 ±5 25 ±2 33 ±4 53 ±4
[1] [2] [3] Adr
(80nM)
Adr +  Adr +  
[1] [2]
Adr +
[3]
A-l 88±11 92±9 83 ±10 26 ±5 19±3 20±4 13±2
N-l 107 ±5 107 ±5 106±3 34±3 16±2 25 ±2 15 ±2
U-l 102 ±5 99±5 99±7 32 ±4 15±1 15±1 17±1
Test compound concentrations
[A-l] 1 =  140/xM [N-l] 1 = 8juM [U-l] 1 =  17/xM
[A-l] 2 =  10fM [N-l] 2 = 4/xM [U-l] 2 =  8.5/xM
[A-l] 3 =  35/xM [N-l] 3 =  2mM [U-l] 3 = 4.25/xM
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Table 3.5.5: Adriamycin in combination with the test compounds in SK-MES-1. Survival
was calculated as percentage growth relative to that measured in a drug-free control and is
the mean of eight replicates. The values also include the standard deviations.
[1] [2] [3] Adr
(5nM)
Adr + 
[1]
Adr + 
[2]
Adr +  
[3]
A -l 74 ±5 88±4 98 ±5 100±5 73 ±4 85 ±5 94±6
N-l 94±4 99±7 100±8 103 ±6 87±4 92±5 98±6
U -l 98±5 100±5 100±7 102±5 89±6 100±5 94±6
[1] [2] [3] Adr
(lOnM)
Adr +  
[1]
Adr + 
[2]
Adr +  
[3]
A -l 73 ±3 86±5 93 ±5 93 ±6 69±3 82±5 87±5
N -l 91 ±6 95 ±4 94 ±4 91 ±8 69±3 70 ±4 89±4
U -l 98±8 101 ± 4  101±6 93 ± 7 61 ±4 80±5 88±6
Test compound concentrations
[A-l] 1 = 140/iM [N-l] 1 = 8/xM [U-l] 1 = 17/xM
[A-l] 2 = 70/xM [N-l] 2 =  4/tM [U-l] 2 = 8.5/tM
[A-l] 3 = 35/xM [N-l] 3 =  2/xM [U-l] 3 = 4.25/xM
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Table 3.5.6: Adriamycin in combination with the test compounds in SK-MES-l/Adr.
Survival was calculated as percentage growth relative to that measured in a drug-free
control and is the mean of eight replicates. The values also include the standard deviations.
[1] [2] [3] Adr
(200nM)
Adr + 
[1]
Adr + 
[2]
Adr + 
[3]
A-l 74±6 88±8 95 ± 7 97±7 77±5 92±8 98±9
N-l 80±13 101 ±12 103 ±10 104± 13 82±8 103± 10 97± 13
U-l 102±14 104±10 103 ±10 97±8 94±8 96±8 99± 13
[1] [2] [3] Adr
(400nM)
Adr + 
[1]
Adr +  
[2]
Adr + 
[3]
A-l 71±7 85 ±6 92±7 93 ±7 85 ± 9 101 ±6 109±7
N-l 73±8 94±10 98± 11 90±11 65 ±7 87 ±10 85± 11
U-l 92±9 95 ±10 99±10 89± 12 86± 10 89± 10 85 ±15
Test compound concentrations
[A-l] 1 = UQ/M 
[A-l] 2 =  lOpM 
[A-l] 3 =  35fxM
[N-l] 1 =  8/xM 
[N-l] 2 = 4 /jlM  
[N-l] 3 =  2/xM
[U-l] 1 = 17/xM 
[U-l] 2 =  8.5/nM 
[U-l] 3 = 4.25/tM
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Table 3.5.7: Adriamycin in combination with the test compounds in SK-MES-l/Adr 
mdrl ribozyme #4. Survival was calculated as percentage growth relative to that measured 
in a drug-free control and is the mean of eight replicates. The values also include the 
standard deviations.
[1] [2] [3] Adr
(20nM)
Adr + 
[1]
Adr + 
[2]
Adr + 
[3]
A-l 77 ±7 81±8 91±8 87±8 67±6 77±6 85 ±7
N-l 82 ±9 86±9 95 ±6 97 ±7 82±8 85 ±5 90±13
U-l 97±8 99±9 100±6 96±8 86±8 88±7 90±9
[1] [2] [3] Adr
(40nM)
Adr + 
[1]
Adr + 
[2]
Adr + 
[3]
A-l 77±4 85 ±6 97±7 98 ±12 74±6 82±6 93±9
N-l 84 ± 7 87±9 96 ±7 94 ±7 79±7 83 ±6 88±8
U-l 94±14 96±5 100±10 93 ±7 87±7 87±5 87±6
Test compound concentrations
[A-l] 1 =  140/xM 
[A-l] 2 = 70/iM 
[A-l] 3 =  35piM
[N-l] 1 =  8/xM 
[N-l] 2 =  4mM 
[N-l] 3 =  2/tM
[U-l] 1 = llfxM 
[U-l] 2 = 8.5/iM 
[U-l] 3 = 4.25/iM
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3.6 Drug Pulse / Scheduling Assays
There are a number of non-chemotherapeutic drugs which enhance chemotherapeutic 
cytotoxicity by mechanisms other than the reversal of drug resistance. However none of 
these are in common clinical use. Thus, the need to test new non-chemotherapeutic drugs 
which enhances the cytotoxicity of chemotherapeutic drugs is needed more than ever.
The results of the previous section (Section 3.5) described the effect of combining five test 
compounds with adriamycin. Three of these compounds were found to enhance the 
toxicity of adriamycin in three of seven cell lines assayed. However, due to the nature of 
the assay, which is an excellent assay for screening test compounds, no information could 
be derived about the mechanism of action of the active test compounds. To investigate the 
synergistic toxic effect of N-l, 0-1 and U -l, an assay was developed to analyse how 
synergism was affected when cells were exposed to the test compounds at different times 
relative to adriamycin exposure (see Section 2.7.4). Briefly, cells were set up in 96-well 
plates and the following day, pulse treated with a chemotherapeutic drug for 2 hours, the 
drug was then removed and the cells washed twice in PBS, they were then exposed to a 
test compound for various time periods.
Initial experiments in DLKP demonstrated that there was a synergistic effect when DLKP 
was exposed to N-l or U-l during the first 24 hour time period after adriamycin exposure 
(Table 3.6.1). No synergism was observed when DLKP was exposed to the test 
compounds from 24 to 48 hours, 48 to 72 hours or from 72 to 96 hours.
Following on from these experiments a number of other test compounds were also 
assayed. These assays were performed on DLKP-SQ, which is a clone derived form 
DLKP (McBride, 1995). DLKP-SQ was used because it was a clonal population and 
therefore could also be used for subsequent flow cytometric analysis. The results of these 
assays are given in Table 3.6.2. N-l, 0-1 and U-l exhibited a synergistic effect during the 
first 24 hour period after a 2 hour pulse exposure to 1/xM adriamycin. The test compounds
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A -l, 1-1 and U-2 had no effect. BSO showed an additive toxic effect with adriamycin but 
verapamil and cyclosporin A had no significant effect when added over this period.
Previous experiments demonstrated that the test compounds N-l, 0-1 and U-l were 
synergistic with adriamycin. These test compounds were also assayed using vincristine 
(Table 3.6.3) and 5-fluorouracil (Table 3.6.4). The test compounds showed a strong 
synergism in combination with vincristine, with an increase of 50% in cytotoxicity when 
N-l was used. BSO was also used in combination with vincristine and there seems to be 
an enhancement of toxicity but this effect may be due to the additive toxicity of BSO. 
Combinations of the test compounds with 5-fluorouracil did not exert any synergistic 
cytotoxic effect.
In order to determine if pre-treatment of DLKP-SQ with the test compounds enhanced 
toxicity. Cells were pre-treated for 24 hours before pulse exposure to adriamycin. 
However, there was no enhanced cytotoxic effect with any test compound studied (Table
3.6.5).
Because treatment with N-l, 0-1 or U-l only worked during the first 24 hours after 
adriamycin treatment, the time period for exposure to a test compound was decreased to 
10 hours. Using this time period N-l exposure was assayed during adriamycin exposure 
and for the 10 hour periods after different adriamycin concentration pulse exposures 
(Table 3.6.6). The assay demonstrated that the greatest effect was observed during the first 
10 hour period after adriamycin exposure (Table 3.6.6). No synergistic effect was 
observed when N-l was added during adriamycin exposure.
Since the active test compounds exerted their synergistic effect during the first 24 hours 
after drug removal, cycloheximide (a protein synthesis inhibitor) and actinomycin D (an 
inhibitor of transcription and translation) were used to try and block the synergistic effect. 
Using a relatively non-toxic level of cycloheximide (75 % cell survival) did not prevent the 
toxic effect of U-l (Table 3.6.7). Actinomycin D in combination with U-l after 
adriamycin exposure did not prevent the toxic effect of U-l (Table 3.6.8).
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The above results demonstrate that the active test compounds, N-l, 0-1 and U-l exert 
their synergistic cytotoxic effect during the first 24 hours post-treatment with adriamycin 
or vincristine but not 5-fluorouracil. Pretreatment with the test compounds for 24 hours 
has no enhanced toxic effect. Co-treatment of U-l with cycloheximide or actinomycin D 
did not prevent the synergistic effect of U-l.
Table 3.6.1: Effect of exposing DLKP cells to 1/xM adriamycin for 2 hours and then treating with 
a test compound (TC) for 24 hour periods from when adriamycin was removed. Survival was 
calculated as percentage growth relative to that measured in a drug-free control and is the mean of 
eight replicates. The values also include the standard deviations.
Control TC
0-24hr
Adr
(1 iM)
Adr+TC
0-24hr
Adr +TC  
24-48hr
Adr +TC  
48-72hr
Adr+TC
72-96hr
N -l
28/xM
100±8 91 ±14 51±6 33 ±4 53 ±8 53 ±7 53 ±4
U -l
140/xM
100±11 90±9 55 ±7 36 ±7 59 ±16 58 ±16 55 ±10
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Table 3.6.2: DLKP-SQ pulse treated with 1/xM adriamycin for 2 hours and then treating 
with a test compound (TC) from when 1/xM adriamycin was removed for 24 hours and 
from 24 to 48 hours after drug removal. Survival was calculated as percentage growth 
relative to that measured in a drug-free control and is the mean of eight replicates. The 
values also include the standard deviations.
Control TC
0-24hrs
TC
24-48hr
Adr (1/iM) Adr +TC  
0-24hr
Adr +TC  
24-48hr
A - l 200/iM 100 ±  15 80 ±12 72 ±10 45 ±6 45 ±6 44±5
BSO 900/xM 100±6 57 ±5 73 ±7 47 ±5 18 ±5 33 ±6
CysA
0.2/ig/ml
100±10 90±8 81 ±9 52 ±6 45 ±7 47 ±5
1-1 60/xM 100± 17 91 ±15 92±14 52 ±9 62 ±10 53 ±7
N -l 28/iM 100± 19 106 ±21 93 ±17 46 ±7 29 ±4 40±5
0-1 130/iM 100±12 109±16 107±7 56 ±9 37 ±7 54± 14
U-l 140/tM 100±13 88 ±12 81 ±8 46±3 30±2 45 ±3
U-2 1/xM 100±16 105 ±11 77 ±9 44±5 39±6 41 ±7
Yer 1/xM 100±12 113 ±9 115 ±9 53 ±8 46±6 48 ±5
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Table 3.6.3: Effect of exposing cells to 60nM Vincristine for 2 hours and then treating 
with various compounds (TC) from when vincristine was removed, for 24 hours and from 
24 to 48 hours after vincristine removal. Survival was calculated as percentage growth 
relative to that measured in a drug-free control and is the mean of eight replicates. The 
values also include the standard deviations.
Control TC
0-24hrs
TC
24-48hr
Vcr
(60nM)
Vcr+TC
0-24hr
Vcr+TC
24-48hr
BSO 900/xM 100±6 80±5 91 ± 5 53±5 19±2 39±6
N-l 28/iM 100±8 105 ± 7 107 ± 8 67 ± 5 19±2 66±6
0-1 130/xM 100±8 102±7 104± 13 68±  12 30±5 77 ±10
U-l 140/xM 100±11 101 ±13 98±  11 53 ± 7 17±3 48±8
Table 3.6.4: Effect of exposing cells to 190/xM 5-Fluorouracil for 2 hours and then 
treating with a compound (TC) from when 5-Fluorouracil was removed, for 24 hours and 
from 24 to 48 hours after 5-fluorouracil removal. Survival was calculated as percentage 
growth relative to that measured in a drug-free control and is the mean of eight replicates. 
The values also include the standard deviations.
Control TC
0-24hrs
TC
24-48hr
5-FU
(190/tM)
FU+TC
0-24hr
FU+TC 
24-48hr
A-l 200(M 100±12 101 ±  14 91 ±  15 109± 13 100±15 87 ±12
N-l 28/xM 100 ±20 104±17 91 ±21 99±21 91 ±12 98±  16
U-l 140/iM 100±14 93 ± 9 76±  11 107±8 88±10 69±10
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Table 3.6.5: Effect of pre-treating DLKP-SQ before pulse treating with l^M adriamycin (Adr)
for 2 hours. DLKP-SQ was exposed to a test compound for various time periods including 24 
hours before drug exposure (-24 to 0), 24 hours before and after adriamycin treatment (-24 to 24) 
and for 24 hours after adriamycin treatment (0 to 24). All concentrations of test compounds used 
were less than 10% toxic. Survival was calculated as percentage growth relative to that measured 
in a drug-free control and is the mean of eight replicates. The values also include the standard 
deviations.
Adr (-24 to 0) (-24 to 24) (0 to 24)
U-l 140/*M 71 ± 6 68±8 33 ± 4 35 ± 4
N-l 2&tM 75 ± 7 75 ± 9 41±4 38±6
A-l 200/tM 86±8 78±7 74±12 93 ±14
Table 3.6.6: Effect of treating DLKP-SQ with N-l during adriamycin exposure and for shorter
time periods (10 hours) after 2 hours exposure to four concentrations of adriamycin. The table 
shows the effect of 28/xM N-l alone, adriamycin at various concentrations alone and adriamycin at 
the various concentrations in combination with N-l during adriamycin exposure, for 10 hours after 
adriamycin exposure (0 - 10) and from 10 hours to 20 hours (10 - 20)Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight 
replicates. The values also include the standard deviations.
[Adr] N-l Adr During Adr 
exposure
0 -1 0 1 0 -2 0
0.25/xM 90±12 88±  10 87±8 96±14 102± 13
0.5/iM 76±  11 74±10 63±8 65 ± 9
1/xM 94 ±13 30±6 34±5 22 ± 4 29 ± 4
2/xM 15 ± 3 13±3 6±2 6±1
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Table 3.6.7: Effect of 50ng/ml cycloheximide (CHX) in combination with 140/xM U-l 
after 2 hours 1/xM adriamycin exposure. Survival was calculated as percentage growth 
relative to that measured in a drug-free control and is the mean of eight replicates. The 
values also include the standard deviations.
Control 1/iM Adr
Control 100±22 56±10
U -l (0 - 24) 81 ±  14 35 ±5
CHX (0 - 24) 75 ± 6 53±13
U -l +  CHX (0-24) 62 ±10 33 ±5
Table 3.6.8: Effect of 0.5ng/ml Actinomycin D (ActD) in combination with 140 /¿M U- 
1 after 2 hours l^M adriamycin exposure. Survival was calculated as percentage growth 
relative to that measured in a drug-free control and is the mean of eight replicates. The 
values also include the standard deviations.
Control 1/tM Adr
Control 100±11 54±6
U -l (0 - 24) 79±5 32±4
ActD (0 - 24) 72±6 44±3
U-l +  ActD (0-24) 56±4 26±3
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3.7 DLKP pHaMDRl/A #2 Scheduling
Exposure of DLKP-SQ to a cytotoxic concentration of adriamycin, followed by treatment 
with a non-toxic concentration of an active test compound, results in an enhancement of 
adriamycin’s toxicity. However, no effect of the test compounds was observed in any P- 
glycoprotein expressing cell line using the standard circumvention assay. Using the 
modified assay (see Section 2.7.4) i.e. pulse treatment with adriamycin, the effect of 6 test 
compounds was assayed on DLKP pHaMDRl/A #2.
DLKP pHaMDRl/A ft2 was pulse treated with adriamycin and exposed to 6 test 
compounds for 24 hour periods (Table 3.7.1). When non-toxic levels of test compound 
were used after adriamycin exposure there was no enhanced toxicity compared to 
adriamycin alone . No synergistic effect with adriamycin was observed with any of the six 
test compounds assayed e.g. U-l exposure did not enhance the toxicity of 1/xM 
adriamycin compared to IpM adriamycin exposure alone. A-l, 1-1, 0-1 and U-2 did 
show some increased toxicity in combination with adriamycin but this was probably due to 
the additive toxicity of the verapamil and the test compounds.
Because the test compounds had displayed no synergy with adriamycin in P-glycoprotein 
positive cells, verapamil was used in combination with the test compounds. Verapamil 
inhibits P-glycoprotein associated, energy-dependent drug-efflux in MDR cells, apparently 
by blocking the binding of drugs to P-glycoprotein (Ford, 1995). Using the test 
compounds and verapamil in combination with adriamycin, there was no restoration of the 
synergistic effect of the test compounds observed in DLKP (Table 3.7.2).
The above experiment was repeated using cyclosporin A instead of verapamil, in 
combination with U -l (Table 3.7.3). Cyclosporin A is an immunosuppressive peptide 
which antagonises MDR through the inhibition of P-glycoprotein. At the lower 
concentration of adriamycin (0.25/zM and 0.5/xM) there was no enhanced toxicity with 
cyclosporin A or with cyclosporin A plus U-l in combination. At 1/xM and 2/xM
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adriamycin concentrations, cyclosporin A enhanced the toxicity of adriamycin. However, 
U-l or U-l plus cyclosporin did not enhance adriamycin toxicity.
These results show that the synergistic toxic effect observed between U-l and adriamycin 
in DLKP was not restored in a DLKP pHaMDRl/A #2 when inhibitors of P-glycoprotein 
was used.
Table 3.7.1: DLKP pHaMDRl/A #2 pulse treated with 1/xM adriamycin for 2 hours and 
treated with a test compound (TC) for 24 hour periods after adriamycin exposure. The 
table shows the drug-free control, test compound controls for 0-24 hours and 24-48 hours 
exposure, adriamycin alone and adriamycin in combination with a test compound for 0-24 
hours and 24-48 hours. Survival was calculated as percentage growth relative to that 
measured in a drug-free control and is the mean of eight replicates. The values also 
include the standard deviations.
TC Control TC
0-24hrs
TC
24-48hr
Adr
(1/tM)
Adr+TC
0-24hr
Adr+TC
24-48hr
A-l 200/xM 100±15 62 ±16 83 ±15 48±5 33±6 46±8
1-1 60/xM 100±16 70±9 103± 11 48±7 43±6 48±8
N-l 28/xM 100±28 130±25 87 ±21 35 ±4 51±5 30±4
0-1 130/tM 100±11 88± 17 82 ±7 37±4 30±5 28±2
U-l 140/iM 100 ±30 102±14 82 ±23 34±3 41 ±6 31 ±4
U-2 I f M 100±12 58±9 75±11 42±6 22±3 36±4
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Table 3.7.2: Effect of combining test compounds with verapamil after 2 hours 1/xM 
adriamycin (Adr) exposure pulse exposure in DLKP pHaMDRl/A #2. The table shows 
the drug-free control, the test compound (TC) alone for 24 hours, verapamil (Ver) for 24 
hours, adriamycin alone, adriamycin in combination with verapamil and adriamycin in 
combination with verapamil plus a test compound for 24 hours. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight 
replicates. The values also include the standard deviations.
Control TC
0-24hr
Ver 0-24 
1/iM
1/tM Adr Adr+ Ver Adr+Ver
+TC
A-l
200/tM
100±15 62 ±16 67±13 48±5 32±6 39±4
l - l
60/tM
100±16 70±9 74 ±21 48±7 39±6 42 ±5
N -l 28/iM 100±28 130±25 112±9 35 ±4 43 ±6 47 ±5
0-1
130/iM
100±11 88±17 69±8 37±4 22 ±4 21 ±3
U -l
140/*M
100±30 102± 19 99± 18 34±3 36±5 38±7
U-2
IfiM
100±12 58±9 75 ±11 42±6 30 ±4 27 ±2
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Table 3.7.3: Effect of Cyclosporin A (CysA) in combination with U-l in DLKP 
pHaMDRl/A til after 2 hours adriamycin exposure. The table shows the drug-free 
control, U-l alone for 24 hours, cyclosporin A for 24 hours, adriamycin alone, 
adriamycin in combination with CysA and adriamycin in combination with CysA plus U-l 
for 24 hours. Survival was calculated as percentage growth relative to that measured in a 
drug-free control and is the mean of eight replicates. The values also include the standard 
deviations.
[Adr] Control CysA
0.2/ig/ml
U-l
140jiM
CysA 
+ U-l
Adr Adr
+
CysA
Adr + 
CysA 
+ U-l
Adr + 
U-l
0.25 jiM 
Adr
100±14 95 ±10 83 ±  1 
3
89±8 85 ±12 88±1
3
82± 11 84±11
0.5/tM
Adr
100±15 113± 1 
9
95 ±1 
0
98± 18 102 ±2  
0
104±
13
92±12 91 ±9
l p M
Adr
100±12 88±8 83±1
4
60±9 46±6 46±6 61 ±5
2/tM
Adr
100±12 94± 19 88±1
4
52±7 19±5 19±5 51 ±3
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3.8 Cell cycle distribution
The results from Section 3.6 demonstrated that the test compounds, N-l, 0-1 and U-l 
exert their synergistic cytotoxic effect during the first 24 hours post-treatment with 
adriamycin or vincristine but not 5-fluorouracil. These experiments were performed using 
a 7 day cell growth assay. In order to investigate the role of these test compounds on 
DLKP-SQ, flow cytometric analysis was used to determine the cell cycle distribution of 
treated samples. A flow cytometer measures the amount of fluorescence from an 
individual cell. Therefore, propidium iodide (which intercalates with DNA) stained cells, 
the amount of DNA fluorescence is measured and this can be used to determine the 
position of a cell in the cell cycle.
Flow cytometric analysis was used to determine the cell cycle distribution in DLKP-SQ 
pulse treated adriamycin, vincristine or 5-fluorouracil for 2 hours and to a test compound 
(A-l, N-l or U-l) for 24 hours. Samples pulsed with a chemotherapeutic drug, followed 
by exposure to a test compound using conditions described in Section 2.8 were analysed to 
determine any effect on the cell cycle.
The effect of the test compounds N -l, U-l and A -l, on the cell cycle distribution of 
DLKP-SQ is given in Figures 3.8.1 - 3.8.3. At 0 hours, test compound was added. 
140/xM U-l treated cells showed an accumulation in the Gi peak at 10 and 13 hours with 
corresponding decrease in the G2/M peak, by 16 hours the cell cycle distribution 
resembled the normal cell cycle distribution of the control untreated sample at 0 hours 
(Figure 3.8.1). This accumulation in the Gt peak suggests a delay or an arrest in Gi 
transition into the S phase. DLKP-SQ exposed to 30/xM N-l also seemed to show an 
accumulation in the GL peak at 12 and 14 hours but by 16 hours resembled a normal cell 
cycle distribution (Figure 3.8.2). A-l exposure did not appear to affect the cell cycle 
distribution (Figure 3.8.3).
U -l in combination with 1/xM adriamycin displayed an increased accumulation in G^ 
early S phase at 4 and 8 hours (Figure 3.8.4 (a)). By 12 and 15 hours there was a delayed
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S peak evident compared to adriamycin alone (Figure 3.8.4 (b)), by 24 hours, U-l treated 
samples were accumulated in the late S and G2/M phase. N-l in combination with ljuM 
adriamycin exhibited a delayed S phase peak at 12, 14 and 16 hours (Figure 3.8.5 (a)) 
compared to adriamycin alone (Figure 3.8.5 (b)). By 19 hours, N-l treated samples were 
accumulated in the late S and G2/M phase compared to the G2/M peak in adriamycin 
alone. There seemed to be no difference in cell cycle distribution patterns of A-l plus 
adriamycin and adriamycin alone (Figure 3.8.6 (a) and 3.8.6 (b)) with no evident 
increased delay in the S phase.
The cell cycle distribution profiles of DLKP-SQ treated with 50ng/ml vincristine in 
combination with U-l are given in Figure 3.8.7 (a). From 10 to 24 hours there was a 
gradual decrease in the Gt peak an increase in the G2/M peak. In the vincristine alone 
treated sample there was an increase in the Gt peak after G2/M arrest at 18 hours with 
a large Gx peak at 24 hours (Figure 3.8.7 (b)). Vincristine and N -l in combination 
(Figure 3.8.8 (a)), displayed a similar profile to vincristine plus U -l. By 12 hours 
there was no Gt peak and an accumulation of cells in the G2/M peak, there was no Gi 
peak by 24 hours compared to vincristine alone which showed an increase in G! by 16 
hours (Figure 3.8.8 (b)). Vincristine plus A-l (Figure 3.8.9) displayed little 
difference between vincristine alone (Figure 3.8.7 (b)).
DLKP-SQ treated with 190/xM 5-fluorouracil alone or in combination with 140/xM U-l 
displayed no difference between the cell cycle distribution over time (Figure 3.8.10 and 
Figure 3.8.11).
Because of the increased Gj/S phase arrest and an increased S phase transition in DLKP- 
SQ treated with adriamycin plus N-l or U -l, increasing concentrations of adriamycin 
alone were analysed. DLKP-SQ treated with 0.5/xM adriamycin for 2 hours showed a 
decrease in the Gi peak and an accumulation in the S phase at 12 hours (Figure 3.8.12), at 
14 hours the Gj peak further decreased and there was a peak at the late S phase. By 19 
and 24 hours there was an accumulation in G2/M. 1/*M adriamycin treated samples 
showed a decrease in the Gj peak and a peak in the early S phase at 12 hours (Figure
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3.8.13). From 14 to 19 hours the S phase peak progresses through the S phase until at 
24 hours the cells accumulate at G2/M. 2/xM adriamycin treated samples displayed a 
decrease in the Gt peak and an accumulation in a peak at the early S phase by 12 
hours (Figure 3.8.14). Over time the G! peak further decreased and the S phase peak 
further progressed through the S phase. By 24 hours this peak had reached the late S 
phase.
Increasing concentrations of vincristine were analysed to investigate if increasing 
concentrations increased G2/M arrest as found when 50ng/ml plus U-l or N-l were 
used in combination. 25ng/ml vincristine for 2 hours caused a decrease in the Gt peak 
and an accumulation in G2/M by 12 hours (Figure 3.8.15). The Gi peak gradually 
increased and the G2 peak decreased at 14 ,16 and 19 hours. There seemed to be a 
normal cell cycle distribution by 24 hours. DLKP-SQ exposed to 50ng/ml (60nM) 
vincristine decreased the Gi peak at 12 and 14 hours and cells accumulated in the 
G2/M phase (Figure 3.8.16). The Gt peak began to increase and the G2/M peak 
decrease at 19 and 24 hours. lOOng/ml vincristine treated cells were delayed longer in 
the G2/M phase with cells accumulated in G2/M from 12 hours until 19 hours, and 
there was a slight increase in the Gi peak at 24 hours (Figure 3.8.17).
These results showed that using an active test compound (U-l or N-l) after 
adriamycin treatment caused an increased Gj/S phase arrest and a delayed S phase 
transition compared to adriamycin alone. Increasing concentrations of adriamycin also 
exhibited this effect. Vincristine in combination with U-l or N -l showed an increased 
G2/M arrest compared to vincristine alone. This G2/M arrest was further delayed when 
increasing concentrations of vincristine was used. DLKP-SQ treated with 190/xM 5- 
fluorouracil alone or in combination with 140/iM U-l displayed no difference between the 
cell cycle distribution over time.
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Figure 3.8.1: Cell cycle distribution of DLKP-SQ treated with 140/iM U-l for 24 hours. The graphs
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the G: peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.2: Cell cycle distribution of DLKP-SQ treated witli 30/tM N-l for 24 hours. The graphs
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the Gt peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.3: Cell cycle distribution of DLKP-SQ treated with 200/tM A-l for 24 hours. The graphs
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the G! peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating tfieir DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.4 (a): Cell cycle distribution of DLKP-SQ treated 1/xM adriamycin for 2 hours plus 140^M U-l 
for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 
individual cells taken at different time points. The x-axis represents relative DNA fluorescence and the y-axis 
represents cell number. The left-hand peak is the Gt peak and represents diploid cells. The peak on the right- 
hand is the G2/M peak and represents tetraploid cells before cytokinesis of mitosis. Cells between the two 
peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing amount of 
DNA fluoresence.
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Figure 3.8.4 (b): Cell cycle distribution of DLKP-SQ treated with l^M  adriamycin for 2 hours. The graphs 
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the Gt peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.5 (a): Cell cycle distribution of DLKP-SQ treated 1/iM adriamycin for 2 hours plus 30/iM N-l 
for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 
individual cells taken at different time points. The x-axis represents relative DNA fluorescence and die y-axis 
represents cell number. The left-hand peak is the G, peak and represents diploid cells. The peak on the right- 
hand is the G2/M peak and represents tetraploid cells before cytokinesis of mitosis, fluoresence. Cells between 
the two peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing 
amount of DNA fluoresence.
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Figure 3.8.5 (b): Cell cycle distribution of DLKP-SQ treated with 1/*M adriamycin for 2 hours. The graphs 
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the Gt peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.6 (a): Cell cycle distribution of DLKP-SQ treated 1/tM adriamycin for 2 hours plus 200/iM A-l 
for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 
individual cells taken at different time points. The x-axis represents relative DNA fluorescence and the y-axis 
represents cell number. The left-hand peak is the Gj peak and represents diploid cells. The peak on the right- 
hand is the G2/M peak and represents tetraploid cells before cytokinesis of mitosis. Cells between the two 
peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing amount of 
DNA fluoresence.
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Figure 3.8.6 (b): Cell cycle distribution of DLKP-SQ treated with 1/xM adriamycin for 2 hours. The graphs 
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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F igure3.8.7 (a): Cell cycle distribution of DLKP-SQ treated with 50ng/ml vincristine for 2 hours plus 
140/iM U -l for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 
000 individual cells taken at different time points. The x-axis represents relative DNA fluorescence and the y- 
axis represents cell number. The left-hand peak is die Gj peak and represents diploid cells. The peak on the 
right-hand is the G2/M peak and represents tetraploid cells before cytokinesis of mitosis. Cells between the 
two peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing amount of 
DNA fluoresence.
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Figure 3.8.7 (b): Cell cycle distribution of DLKP-SQ treated with 50ng/ml vincristine for 2 hours. The 
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating dieir DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.8 (a): Cell cycle distribution of DLKP-SQ treated with 50ng/ml vincristine for 2 hours plus 
30/tM N-l for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 
000 individual cells taken at different time points. The x-axis represents relative DNA fluorescence and the y- 
axis represents cell number. The left-hand peak is the Gi peak and represents diploid cells. The peak on the 
right-hand is die G2/M peak and represents tetraploid cells before cytokinesis of mitosis. Cells between the 
two peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing amount of 
DNA fluoresence.
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Figure 3.8.8 (b): Cell cycle distribution of DLKP-SQ treated with 50ng/ml vincristine for 2 hours. The 
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.9: Cell cycle distribution of DLKP-SQ treated with 50ng/ml vincristine for 2 hours plus
200/xM A-l for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 
000 individual cells taken at different time points. The x-axis represents relative DNA fluorescence and the y- 
axis represents cell number. The left-hand peak is the Gt peak and represents diploid cells. The peak on the 
right-hand is the G2/M peak and represents tetraploid cells before cytokinesis of mitosis. Cells between the 
two peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing amount of 
DNA fluoresence.
170
U 3 :2 0 / '5 /0 0 2 \F L 2 - A \F L l- A r e a  
5 - F l u o r o u r c i l  
T = 0  h r s
QD<M
V3 s2 0 /5 /0 0 3 N F L 2 -A N F L 1- A r e a
T = 1 0 h r s
,L A . [M
0  2 0 0  4 0 0  6 0 0  300
U 3: 2 0 /5 /0 0 4 \F L 2 - A \F L 1- A r e a
1000
U3:20/-5/005-vFL2-A\FL 1 -Area
16 h r s
iMPW*
2 0 0  4 0 0  6 0 0  300  1000
U 3 :2 0 /5 /0 0 7 v F L 2 -A \F L l-A re a
T = 2 4  h r s
§1tu
Figure 3.8.10: Cell cycle distribution of DLKP-SQ treated with 190/xM 5-fluorouracil for 2 hours. The
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the G! peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.11: Cell cycle distribution of DLKP-SQ treated with 190/iM 5-fluorouracil for 2 hours plus
140/iM U-l for 24 hours. The graphs represent the DNA fluorescence as measured by flow cytometry of 10, 
000 individual cells taken at different time points. The x-axis represents relative DNA fluorescence and the y- 
axis represents cell number. The left-hand peak is the Gi peak and represents diploid cells. The peak on the 
right-hand is the G2/M peak and represents tetraploid cells before cytokinesis of mitosis. Cells between the 
two peaks are in the S phase, i.e. cells which are replicating their DNA and thus have an increasing amount of 
DNA fluoresence.
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Figure 3.8.12: Cell cycle distribution of DLKP-SQ treated with 0.5/xM adriamycin for 2 hours. The
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.13: Cell cycle distribution of DLKP-SQ treated with 1/tM adriamycin for 2 hours. The graphs
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is the peak and represents diploid cells. The peak on the right-hand is die G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.14: Cell cycle distribution of DLKP-SQ treated with 2/xM adriamycin for 2 hours. The graphs
represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at different 
time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. The left- 
hand peak is die Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak and 
represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in die S phase, i.e. 
cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.15: Cell cycle distribution of DLKP-SQ treated with. 25ng/ml vincristine for 2 hours. The
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.16: Cell cycle distribution of DLKP-SQ treated with 50ng/ml vincristine for 2 hours. The
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the Gx peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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Figure 3.8.17: Cell cycle distribution of DLKP-SQ treated with lOOng/ml vincristine for 2 hours. The
graphs represent the DNA fluorescence as measured by flow cytometry of 10, 000 individual cells taken at 
different time points. The x-axis represents relative DNA fluorescence and the y-axis represents cell number. 
The left-hand peak is the Gi peak and represents diploid cells. The peak on the right-hand is the G2/M peak 
and represents tetraploid cells before cytokinesis of mitosis. Cells between the two peaks are in the S phase, 
i.e. cells which are replicating their DNA and thus have an increasing amount of DNA fluoresence.
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3.9 Time-Lapse Videomicroscopy
The results from Section 3.6 demonstrated that the test compounds, N -l, 0-1 and U-l 
exert their synergistic cytotoxic effect during the first 24 hours post-treatment with 
adriamycin or vincristine but not 5-fluorouracil. Flow cytometric analysis (Section 3.8) 
showed that there was a difference in cell cycle distribution during the first 24 hours after 
pulse exposure between adriamycin and adriamycin plus U-l or N-l and between 
vincristine and vincristine plus U-l or N-l. Therefore, while there was an increased 
cytotoxicity in cells were exposed to N-l, 0-1 or U-l after adriamycin or vincristine 
exposure, and there was a difference in cell cycle distribution, there was no indication as 
to when the cells undergo cell death.
Time-lapse videomicroscopy permits the observation of the events which happen to cells 
following drug treatment. With this technique it was possible to follow in real time events 
such as cell rounding for mitosis and apoptosis. Mitosis was characterised by the rounding 
up of adherent cells followed by cytokinesis and reattachment of daughter cells to the 
surface of the flask. Cell death was classified as apoptotic on the basis of morphological 
events starting with rounding up of adherent cells, subsequent cell shrinkage and/or break­
up into apoptotic bodies.
Using time-lapse videomicroscopy the kinetics of mitosis and apoptosis was followed in 
DLKP-SQ treated with U-l alone for 24 hours, 2 hours pulse exposure to increasing 
concentrations of adriamycin, adriamycin and U-l in combination, vincristine and 
vincristine plus U-l in combination. Experiments were performed in 25cm2 flasks and 
recording was started after cells were exposed to chemotherapeutic drug for two hours and 
washed twice with PBS (see Section 2.9).
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Figure 3.9 .1 : DLKP-SQ exposed to 140/iM U -l for 24 hours and compared to the mitotic
events in a drug-free control. Cell death was classified as apoptotic on the basis of morphological 
events starting with rounding up of adherent cells, subsequent cell shrinkage and/or break-up into 
apoptotic bodies. Cell death and mitosis were scored at the time when rounding up o f the cells first 
occurred. Typically 100 cells in the microscope field were followed.
Treatment of DLKP-SQ with 140/xM U-l for 24 hours initially decreased the rate of 
mitosis (Figure 3.9.3). After 3 hours the rate increased to a rate similar to the drug free 
control. There was a low level of apoptosis during the first 6 hours of exposure.
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Figure 3.9.2: Adriamycin alone and in combination with U -l. Cell death was classified as
apoptotic on the basis of morphological events starting with rounding up of adherent cells, 
subsequent cell shrinkage and/or break-up into apoptotic bodies. Cell death and mitosis were 
scored at the time when rounding up of the cells first occurred. Typically 100 cells in the 
microscope field were followed.
Time (Hours)
The apoptotic rate in l^M treated adriamycin was low during the first 24 hours, the rate 
subsequently increased after 24 until 96 hours (Figure 3.9.2). The rate of apoptosis in 
1/xM treated samples exposed to 140/xM U-l for 24 hours followed a similar pattern to 
IpM adriamycin alone i.e. the apoptotic rate was low during the first 24 hours and the rate 
increased after 24 until 96 hours. No mitotic events was observed in l^M adriamycin or 
1/xM adriamycin plus 140/xM U-l treated samples.
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Figure 3.9.3: Rate of apoptosis and mitosis in vincristine treated and vincristine plus U-l treated
DLKP-SQ. Cell death was classified as apoptotic on the basis of morphological events starting 
with rounding up of adherent cells, subsequent cell shrinkage and/or break-up into apoptotic 
bodies. Cell death and mitosis were scored at the time when rounding up of the cells first 
occurred. Typically 100 cells in the microscope field were followed.
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The rate of mitosis in 60nM vincristine treated DLKP-SQ cells was low up to 12 hours 
after exposure, the rate increased from 12 to 24 hours and then slowed from 24 to 48 
hours (Figure 3.9.3). The rate of apoptosis steadily increased during the first 24 hours 
after exposure. After 24 hours there were no apoptotic events. In contrast to 60nM 
vincristine treated cells alone, subsequent exposure to 140^M U-l resulted in an abolition 
of mitosis, with some mitosis occurring 36 hours after vincristine was removed. The rate 
of apoptosis increased dramatically during the first 12 hours of U-l exposure, this rate 
decreased from 12 to 36 hours. No apoptosis was observed after 36 hours. U-l alone 
induced a low level of apoptosis (Figure 3.9.1).
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Figure 3.9.4: The rate of mitosis and apoptosis in 0.5/xM adriamycin treated DLKP-SQ hours
and compared to the mitotic events in a drug-free control. Cell death was classified as apoptotic on 
the basis of morphological events starting with rounding up of adherent cells, subsequent cell 
shrinkage and/or break-up into apoptotic bodies. Cell death and mitosis were scored at the time 
when rounding up of the cells first occurred. Typically 100 cells in the microscope field were 
followed.
The rate of mitosis and apoptosis in 0.5^M adriamycin treated DLKP-SQ is given in 
Figure 3.9.4.
The rate of mitosis slowed during the initial 24 hours after exposure to 0.5piM adriamycin. 
After this time the rate of mitosis increased to that similar in the drug-free treated control. 
The rate of apoptosis increased 12 to 24 hours after adriamycin exposure and remained 
elevated until 36 hours.
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Figure 3.9.5: Kinetics of cell death in DLKP-SQ treated with increasing concentrations of
adriamycin. Cell death was classified as apoptotic on the basis of morphological events starting 
with rounding up of adherent cells, subsequent cell shrinkage and/or break-up into apoptotic 
bodies. Cell death and mitosis were scored at the time when rounding up of the cells first 
occurred. Typically 100 cells in the microscope field were followed.
Kinetics of cell death in DLKP-SQ treated with increasing concentrations of adriamycin is 
given in Figure 3.9.5. In the 0.5/nM adriamycin treated sample, the rate of apoptosis 
increased sharply 12 to 24 hours after adriamycin exposure and remained high until 36 
hours. The apoptotic rate in lptM treated adriamycin was similar to the rate for 0.5/xM 
adriamycin during the first 24 hours. After this time the rate increased dramatically until 
60 hours. 2/xM adriamycin treatment resulted in apoptosis from 18 to 48 hours after 
exposure, after this time, the rate of apoptosis increased further. No mitotic events were 
observed in 1/xM or 2fiM adriamycin treated samples.
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These results demonstrated that exposure of DLKP-SQ cells to increasing concentrations 
of adriamycin induced apoptosis predominantly 24 hours after drug removal. Mitosis was 
abolished with increasing concentrations. 140/xM U-l delayed mitosis for 12 hours and 
induced a low level of apoptosis during exposure. 1/xM Adriamycin and U-l in 
combination displayed no difference in the rate of apoptosis induced compared to 
adriamycin alone. This was surprising since the combination of adriamycin and U-l 
demonstrated increased cytotoxicity to the cells. A 2 hour exposure to 60nM vincristine 
delayed mitosis for 12 hours; the rate increased from 12 to 24 hours and then slowed from 
24 to 48 hours. The rate of apoptosis increased during the first 24 hours after exposure. 
60nM vincristine treatment and subsequent exposure to 140/nM U-l resulted in an 
increased rate of apoptosis during the first 12 hours of U-l exposure, which decreased 
from 12 to 36 hours, there were mitotic events until 12 hours after U-l removal.
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3.10 Cyclin E/CDK2 kinase activity
The adriamycin pulse exposure assays demonstrated that the enhanced cytotoxicity of 
adriamycin by N -l, 0-1 and U-l occurred during the first 24 hours after adriamycin 
removal (Section 3.7). Flow cytometric analysis (Section 3.8) also showed that by 24 
hours the cells were arrested in the G2/M phase. Previous to this arrest however was an 
increased delay in G,/S and in the S phase transition.
To understand the effect of adriamycin and adriamycin plus U-l in combination on the 
increased Gi/S delay, cyclin E/CDK2 complex kinase activity was studied. The transition 
from Gl into S is controlled by die cyclin E/CDK2 complex and this is essential for the 
cell to begin DNA replication (see Section 1.3.1). The levels of cyclin E are regulated so 
that it is only transcribed during late G, and early S phase. Very little is known about the 
substrates of cyclin E but it is thought to activate E2F and thus transcription of S phase 
genes. Once cells enter the S phase cyclin E is rapidly degraded. Therefore by 
investigating the activity of the cyclin E/CDK2 complex it would be possible to examine 
the role that adriamycin plus U-l in combination has on the increased GL arrest and 
delayed S phase transition as observed by flow cytometric analysis.
The kinase activity of the cyclin E/CDK2 complex was assayed as described in Section 
2.12. Briefly, cells were set up in 25cm flasks 4 days before the experiment, they were 
then exposed to adriamycin or drug free media for two hours, washed twice with PBS, 
and drug-free media or U-l added as appropriate. Samples were taken at various time 
points by trypsinising the cells and resuspending the resultant pellet in RIPA lysis buffer 
and stored at -80°C. The protein was quantified and 100/xg of protein was 
immunoprecipated with cyclin E (Section 2.10), the immunoprecipitated cyclin E was 
resuspended in kinase buffer, and 32P-labelled ATP and histone HI (substrate) was added. 
The reaction mixture was left at 30°C for 30 minutes and stopped by adding loading 
buffer. Aliquots were run on a 15 % acrylamide gel, the gel was dried and then exposed to 
autoradiographic film. Autoradiographs obtained during kinase assays were scanned using
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a densitometer and all bands were compared to the control (treated with drug-free media 
for 2 hours) at 0 hours, which was arbitrarily taken as 1.
The cyclin E/CDK2 kinase activity of U-l treated samples (see Figure 3.10.1) 
demonstrated that the activity increased steadily up to 19 hours and then decreased. 
Adriamycin treated samples (Figure 3.10.2) show a decrease at 0 hours, i.e. immediately 
following drug removal. The level of activity in this sample had increased at 10 hours but 
then decreased. Adriamycin plus U-l (Figure 3.10.3) demonstrated an increase at 10 
hours which then decreased steadily. A graph of the scanned autoradiographs is given in 
Table 3.10.1.
187
Table 3.10.1: Plot of the cyclin E/CDK2 kinase activity in U -l, adriamycin (Adr) and 
adriamycin plus U-l treated samples. Autoradiographs were scanned using a densitometer 
and all bands were compared to the drug free treated control at 0 hours, which was 
arbitrarily taken as 1.
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Figure 3.10.1: Cyclin E/CDK2 kinase activity in U-l treated samples. Activity was 
measured as described in Section 2.11.
Time (hours) Control (0) 10 13 16 19 24
Figure 3.10.2: Cyclin E/CDK2 kinase activity in adriamycin treated samples. Activity was 
measured as described in Section 2.11.
Time (hours) 0 10 13 16 19 24
Figure 3.10.3: Cyclin E/CDK2 kinase activity in adriamycin plus U-l treated samples. 
Activity was measured as described in Section 2.11.
Time (hours) 0 10 13 16 19 24
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3.11 Cyclin E/CDK2 protein analysis
Cyclin E/CDK2 kinase activity results (Section 3.10) demonstrated that there was an effect 
on the activity in adriamycin alone versus the adriamycin plus U-l treated samples. 
Therefore by investigating the levels of cyclin E and CDK2, it would be possible to 
examine the compare the proteins to the cyclin E/CDK2 complex kinae activity and 
investigate the role of these proteins an increased Gi arrest and delayed S phase transition.
Cyclin E and cyclin dependent kinase 2 (CDK2) protein levels were analysed using 
western blotting. Experiments were performed as described in Section 2.10. Briefly, cells 
were set up in 25cm flasks 4 days before the experiment, they were then exposed to 
adriamycin or drug free media for two hours, washed twice with PBS and drug-free media 
or U-l added as appropriate. Samples were taken at various time points by trypsinising the 
cells and resuspending the resultant pellet in RIPA lysis buffer and stored at -80°C. 
Protein quantification was performed on the samples and lOug of loaded on a 15% 
acrylamide gel. The proteins were transferred onto a nitro-cellulose membrane and equal 
sample loading was confirmed by staining the membrane. They were then incubated 
overnight with anti-cyclin E or anti-CDK2 antibodies. The membranes were then 
developed using an enchanced chemiluminesence kit.
The levels of CDK2 in the drug-free control samples seemed to increased steadily from 0 
hours to 16 hours, the level decreased at 19 hours and increased again at 24 hours (Figure 
3.11.1). CDK2 levels in U-l alone treated samples increased steadily until 13 hours but 
then decreased slowly at 16, 19 and 24 hours (Figure 3.11.2). Adriamycin treated 
samples showed an increase in levels until 10 hours, the levels decreased at 13 and 16 
hours but increased again at 19 and 24 hours (Figure 3.11.3). Adriamycin plus U-l in 
combination treated samples were similar to adriamycin alone (Figure 3.11.4). The 
samples showed an increase in levels until 13 hours, the levels decreased at 16 hours but 
increased again at 19 and 24 hours.
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At least 3 forms of endogenous cyclin E protein have been detected in rat and human 
fibroblasts (Ohtsubo and Roberts, 1993) and HeLa cells (Dulic et al., 1992). A 50kDa 
form is maximally expressed during late Gj and early S phase of the cell cycle while a 40 
kDa is thought to result from proteolytic degradation of over-expressed cyclin E. The 
higher molecular weight form (55kDa) has been observed in G2 and early to mid-Gt.
The levels of cyclin E in drug-free control samples displayed an increase in levels of the 
higher molecular weight cyclin E at 10 hours with a large > 67kDa band was gone by 13 
hours. A band at >49kDa increased at 10 hours and remained elevated at 13 and 16 
hours. A > 37.5kDa band was observed at 0 hours. This band disappeared at 10 hours and 
the levels increased at 13 and 16 hours (Figure 3.11.5).
In U-l samples, levels of the higher molecular weight cyclin E increased from 10 -13 
hours, decreased by 16 hours and there was an increase in the 37.5kDa band from 16 
hours (Figure3.11.6).
In the adriamycin treated samples the level of the higher molecular weight cyclin E 
(67kDa) increased at 10 hours, decreased slightly at 13 hours and then disappeared until 
24 hours. The lower molecular weight (=37.5kDa) band disappeared at 10 hours but then 
reappeared at 13 hours. The level of the band increased at 16 and 19 hours and decreased 
at 24 hours (Figure 3.11.7). The =49kDa band increased from 0 hours to 13 hours and 
then decreased sharply. The levels increased again at 19 and 24 hours.
Cyclin E levels in adriamycin plus U-l samples were similar to adriamycin alone but at 
13 hours the high molecular weight band appears stronger while the <37.5kDa band has 
decreased compared to adriamycin (Figure 3.11.8). The level of the higher molecular 
weight cyclin E (67kDa) increased at 10 to 13 hours then disappeared until 24 hours. The 
lower molecular weight (=37.5kDa) band remained at a low level until 16 and 19 hours 
and decreased at 24 hours. The =49kDa band increased from 0 hours to 13 hours and 
decreased sharply after 13 hours and increased again at 19 and 24 hours.
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The above results show that the levels of CDK2 varied over a 24 hour period in untreated 
DLKP-SQ cells and cells treated with U-l, adriamycin and the adriamycin/U-1 
combination. There seems to be no correlation between CDK2 levels and the cell cycle 
distribution. Cyclin E protein levels seem to indicate that an increased amount of the 
higher molecular weight form represents cells in Gi/Gj arrest, the form around 49 kDa 
seems to represent active cyclin E, while the lower molecular weight form (37.5 kDa) 
represents cells in late S and G2/M.
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Figure 3.11.1: CDK2 protein levels in control, drug-free treated samples. Western
blotting was performed as described in Section 2.10.
Time (hours) Control (0) 10 13 16 19 24
Figure 3.11.2: CDK2 protein levels in 140/xM U-l treated samples. Western blotting was 
performed as described in Section 2.10.
Time (hours) Control (0) 10 13 16 19 24
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Figure 3.11.3: CDK2 protein levels in IfiM adriamycin treated samples. Western blotting 
was performed as described in Section 2.10.
Time (hours) Control (0) 0 10 13 16 19 24
Figure 3.11.4: CDK2 protein levels in lpcM adriamycin plus 140^M treated samples. 
Western blotting was performed as described in Section 2.10.
Time (hours) Control (0) 0 10 13 16 19 24
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Figure 3.11.5: Cyclin E protein levels in control, drug-free treated samples.
Western blotting was performed as described in Section 2.10.
Time (hours) Control (0) 10 13 16 19 24
6 7 -  
4 9 -
3 7 .5 -
Flgure 3.11.6: Cyclin E protein levels in 140/nM U-l treated samples. Western blotting 
was performed as described in Section 2.10.
Time (hours) Control (0) 10 13 16 19 24
6 7 -
4 9 -
3 7 .5 -
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Figure 3.11.7: Cyclin E protein levels in 1/^ M adriamycin treated samples. Western 
blotting was performed as described in Section 2.10.
Time (hours) Control (0) 0 10 13 16 19 24
6 7 -
4 9 -
3 7 .5 -
Flgure 3.11.8: Cyclin E protein levels in 1/xM adriamycin plus 140jiM treated samples. 
Western blotting was performed as described in Section 2.10.
Time (hours)
6 7 -
4 9 -
37.5-
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Discussion
The effect of combinations of different drugs on toxicity to cancer cells in vitro was 
examined in this thesis. Combinations of existing anticancer agents were first 
analysed. Combinations with the glutathione depleting agent, BSO, with and without 
verapamil were then studied. Cellular models transfected with the MDR1 gene and an 
anti-MDRl ribozyme were also developed. The main part of the thesis concerned 
combinations of a known anticancer agent with one of a series of coded non-toxic 
compounds known to be safe for human use. These were examined in a number of 
cell lines and their mechanism of action further explored.
4.1 Chemotherapeutic drug combination
The use of multiple drugs in combination is a standard treatment for cancer patients (Patel 
and Rideout, 1992). Clinical studies have shown that drug combinations generally produce 
higher response rates than those produced by single agents alone. Agents active for a 
certain tumour type are first identified and the use of these active drugs in combination 
then depends on the predicted toxicity of the drug. This is to prevent overlapping of 
toxicity e.g. the relatively low toxicity of vincristine for normal marrow means it is often 
included in combination chemotherapy with other myelosuppressive agents (Pratt et al., 
1994). However, it is likely that for a given patient, some of the drugs in a combination 
are not effective and may be antagonistic to the effective agents.
This series of experiments was performed to investigate the efficacy of combining two 
common chemotherapeutic drugs at three different ratios and to investigate if the 
combination was synergistic, additive or antagonistic in DLKP and DLKP-A. DLKP is a 
human lung carcinoma cell line which is sensitive to chemotherapeutic drugs and DLKP-A 
is a MDR derivative of DLKP which overexpresses P-glycoprotein (Redmond, 1991; 
Cleary, 1995).
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Adriamycin and carboplatin used in combination in DLKP (Table 3.1.1) were antagonistic 
at respective ratios of 1:10 and 1:100. The ratio of adriamycin to carboplatin at 1:40 
displayed some additive effects at high concentrations of the combination. Combinations 
of adriamycin and carboplatin in DLKP-A (Table 3.1.2) were similar to combinations in 
DLKP. The combination in a 1:40 ratio in DLKP-A was additive although some 
concentrations did show synergy, while the combination at ratios of 1:10 and 1:100 were 
antagonistic. Carboplatin is not an P-glycoprotein substrate and this may explain the slight 
synergistic effect in DLKP-A.
Vincristine and carboplatin was assayed in DLKP-A (Table 3.1.3). The combination at 
ratios of 1:10 and 1:100 were antagonistic but the combination at the 1:40 ratio did show 
slight synergy at some concentrations, with an additive effect observed at the higher 
concentrations. These results are similar to those observed with the combination of 
adriamycin and carboplatin in DLKP-A. Other researchers have shown that carboplatin 
and etopside can be effective in breast cancer (Crown et al., 1993).
Adriamycin and vincristine in DLKP (Table 3.1.4) were antagonistic initially but then 
showed some synergy at higher concentrations. However, at higher concentrations the 
percentage survival was very low (<20%). At ratios of 1:1, 4:1 and 1:4 in DLKP-A 
(Table 3.1.5), adriamycin and vincristine were antagonistic at the lower concentrations 
used but then showed some synergism at higher concentrations. Once again, at the higher 
concentrations the percentage survival was very low (<20%).
Vincristine and VP-16 were assayed at 1:1, 1:5 and 5:1 combinations in DLKP (Table
3.1.6). The combinations were antagonistic initially but were synergistic at higher 
concentrations of the combinations which had a very low percentage survival (<  10%). 
Vincristine and VP-16 in combination in DLKP-A (Table 3.1.7) did show synergism in 
each combination at all concentrations used.
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The above results demonstrated that a combination of carboplatin and adriamycin or 
vincristine was additive in DLKP-A but antagonistic in DLKP. The combinations of 
adriamycin plus vincristine were antagonistic to both cell lines. Vincristine plus VP-16 
was antagonistic in DLKP but did show synergism in DLKP-A. This result was 
unexpected since vincristine and VP-16 are both P-glycoprotein substrates. However, VP- 
16 is a topoisomerase II inhibitor and vincristine is an inhibitor of the mitotic spindle (see 
Section 1.2), therefore, synergy may result from each drug targeting different cellular 
processes. Further work should be undertaken to confirm the synergy found.
Clinical studies have shown that drug combinations generally produce higher response 
rates in treated populations than those produced by single agents. Therefore, while the 
above results show an additive effect between carboplatin and adriamycin or vincristine in 
DLKP-A, the combination in vivo could have a limited applicability in cancers where 
chemotherapy efficacy is low e.g. colorectal cancer and non-small cell lung cancer. 
Therefore other approaches to improve chemotherapy must be undertaken.
4.2 Circumvention
The majority of metastatic cancers are not curable currently by chemotherapy or by any 
other form of therapy. This is because a population within a tumour displays resistance to 
a number of chemotherapy drugs, even if they are structurally dissimilar and have 
different mechanisms of action. This is called Multidrug Resistance (MDR). MDR may be 
intrinsic or induced in the tumour population and a variety of mechanisms have been 
described to account for this phenomenon (see Section 1.9 and 1.10). Currently the best 
characterised mechanism of MDR is the resistance mediated by the MDR1 gene product 
(P-glycoprotein) a 170 kDa glycoprotein which acts as an energy-dependent 
transmembrane efflux pump that actively transports chemotherapeutic agents out of the 
cell. Inhibition of this pump can lead to a restoration of the level of cytotoxic drug 
accumulation in MDR cells observed in sensitive cells.
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A number of compounds have been identified which inhibit the efflux of chemotherapeutic 
drugs by P-glycoprotein and reverse cellular resistance in experimental systems, e.g. 
verapamil, a calcium antagonist, and cyclosporin A, an immunosuppressive drug.
However, there are a number of non-chemotherapeutic drugs which enhance 
chemotherapeutic cytotoxicity by mechanisms other than the inhibition of efflux pumps. 
One of these drugs, buthionine sulfoximine (BSO), reduces cellular glutathione levels by 
irreversibly inhibiting y-glutamylcysteine synthetase, the first enzyme involved in de novo 
glutathione synthesis. Glutathione helps to protect cells both by conjugating with cytotoxic 
electrophile drug derivatives and by binding with drug generated reactive oxygen 
compounds such as peroxides (Pratt et al., 1994). High glutathione levels were found to 
be associated with decreased DNA cross-link formation by some chemotherapy drugs. 
This reduction in DNA cross-link formation was probably due to intracellular drug 
inactivation by glutathione rather than an increased rate of DNA repair (Stewart and 
Evans, 1989). BSO also inhibits glutathione transferase activity, and inhibits the uptake of 
cysteine, a precursor of glutathione (Stewart and Evans, 1989). While BSO decreased 
glutathione concentrations in most normal tissues, the degree of glutathione reduction in 
these normal tissues has not been as great as in tumour tissues. Chemotherapeutic toxicity 
to normal tissues (including bone marrow) was generally not augmented at BSO doses that 
enhanced chemotherapy efficacy against tumours (Lee et al., 1987; Stewart and Evans, 
1989; Siemann and Beyers, 1993).
This series of experiments was performed to investigate the efficacy of BSO plus a P- 
glycoprotein inhibitor (verapamil) in combination with adriamycin in DLKP and DLKP-A 
cell lines.
The effect of BSO on the cytotoxicity of adriamycin in DLKP is given in Table 3.2.1 and 
the Combination Index (Cl) values (see Section 2.7.6) are given in Table 3.2.2. These 
results show that at higher concentrations of BSO, the Cl value was approximately 1.
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This implies that there was an additive cytotoxic effect. A synergistic cytotoxic effect (i.e. 
Cl value < 1) was observed at lOng/ml adriamycin when 1/xg/ml of BSO was used.
Verapamil in combination with adriamycin showed little enhanced cytotoxic effect in 
DLKP (Table 3.2.5). At the lower concentrations of BSO (0.125^ g/ml and 0.25/xg/ml), 
there was synergism in toxicity (Table 3.2.6). However, BSO plus verapamil in 
combination with adriamycin did not enhance the toxicity of adriamycin compared to BSO 
with adriamycin (Table 3.2.7).
The effect of BSO on the cytotoxicity of adriamycin in DLKP-A is given in Table 3.2.3 
and the Combination Index (Cl) values are given in Table 3.2.4. These results show that 
at the lowest concentration of BSO, l^ g/ml, the Cl values were less than 1, i.e. there was 
a synergistc toxic effect with all the concentrations of adriamycin used. At higher 
concentrations of BSO, the Cl values were > 1 thereby indicating an antagonistic 
combination.
Verapamil did show enhanced cytotoxicity in combination with adriamycin in DLKP-A 
(Table 3.3.8). This was expected because P-glycoprotein, which is inhibited by verapamil, 
is overexpressed in DLKP-A (Redmond, 1991; Cleary, 1995). However, BSO did not 
significantly affect adriamycin toxicity (Table 3.3.9). The combination of BSO plus 
verapamil was synergistic with adriamycin (Table 3.2.11); however, it was not clear if 
this effect was due to verapamil alone or the combination of BSO and verapamil. 
Therefore a more detailed experiment using a number of combinations of BSO and 
verapamil with adriamycin was performed (Table 3.2.11). This showed that the 
combination of BSO plus verapamil with adriamycin was synergistic. For example, when 
the 0.5mg/ml concentration of verapamil was used and the concentration of BSO was 
increased, the toxicity of adriamycin was enhanced from 63% to 43% cell survival. 
Conversely, when the 0.125mg/ml concentration of BSO was used and the concentration 
of verapamil was increased, the toxicity of adriamycin was also enhanced e.g. from 80% 
to 63% cell survival. This is in agreement with other researchers, who showed that BSO
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plus verapamil in combination with daunorubicin, in myeloid leukaemic cells, further 
induced internucleosomal DNA fragmentation (Quilletmary et al., 1996).
The above results demonstrate the effectiveness of BSO to enhance the toxicity of 
adriamycin in drug sensitive and drug resistant human lung carcinoma cell lines. BSO in 
combination with verapamil demonstrated an enhanced cytotoxicity and it would be 
interesting to repeat the experiment in DLKP-A using cyclosporin A instead of verapamil, 
in combination with BSO and adriamycin. While BSO may have a future role in 
enhancing chemotherapy in a resistant population, the results of other circumvention 
compounds in clinical trials have been disappointing due to non-specific effects 
(verapamil) or toxic effects (cyclosporin A) of the circumvention agent (Ford, 1995). 
Therefore, other alternatives need to be explored.
4.3 MDR1 ribozyme transfection
Currently the best understood mechanism of MDR is the resistance mediated by the 
MDR1 gene product, P-glycoprotein (see Section 4.2). Attempts at chemomodulation of 
P-glycoprotein have been investigated using various P-glycoprotein antagonists. The 
results of circumvention compounds in clinical trials have been disappointing due to non­
specific effects (calcium antagonists) or toxic effects (cyclosporin A) of the circumvention 
agent (Ford, 1995). Therefore, a more specific modulation of MDR is necessary for an 
improved reduction in drug resistance. One alternative is to use antisense techniques such 
as ribozymes.
Ribozymes are RNA molecules which have catalytic activity. The hammerhead ribozyme 
is the smallest of the ribozymes and the target RNA cleavage sites have the least 
constraints with respect to sequence. Therefore, the hammerhead ribozyme has the most 
abundant target sites compared to other ribozyme types (Sullivan, 1994). To test the 
efficacy of antisense in vitro, a hammerhead ribozyme which cleaves the 3’-end of the
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GUC sequence in codon 880 of mdrl RNA was transfected into the adriamycin resistant 
human lung carcinoma cell line SK-MES-l/Adr (see Figure 4.3.1). SK-MES-l/Adr is a 
derivative of the chemotherapeutic drug sensitive cell line SK-MES-1, and was selected by 
exposure to increasing concentrations of adriamycin. Its mechanism of drug resistance is 
primarily thought to be due to P-glycoprotein overexpression (Redmond, 1991; Cleary, 
1995).
Three clones were isolated when SK-MES-1/Adr was electroporated with the anti-MDRl 
ribozyme plasmid. The clones were selected in 96-well plates by continuous exposure to 
200/xg/ml geneticin in ATCC media. These clones were assayed for their resistance to 
three chemotherapeutic drugs (adriamycin, vincristine and VP-16) and compared to the 
sensitive parent SK-MES-1 and the resistant parent SK-MES-l/Adr (Figures 3.3.1 - 
3.3.3). These graphs demonstrate that each clone displays a decreased resistance to 
adriamycin, vincristine and VP-16 compared to the resistant parent cell line, SK-MES- 
l/Adr. Clone #:2 is the most resistant of the three clones. Clone #3 and clone #4 showed a 
similar resistance profile.
RT-PCR analysis of RNA isolated from SK-MES-1, SK-MES-l/Adr and each ribozyme 
clone was performed (Figure 3.2.4). No MDR1 mRNA expression was detected in SK- 
MES-1. A decreased expression of MDR1 mRNA was detected in the three MDR1 
ribozyme transfectants compared to the resistant parent. Of the ribozyme transfectants, 
clone #4 expressed the least amount of MDR1 mRNA while clone #2 expressed the 
greatest amount MDR1 mRNA. Therefore, clone #4, which showed the least amount of 
MDR1 mRNA expression, was also the clone most sensitive to adriamycin, vincristine 
and VP-16 as predicted.
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Figure 4.3.1 Structure of the anti-MDRl hammerhead ribozyme.
The hammerhead ribozyme is in bold. The £  represents the cleavage site of the mdrl mRNA (Holm et al. , 
1994). .
Fold resistance values found (Table 3.3.3) show that the ribozyme transfectant clones 
displayed a reduction of approximately 50% in resistance to adriamycin. Their resistance 
to vincristine and VP-16 varied, with clone #2, 60 and 4.9 fold resistant to vincristine and 
VP-16, clone #4 40 and 3.7 fold resistant respectively.
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Further studies on these cell populations should include western blot analysis of the 
ribozyme transfectants compared to SK-MES-1 and SK-MES-l/Adr to establish the levels 
of P-glycoprotein being expressed. To further confirm that the chemosensitivity conferred 
on the transfectants was due to the ribozyme plasmid, PCR should be performed to 
establish that the plasmid is present in the cell lines and RT-PCR to confirm that the 
ribozyme is being expressed.
The use of ribozymes to control the expression of P-glycoprotein is a new technology and 
the experiments performed highlight some of the drawbacks of the technique. Transfection 
of the anti-MDRl ribozyme does work as has been shown previously by other workers 
(Holm et al., 1994; Kiehntopf et al., 1994; Bertram et al., 1995; Daly et al., 1996). 
However, all of the clones isolated still expressed some MDR1 mRNA. Perhaps with the 
introduction of a site specific plasmid vector or the use of a retroviral vector this limitation 
may be overcome. This approach would allow the introduction of the ribozyme into a 
specific area of the genome where it would not be detrimental to the cell and where it 
could be under the control of a strong promoter. Although the ribozyme did not 
completely abrogate MDR1 expression, the use of ribozymes is a significant step forward 
since it bypasses the need for the repeated use of antisense oligonucleotides. In the future 
ribozyme technologies may surpass the use of pharmacological circumvention agents.
4.4 MDR1 transfection
MDR is generally a multifactorial phenomenon with a number of resistance mechanisms 
usually co-expressed within a cell. DLKP-A is an MDR cell line derived from DLKP by 
sequential exposure to increasing concentrations of adriamycin. Nine clones were isolated 
from DLKP-A, each with different levels of resistance and combinations of resistance 
mechanisms (Heenan, 1994). However, no clone expressed P-glycoprotein as the sole 
mechanism of resistance. Therefore, DLKP was electroporated with the pHaMDRl/A 
plasmid, which encodes the full cDNA for the human MDR1 gene (Pastan et al., 1988),
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to develop a low level resistant DLKP clone whose only mechanism of resistance would 
be the expression of P-glycoprotein. These clones would then be a realistic model of the in 
vivo situation and could be used for subsequent studies aimed at enhancing the effect of 
chemotherapy.
Two clones were isolated when DLKP was transfected with the pHaMDRl/A plasmid and 
selected by continuous exposure to 50ng/ml adriamycin in ATCC media. This adriamycin 
concentration represents approximately 3 times the IC50 value for DLKP. Control cells 
did not survive when exposed to this concentration and the clones selected were resistant 
to adriamycin.
Toxicity assays were performed on each clone using adriamycin, vincristine and VP-16 
(Figures 3.4.1 - 3.4.3). These graphs demonstrate that each clone had an increased 
resistance to adriamycin, vincristine and VP-16 compared to the sensitive parent cell line, 
DLKP. Clone #\ demonstrated an increased resistance to adriamycin and vincristine 
compared to clone #2. In contrast, clone #2 showed a greater resistance to VP-16 than 
clone #1. The IC50 values for adriamycin, vincristine and VP-16 of each clone are given 
in Table 3.4.2 and are compared to DLKP and DLKP-A. The values show that the MDR1 
transfectants were more resistant to each chemotherapeutic drug tested compared to DLKP 
but were not as resistant as DLKP-A . The fold resistance values (Table 3.4.3) showed 
that the clone #1 and clone #2 were 37 and 15 fold more resistant to adriamycin compared 
to DLKP but 8 fold and 13.6 fold more resistant to VP-16 respectively.
RT-PCR analysis of RNA isolated from DLKP, the two MDR1 transfectants and DLKP- 
A was performed (Figure 3.2.4). As expected no MDR1 expression was detected in 
DLKP. An increased expression of MDR1 mRNA was detected in DLKP-A and the two 
MDR1 transfectants with the expression of MDR1 in DLKP-A being much greater than in 
the two transfectant clones. Time did not permit western blot analysis of the MDR1 
transfectants compared to DLKP and DLKP-A to establish the levels of P-glycoprotein 
being expressed. To further confirm that the resistance conferred to the transfectants was
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due to the pHaMDRl/A plasmid, PCR should be performed to establish that the plasmid 
is present in the cell lines.
The toxicity data also demonstrated that clone #\ was more resistant to adriamycin and 
vincristine than clone #2 but that clone #2 was more resistant to VP-16 than clone # 1. 
Thus, even though these clones were derived from the same parent cell line and were 
transfected with the same plasmid, they displayed different resistance profiles to the 
chemotherapeutic drugs tested. This may be due to plasmid insertion at different locations 
of the genome. Alternatively, DLKP has previously been shown to be polyclonal and to be 
composed of three cell distinguishable populations (McBride, 1995). Therefore, the 
difference in resistance profiles of the two MDR1 transfectants may be due to the 
transfection of two different clones within DLKP, although there was little difference 
between each clone and chemotherapeutic drug sensitivity (McBride, 1995). Examining 
the morphology of each transfectant and comparing them to the known morphology of the 
subclones of DLKP may verify this theory. Transfection of the different clones of DLKP 
with pHaMDRl/A would establish if MDR1 expression within different clones displays a 
different resistance profile to chemotherapeutic drugs.
4.5 Test compound screening
There are a number of non-chemotherapeutic drugs which enhance chemotherapeutic 
cytotoxicity by mechanisms other than the reversal of drug resistance (reviewed in Stewart 
and Evans, 1989). These include buthionine sulfoximine (BSO) and other glutathione 
depletors, the nitroimidazoles and the methylxanthines. However, none of these are in 
common clinical use. Thus, the need to test new non-chemotherapeutic drugs which 
enhance the cytotoxicity of chemotherapeutic drugs is essential. This series of experiments 
investigated possible cytotoxic synergy between an anticancer agent with one of a series 
of coded non-toxic test compounds known to be safe for human use (A-l, N -l, 0-1, 
U-l and U-2).
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Seven cell lines were tested to investigate the presence of any synergistic toxic effect 
between adriamycin and the five test compounds in drug sensitive and drug resistant cell 
lines. These cell lines were resistant variants derived from 2 parental cell lines, DLKP and 
SK-MES-1 both lung carcinoma cell lines. DLKP-SQ is a clone of DLKP a human lung 
carcinoma cell line, which is sensitive to chemotherapeutic drugs (McBride, 1995); 
DLKP pHaMDRl/A #2 is a clone of DLKP which was transfected with the MDR1 gene 
and has been found to overexpress MDR1 mRNA (see Section 3.4); DLKP-A-2B is a 
low level resistant clone derived from the MDR cell line DLKP-A (Heenan, 1994), and 
expresses a number of MDR mechanisms including overexpression of P-glycoprotein; 
DLKP-A-2B IC7 is a MDR1 ribozyme transfectant of DLKP-A-2B, in which the 
expression of P-glycoprotein mRNA is inhibited (McBride, 1995). SK-MES-1 is also a 
human lung carcinoma cell line, which is sensitive to chemotherapeutic drugs, but whose 
resistance to adriamycin is approximately 3 fold that of DLKP; SK-MES-l/Adr is an 
MDR derivative of SK-MES-1, which was exposed to increasing concentrations of 
adriamycin; SK-MES-l/Adr MDR1 ribozyme clone #4 was the most sensitive clone 
obtained after transfection of SK-MES-l/Adr with a MDR1 ribozyme, although P- 
glycoprotein mRNA expression was not completely inhibited (see Section 3.2).
The results demonstrated that the test compounds N-l, 0-1 and U -l, at non-toxic 
concentrations, were found to enhance the toxicity of adriamycin in three cell lines; DLKP 
(Table 3.5.1), DLKP-A-2B IC7 (Table 3.5.4) and SK-MES-1 (Table 3.5.5). No test 
compound demonstrated any enhanced toxic effect in DLKP-A-2B (Table 3.5.3), DLKP 
pHaMDRl/A#2 (Table 3.5.2), SK-MES-l/Adr (Table 3.5.6) and SK-MES-l/Adr mdrl 
ribozyme #4 (Table 3.5.7). A brief summary of these results is given in Table 4.5.1.
Therefore, the cell lines which were found to be sensitive to the synergistic effect of the 
test compounds were drug sensitive, DLKP and SK-MES-1 or a low level resistant variant 
which does not express MDR1 (DLKP-A-2B IC7). All cell lines found to be unresponsive 
to the test compounds were multidrug resistant P-glycoprotein overexpressing cell lines.
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These results show that the enhanced toxicity of adriamycin by N-l, 0-1 and U-l 
occurred in those cell lines where there was no P-glycoprotein expression i.e. DLKP, SK- 
MES-1 and DLKP-A-2B IC7. It is interesting that DLKP-A-2B IC7 continues to exhibit a 
low level of resistance, this may in part be due to decreased levels of topoisomerase II 
which is found in DLKP-A-2B (Heenan, 1994). DLKP which was sensitive to the above 
effect was rendered insensitive when transfected with the MDR1 gene. All of the cell lines 
tested in which the test compounds had no effect all over-expressed P-glycoprotein. This 
suggests that adriamycin may not be present in the cell in sufficient quantity or the test 
compounds may also be P-glycoprotein substrates. However N-l has been shown to 
accumulate in P-glycoprotein positive cells within minutes of being added to media 
(C.Elliot, personal communication). Thus, while the test compounds may not be P- 
glycoprotein substrates, P-glycoprotein does affect their ability to enhance the cytotoxicity 
of adriamycin presumably by decreasing its intracellular concentration. This effect may 
not be related to the test compounds but the effect could be due to efflux of adriamycin 
from the cells.
Table 4.5.1: Summary of the effect on cell lines screened for synergy between the test compounds and 
adriamycin.
Cell Line Synergy Comment
DLKP-SQ Yes Sensitive
DLKP pHaMDRl/A No MDR1 transfectant
DLKP-A-2B No Low level resistant
DLKP-A-2B IC7 Yes MDR1 ribozyme transfectant
SK-MES-1 Yes Sensitive
SK-MES-1/Adr No Resistant
SK-MES-1/Adr ribo #4 No MDR1 ribozyme transfectant
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4 .6  Scheduling
The results of Section 3.5 described the effect of combining five test compounds with 
adriamycin. Three of these compounds were found to enhance the toxicity of adriamycin 
in three of seven cell lines assayed. The standard circumvention assay used allowed the 
screening of test compounds in combination with adriamycin. However it did not provide 
an insight into the mechanism of the synergistic action. An assay was developed to analyse 
how synergy was affected when cells were exposed to the test compounds at different 
times relative to adriamycin exposure. Cells were pulse treated with adriamycin for 2 
hours which resulted in approximately 50% cell survival. When the adriamycin was 
washed off, the cells were exposed to high non-toxic levels of a test compound for short 
periods of time (24 hours).
Using these assays, non-toxic levels of N-l, 0-1 and U-l were shown to enhance 
adriamycin toxicity in DLKP (Table 3.6.1) and DLKP-SQ (a sub-clone of DLKP). A -l, I-
1 and U-2 as expected had no effect (Table 3.6.2). During the first 24 hours after 
adriamycin exposure, DLKP-SQ cells were sensitive to the effect of N -l, 0-1 and U-l but 
not during any other 24 hour time period following the initial 24 hours. Pretreatment for 
24 hours had no effect (Table 3.6.5). Treating cells with adriamycin and a test compound 
together did not enhance the cytotoxic effect of adriamycin possibly due to the short 
duration of co-exposure (Table 3.6.6). While a synergistic toxic response might have been 
expected with this combination, the test compound exposure with adriamycin was only for
2 hours compared to the other assays which did display synergy, where exposure was for 
24 hours. Exposure to N-l for shorter periods (10 hours) was assayed after pulse exposure 
with different concentrations of adriamycin (Table 3.6.6). The toxic effect of N-l was 
evident during the initial two 10 hour periods after adriamycin exposure. However, while 
there was a consistent trend, the results from these experiments were just outside the error 
values. The clonogenic assay, which determines the number of colonies formed after drug 
exposure, could be used instead of the growth assay used in this thesis. This assay may be 
more sensitive and thus could indicate shorter time periods when exposure to a test 
compound may be important.
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Since the active test compounds exerted their synergistic effect during the first 24 hours 
following drug removal, cycloheximide and actinomycin D were used to try and block the 
synergistic effect. Cycloheximide, a protein synthesis inhibitor, was used in combination 
with U-l after adriamycin exposure (Table 3.6.7). A relatively non-toxic level of 
cycloheximide was used (75% cell survival). However at this concentration of 
cycloheximide, there was no inhibition of the enhanced toxic effect of U-l. This would 
suggest that the synergistic effect of U-l is independent of protein synthesis. Actinomycin 
D, an inhibitor of transcription and translation, was also used at non-toxic concentrations 
in combination with U-l after adriamycin exposure (Table 3.6.8). Actinomycin D did not 
inhibit the toxic effect of U-l. This would suggest that the synergistic effect of U-l is also 
independent of transcription and translation. To prove conclusively that protein synthesis, 
transcription and translation do not prevent the effect of U-l, studies to confirm that the 
level of cycloheximide used does inhibit protein synthesis and that the level of actinomycin 
D does inhibit transcription and translation in DLKP-SQ would need to be performed in 
these cell lines.
Two active (N-l and U-l) and one inactive (A-l) test compounds were further studied in 
combination with two other commonly used chemotherapeutic drugs:- vincristine and 5- 
fluorouracil. 0-1 and U-l continued to cause an increase in observed toxicity during the 
first 24 hours after vincristine exposure (Table 3.6.3). It is interesting that there was a 
greater cytotoxic effect observed with vincristine in combination with the active test 
compounds as compared to adriamycin. No enhanced cytotoxic effect was observed with 
vincristine plus A -l in combination. No test compound showed any effect with 5- 
fluorouracil (Table 3.6.4).
These results show that 0-1 and U-l at non-toxic levels enhance the toxicity of adriamycin 
and vincristine but not 5-fluorouracil. Interestingly, adriamycin and vincristine are both P- 
glycoprotein substrates while 5-fluorouracil is not. This seems to correlate with the results 
from Section 3.5, which show that cell lines expressing P-glycoprotein do not exhibit 
enhanced toxicity to adriamycin using any of the test compounds. However it raises the
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question as to why the test compounds do not work with 5-fluorouracil. One possibility is 
that chemotherapeutic drugs may induce different apoptotic pathways within a sensitive 
cell. Further studies screening other chemotherapeutic drugs and other cell lines expressing 
alternative resistance mechanisms, for example P-glycoprotein related proteins like MRP 
and LRP, would also be relevant.
One of the advantages of the assay developed is that pulse exposure of the cells in vitro 
mimics the treatment of a patient in vivo. The high concentration (lpiM adriamycin) and 
short time exposure (2 hours) is an approximate imitation of the initial adriamycin 
concentration in the body (Piscitelli et al., 1993). Thus, the test compounds could be used 
concurrently with chemotherapeutic drug treatment in vivo and for an extended period 
after the chemotherapeutic agent has been metabolised. This is unlike other circumvention 
agents such as verapamil or cyclosporin A which must be present during chemotherapeutic 
drug exposure in order to exert their effect.
Further studies could be performed to investigate the effect of synchronising cells in 
specific phases of the cell cycle, pulse treated with a chemotherapeutic drug, followed by 
exposure to an active test compound, would there be an increase or decrease in sensitivity? 
In these experiments the cell cycle progression could be followed using flow cytometry 
and apoptotic events could be examined by time-lapse videomicroscopy.
4.7 DLKP pHaMDRl/A #2 Scheduling
The results from Section 3.6 demonstrate that the active test compounds, N -l, 0-1 and U- 
1 exert their synergistic cytotoxic effect during the first 24 hours post-treatment with 
adriamycin. Previous results also demonstrated that the test compounds N-l, 0-1 and U-l 
were shown to have no synergistic effect in combination with adriamycin in DLKP 
pHaMDRl/A #2 or any other P-glycoprotein over-expressing cell line using the standard 
circumvention assay. Therefore, DLKP pHaMDRl/A #2 was assayed using the modified
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assay, i.e. pulse treating with adriamycin and then exposing to a high concentration of a 
test compound for 24 hour periods.
DLKP pHaMDRl/A #2 was pulse treated with adriamycin and exposed to 6 test 
compounds for 24 hour periods (Table 3.7.1). No synergistic effect with adriamycin was 
observed with any of the six test compounds assayed.
Because the test compounds had displayed no synergy with adriamycin in the P- 
glycoprotein positive cells inhibitors of P-glycoprotein were used to try and restore the 
synergistic effect of the test compounds. Verapamil inhibits P-glycoprotein associated 
energy-dependent drug-efflux in MDR cells, apparently by blocking the binding of drugs 
to P-glycoprotein (Ford, 1995). Using the test compounds and verapamil in combination 
with adriamycin, there was no restoration of the synergistic effect induced by the test 
compounds as observed in DLKP (Table 3.7.2). These experiments were repeated using 
cyclosporin A instead of verapamil. Cyclosporin A is an immunosuppressive peptide 
which has been found to act as an MDR substrate and antagonise MDR at least in part 
through inhibition of P-glycoprotein-mediated efflux of cytotoxic drugs (Ford, 1995). 
Again the synergistic effect observed between the test compounds and adriamycin was not 
restored.
Even in the presence of P-glycoprotein inhibitors, there was no restoration in 
chemosensitivity caused by the test compounds. During the assay, various cytotoxic levels 
of adriamycin were used. Therefore, even though there was cytotoxic injury to the MDR 
cells, exposure to the test compounds, which are apparently P-glycoprotein-mediated 
transport independent substrates (C.Elliot, personal communication), did not enhance 
cytotoxicity even when P-glycoprotein inhibitors were used in combination. One 
possibility is that chemotherapeutic drugs may induce different types of cytotoxic damage 
in sensitive versus resistant cells. This could be investigated by analysing the toxic effect 
of a chemotherapeutic drug on cell lines with different drug sensitivities. Therefore, 
treatments which induce 75% or 50% cell survival could be compared between the cell 
lines to ascertain a difference in cell cycle distribution by flow cytometry. Alternatively
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chemotherapeutic drugs may induce different apoptotic pathways in sensitive and drug 
resistant cell lines.
4.8 Cell cycle distribution
The results from Section 3.6 demonstrated that the test compounds, N -l, 0-1 and U-l 
exert their synergistic cytotoxic effect during the first 24 hours post-treatment with 
adriamycin or vincristine but not 5-fluorouracil. In order to further investigate the role of 
these test compounds on DLKP-SQ, flow cytometric analysis was used to determine the 
cell cycle distribution of treated samples. Using a flow cytometer the amount of DNA 
fluorescence from propidium iodide stained cells (which intercalates with DNA), can be 
measured and this can be used to determine the position of a cell in the cell cycle.
Flow cytometric analysis was used to determine the cell cycle distribution in DLKP-SQ 
pulse treated with adriamycin, vincristine or 5-fluorouracil for 2 hours alone and in 
combination with a test compound (A-l, N-l or U-l) for 24 hours.
U-l on its own was shown to induce a Gs/S arrest for up to 10 hours (Figure 3.8.1). 
There was no apparent effect on the cell cycle distribution using A -l or N-l (Figure 3.8.2 
and Figure 3.5.3).
The active test compounds (U-l or N-l) in combination with adriamycin displayed an 
increased G^S arrest with a delayed S peak evident at 13 to 19 hours compared to 
adriamycin alone (Figure 3.8.4 and Figure 3.8.5). Thus the addition of an active test 
compound causes an increased delay in the Gi phase and the S phase compared to 
adriamycin alone. This delay was not observed with A -l (inactive) and adriamycin 
treatment (Figure 3.8.6). Because of the increased G^S phase arrest and an increased S 
phase transition in DLKP-SQ treated with adriamycin plus N-l or U-l, increasing 
concentrations of adriamycin alone were analysed. These results show that there was an 
increased G^S phase arrest, a delay in S and a G2/M arrest approximately 24 hours after
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drug removal, when increasing drug concentrations were used to pulse treat cells (Figure 
3.8.12 - 3.8.14). It is known that low concentrations of adriamycin induce G2 arrest, and 
that higher concentrations or exposure to drug for longer periods of time induces a G, 
arrest and a delay in S phase traverse (Barlogie et at, 1976).
U-l or N-l in combination with vincristine (Figure 3.8.7 (a) and 3.8.8 (a) respectively), 
showed an increased G2/M arrest compared to vincristine treated cells alone (Figure 3.8.7 
(b) and 3.8.8 (b)). In each combination, there was a large increase in the Gj peak at 24 
hours in vincristine treated cells compared to the large G2/M peak when U-l or N-l were 
combined in combination with vincristine. This G2/M arrest was expected since vincristine 
is a mitotic inhibitor. This means (in vincristine treated cells) that by 24 hours the G2/M 
arrest was overcome, while in the N-l/U-1 plus vincristine combination there was still a 
G2/M arrest. Therefore, the addition of an active compound after vincristine exposure 
causes an increased delay in G2/M. Vincristine and A-l in combination did show a slight 
cell cycle delay in G^S at 12 - 15 hours but this was not as striking as in U-l or N-l 
treated cells (Figure 3.8.9). Increasing concentrations of vincristine were analysed to 
investigate if increasing concentrations increased G2/M arrest as found when 50ng/ml 
plus U-l or N-l were used in combination (Figure 3.8.15 - 3.8.17). Increasing 
concentrations of vincristine showed a decrease in the G[ peak and an increased G2/M 
peak representing an increased G2/M arrest as compared to untreated cells.
DLKP-SQ treated with 5-fluorouracil alone and in combination with U-l showed no effect 
on the cell cycle distribution (Figure 3.8.10 and Figure 3.8.11). These results were 
expected since there was no synergy between any test compound and 5-fluorouracil when 
previously assayed (Table 3.6.4).
These results seem to suggest that the effect of U-l and N-l in combination with a 
chemotherapeutic drug (adriamycin and vincristine but not 5-fluorouracil), may mimic 
higher chemotherapeutic drug combinations. For example, the cell cycle distribution of 
ljiM  adriamycin and U-l in combination seems similar to 2/j.M adriamycin alone (Figure
3.8.4 (a) and Figure 3.8.14) and 50ng/ml vincristine and U-l in combination (Figure
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3.8.7(a)) seems similar to lOOng/ml vincristine alone (Figure 3.8.17). This effect may be 
the result of increased cytotoxic action due to the higher concentration causing a greater 
cytotoxic insult to the cell and thus the increased G^S delay, S phase traverse and G2/M 
delay. It is interesting to note that cells which have been synchronised in the S or the G2 
phase are more sensitive to adriamycin cytotoxicity than cells in Gt (Krishan and Frei, 
1976). These above results show that the active test compounds have an effect on the cell 
cycle which is different from the pulsed chemotherapeutic drug alone and this effect may 
mimic increased concentrations of the chemotherapeutic drug alone. HPLC analysis of 
cells treated with drug could be used to determine the intracellular levels of a 
chemotherapeutic drug and the test compound. This would demonstrate if there was an 
increased accumulation of chemotherapeutic drug in samples treated with chemotherapy 
and an active test compound.
4.9 Cell death kinetics
The test compounds, N -l, 0-1 and U-l exert their synergistic cytotoxic effect during the 
first 24 hours post-treatment with adriamycin or vincristine. Flow cytometric analysis 
(Section 3.8) showed that there was a difference in cell cycle distribution during the first 
24 hours after pulse exposure between adriamycin and adriamycin plus U-l or N-l and 
between vincristine and vincristine plus U-l or N -l. Therefore, while there was an 
increased cytotoxicity in cells which were exposed to N -l, 0-1 or U-l after adriamycin or 
vincristine exposure, and there was a difference in cell cycle distribution, there was no 
indication as to why or when the cells undergo cell death.
Time-lapse videomicroscopy permits the continuous observation of cells following drug 
treatment. With this technique it was possible to follow, in real time events such as cell 
rounding for mitosis or apoptosis. Mitosis was characterised by the rounding up of 
adherent cells followed by cytokinesis and reattachment of daughter cells to the surface of 
the flask. Cell death was classified as apoptotic on the basis of morphological events
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starting with rounding up of adherent cells, subsequent cell shrinkage and/or break-up of 
the cell into apoptotic bodies.
Using time-lapse videomicroscopy the kinetics of mitosis and apoptosis was followed in 
DLKP-SQ treated with U-l alone for 24 hours, 2 hours pulse exposure to increasing 
concentrations of adriamycin, adriamycin and U-l in combination, 2 hours pulse exposure 
to vincristine, and vincristine plus U-l in combination.
The results show that exposure of DLKP-SQ to 140/xM U-l has no detrimental effect on 
the cells, although initially there was a low level of apoptosis and a temporary inhibition of 
mitosis compared to the drug free control (Figure 3.9.3). Apoptosis was induced 24 hours 
after 1/xM adriamycin removal, however, when U-l was used in combination with 
adriamycin there was no difference in the rate at which apoptosis was induced compared 
to adriamycin alone (Figure 3.9.2). In the adriamycin plus U-l treated sample, apoptosis 
was also induced after 24 hours and the rate of apoptosis was similar to adriamycin alone. 
Mitosis was abolished in both samples. This result was unexpected since it was thought 
that apoptosis may have been induced sooner when U-l was used because of the observed 
synergy, although a similar rate of apoptosis in both samples may be related to the effect 
of adriamycin on the cell cycle. In contrast, vincristine exposure induced a different 
response (Figure 3.9.3). 60nM vincristine exposure inhibited mitosis for 12 hours but 
induced apoptosis continuously for the first 24 hours following exposure which then 
stopped. Vincristine followed by U-l exposure inhibited mitosis completely and induced a 
high level of apoptosis for approximately the first 12 to 18 hours after vincristine removal.
Therefore the above results show that different chemotherapeutic drugs induce apoptosis at 
different times. This seems to suggest that different chemotherapeutic drugs induce 
different apoptotic pathways.
Further analysis of a range of adriamycin concentrations was performed to investigate if 
varying the concentrations induced different rates of apoptosis. 2 hour exposure to 0.5/xM 
adriamycin, delayed mitosis for 24 hours and induced a low rate of apoptosis from 12
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hours (Figure 3.9.4). 1/zM and 2/xM adriamycin concentrations inhibit mitosis completely 
and induce apoptosis 24 to 48 hours after exposure. It is interesting that with the l^ M 
adriamycin concentration, apoposis was induced 24 hours after exposure and continued 
until 72 hours, while 2/xM adriamycin induced apoptosis after 48 hours which continued 
until the experiment finished i.e. 96 hours. Therefore, there is a possibility that higher 
concentrations of adriamycin “shock” or cause so much damage to the cell that it delays 
the induction of apoptosis.
It is interesting to correlate these microscopical results with the flow cytometric data. A 
two hour 1/xM adriamycin exposure induced apoptosis 24 hours after it was removed. By 
this time, most of the cells would be arrested in the G2/M phase. In contrast, vincristine 
treated cells arrest almost immediately in the G2/M phase. Further work could be 
undertaken to try and determine at what stage of the cell cycle DLKP-SQ cells undergo 
apoptosis. These results might also explain why the active test compounds enhance the 
toxicity of vincristine to a greater extent than adriamycin and why there seemed to be no 
difference in the rate of apoptosis in adriamycin only as compared to adriamycin plus U-l 
treated samples. However it seems that the active test compounds do not need to be 
present in order for apoptosis to occur. Apoptosis occurs 24 hours after the removal of 
adriamycin, while it has already been shown that exposure to an active test compound is 
necessary during the first 24 hours subsequent to adriamycin exposure to enhance the 
toxicity of adriamycin. This suggests that the active test compounds may enhance 
apoptosis at an early stage in the apoptotic pathway. This could be further investigated by 
determining the levels of proteins involved in early stages of apoptosis e.g. members of 
the bcl-2 family.
It has previously been shown in human B-cell lymphoma cells that an inhibition of DNA 
fragmentation (one of the early stages of apoptosis) occurs at high concentrations of 
adriamycin and this was closely linked to the inhibition of S phase traverse (Smith et al., 
1994). The authors concluded that the presence of drug or DNA damage is not sufficient 
to induce DNA fragmentation but that the unregulated commitment to S phase traverse is
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an important factor in the activation of apoptosis. Since increasing concentrations of 
adriamycin disrupt the S phase in DLKP-SQ, deregulation of the S phase traverse could be 
a factor in the activation of apoptosis.
The adriamycin pulse exposure assays (Section 4.7) demonstrated that the enhanced 
cytotoxicity of N-l, 0-1 and U-l occurred during the first 24 hours after adriamycin 
removal. Flow cytometric analysis (Section 4.8) displayed an increased delay in the Gi 
phase and in the S phase transition until there was a G2/M arrest approximately 24 hours 
after adriamycin removal. Time-lapse videomicroscopy demonstrated that apoptosis was 
induced 24 hours after 1/*M adriamycin removal. In the adriamycin plus U-l treated 
sample, apoptosis was also induced after 24 hours but the rate of apoptosis was similar to 
adriamycin alone (Figure 3.9.2). However it is thought that the unregulated commitment 
to S phase traverse in response to adriamycin is an important factor for the activation of 
apoptosis (Smith et al., 1994). Since increasing concentrations of adriamycin disrupt the 
S phase in DLKP-SQ, deregulation of the S phase traverse and the proteins that control the 
transition from Gt into the S phase may have an important role in the activation of 
apoptosis.
4.10 Cell cycle proteins
To understand the effect of adriamycin and adriamycin plus U-l in combination on the 
increased Gi/S delay, the kinase activity of the cyclin E/CDK2 complex (Section 3.10) 
and the levels of cyclin E and CDK2 were studied (Section 3.11). The transition from Gj 
into S is controlled by the cyclin E/CDK2 complex and this is essential for the cell to 
begin DNA replication (see Section 1.3.1). Therefore, the cyclin E/CDK2 complex must 
be activated to overcome Gt arrest. The level of cyclin E is regulated so that it is only 
transcribed during late Gi and early S phase. Very little is known about the substrates of 
the cyclin E/CDK2 complex but it is thought to activate E2F and thus transcription of S 
phase genes. Once cells enter the S phase cyclin E is rapidly degraded. Therefore, by
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investigating the role of cyclin E and CDK2 it would be possible to see if alterations in 
their levels are responsible for the G1 arrest and delayed S phase transition caused by 
adriamycin and adriamycin plus U-l in combination as observed by flow cytometric 
analysis.
At least 3 forms of endogenous cyclin E protein have been detected in rat and human 
fibroblasts (Ohtsubo and Roberts, 1993) and HeLa cells (Dulic et al., 1992). A 50kDa 
form is maximally expressed during late and early S phase while a 40 kDa form is 
thought to result from proteolytic degradation of overexpressed cyclin E or from 
translation initiation at an internal methionine residue (Ohtsubo and Roberts, 1993). A 
higher molecular weight form (55kDa) has been observed in G2 and early to mid-Gj when 
kinase activity is low but from late-G! the 50 kDa form is expressed.
The cyclin E/CDK2 kinase activity of U-l treated samples demonstrated that the activity 
increased steadily up to 19 hours and then decreased at 24 hours. Adriamycin treated 
samples show a decrease in activity at 0 hours, which was when drug was removed after 
two hours drug exposure, compared to a control sample treated with drug free media for 2 
hours. The activity increased slightly at 10 hours but then decreased gradually until 24 
hours. When adriamycin and U-l were combined there was an increase in activity at 10 
hours which then decreased steadily until 24 hours (see Table 3.10.1). The kinase activity 
of cells treated with adriamycin plus U-l was elevated compared to adriamycin alone. 
Activity treated with adriamycin may have peaked at an earlier time and then decreased, 
while activity in cells treated with adriamycin plus U-l peaked at 10 hours. This could 
correlate to the observed delay in the cell cycle studies where the adriamycin plus U-l 
samples enter the S phase later than adriamycin samples alone.
The levels of CDK2 varied over a 24 hr period in untreated DLKP-SQ cells and cells 
treated with U -l, adriamycin and the adriamycin plus U-l combination (Figure 3.11.1 - 
3.11.4). The levels increased initially, then decreased and subsequently increased again in 
each case. However, there seems to be no correlation between CDK2 levels and the cell 
cycle distribution (Figure 3.8.2, 3.8.4 and 3.8.7).
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Untreated control samples showed an increase in levels of a higher molecular weight 
cyclin E (67kDa) at 10 hours; a 49 kDa band was evident from 10 to 16 hours which 
decreased with time until 24 hours (Figure 3.11.5). In U-l treated samples, levels of 
another high molecular weight cyclin E (=49kDa) increased from 10-13 hours, but had 
then decreased by 16 hours. There was also an increase in a 37.5 kDa band from 16 hours 
onwards (Figure 3.11.6). The level of the higher molecular weight (67kDa) cyclin E in 
adriamycin treated cells increased at 10-13 hours. A lower molecular weight band 
(37.5kDa) increased at 16 and 19 hours but decreased by 24 hours (Figure 3.11.7). Cyclin 
E levels in adriamycin and U-l treated samples were similar to adriamycin treatment alone 
but at 13 hours the high molecular weight band (67kDa) appears stronger while the 37.5 
kDa band has decreased compared to adriamycin (Figure 3.11.8).
Thus, the western blots of cyclin E in Figures 3.11.5 - 3.11.8 seem to indicate that an 
increased amount of the higher molecular weight form (67kDa) represents cells in Gj or 
Gj arrest; the form around 49 kDa seems to represent active cyclin E, while the lower 
molecular weight form (37.5 kDa) represents cells in late S and G2/M. This would seem 
to correlate with the flow cytometry results and entry from Gt into S. These results would 
also seem to indicate that the Gj/S delay is released when the higher molecular weight 
form of cyclin E decreases.
Levels of cyclin E were not elevated in U-l treated samples compared to the control, 
while the kinase activity of the cyclin E/CDK2 did increase over time. However these 
results do not show the cyclinE/CDK2 kinase activity levels of control samples for each 
time point. Thus it is assumed that the activity of the control samples are approximately 
the same as or higher than U-l treated samples. In contrast, the levels of cyclin E in 
adriamycin and adriamycin plus U-l treated samples increased significantly compared to 
the control and U-l samples. When cyclin E is overexpressed in cells, the cells progress 
through Gi and into the S phase at a faster rate (Ohtsubo and Roberts, 1993). Thus, 
overexpression of cyclin E above would be expected to decrease the length of time a cell 
remained in GL. Even though there were elevated levels of cyclin E there was no 
corresponding increase in kinase activity, in fact the kinase activity decreased. Therefore
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the increase in protein levels but decrease in kinase activity suggests that cyclin E/CDK2 
activity was inhibited. It has been previously shown that the activation of the cyclin 
E/CDK 2 complex appears to be the point at which radiation damage in the Gj phase can 
delay the cell cycle (Dulic et al., 1994). Therefore inhibition of cyclin E/CDK2 would 
lead to an arrest in G1 and a delay in the S phase transition.
Due to the increased rate of apoptosis during the initial 24 hours after vincristine treatment 
in U-l treated samples, work investigating the role of cyclin E and CDK2 proteins in 
vincristine treated cells would be very interesting. Although cyclin E is one protein that 
controls the G^S transition (see Section 1.3.1), Gi arrest may also be due to the inhibition 
of Rb, cyclin D1-CDK4/6 and/or due to the induction of p21, p27, pl6 and other CKIs 
which inhibit cyclin-CDK complexes. Some of these proteins may be involved in the Gt/S 
delay induced by adriamycin and they would be interesting proteins to investigate.
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5.0 Conclusions
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This thesis examined the effect of combinations of different drugs on toxicity to 
cancer cells in vitro. The effects of combining existing anticancer agents were 
analysed first. A combination of carboplatin and adriamycin or vincristine was found to 
be additive in DLKP-A but antagonistic in DLKP. The combinations of adriamycin plus 
vincristine were antagonistic in both cell lines. Vincristine plus VP-16 was antagonistic in 
DLKP but did show synergism in DLKP-A. This synergy may result from each drug 
targeting different cellular processes.
Combinations with the glutathione depleting agent, BSO, with and without verapamil 
were also studied in DLKP and DLKP-A. The effect of BSO on the cytotoxicity of 
adriamycin in DLKP-A showed a synergistic toxic effect at the lowest concentration of 
BSO. At higher concentrations of BSO, the Cl values were, in general, antagonistic. BSO 
plus verapamil in combination with adriamycin did not enhance the toxicity of adriamycin 
compared to a combination of BSO and adriamycin only, in DLKP. The combination of 
BSO plus verapamil in combination was synergistic with adriamycin in DLKP-A.
Different cellular models were also developed by transfection of the mdr-1 cDNA into 
sensitive cells, and by transfection of an anti-mdr-1 ribozyme into a P-glycoprotein 
over-expressing cell line.
The main part of the thesis concerned combinations of a known anticancer agent 
(adriamycin, vincristine and 5-fluorouracil) with one of a series of coded non-toxic 
compounds known to be safe for human use. Seven cell lines were tested. These cell 
lines were resistant variants derived from 2 parental human lung carcinoma cell lines, 
DLKP and SK-MES-1. These assays demonstrated that three of the test compounds N-l,
0-1 and U -l, at non-toxic concentrations were found to enhance the toxicity of adriamycin 
in three cell lines; DLKP, DLKP-A-2B IC7 and SK-MES-1. No test compound 
demonstrated any enhanced toxic effect in DLKP-A-2B, DLKP pHaMDRl/A#2, SK- 
MES-l/Adr and SK-MES-l/Adr mdrl ribozyme #4. Therefore the cell lines which were 
found to be sensitive to the synergistic effect of the test compounds were all drug sensitive 
(DLKP and SK-MES-1) or a low level resistant variant which does not express MDR1
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(DLKP-A-2B IC7). All cell lines found to be insensitive to the test compounds were 
multidrug resistant P-glycoprotein overexpressing cell lines. Thus the mechanism of the 
test compounds involved was not inhibition of the P-glycoprotein drug efflux pump. 
Further studies, to characterise the effect of the test compounds should be performed 
in cell lines with different mechanisms of resistance. DLKP-A-2B IC7 has a low level 
of resistance possibly due to decreased levels of topoisomerase II (Heenan, 1994). 
Therefore the test compounds may be active in cell lines with mechanisms of 
resistance other than P-glycoprotein. It would be interesting to undertake similar 
investigations in cell lines overexpressing other drug efflux pumps including MRP and 
LRP. One derivative of DLKP developed by pulse exposure to adriamycin displays a 
five fold resistance to adriamycin compared to the sensitive parent (R. NicAmhlaoibh, 
personal communication). This cell line is a better in vitro model of drug resistance as 
it develops in vivo and examining effects of the test compounds on this cell line would 
be interesting.
Significant enhancement of toxicity with vincristine but not 5-fluorouracil, was 
observed with the three active test compounds. Interestingly, adriamycin and vincristine 
are both P-glycoprotein substrates while 5-fluorouracil is not. This seems to correlate with 
the results which show that cell lines expressing P-glycoprotein do not exhibit enhanced 
toxicity to adriamycin using any of the test compounds.
The standard circumvention assay used allowed the screening of test compounds in 
combination with adriamycin but did not provide an insight into the mechanism of the 
synergistic action. An assay was developed to analyse how synergy was affected when 
cells were exposed to the test compounds at different times relative to adriamycin 
exposure. Cells were pulse treated with adriamycin for 2 hours, adriamycin removed 
and the cells exposed to high levels of a test compound for short periods of time. 
Activity of the active test compounds was observed only during the 24 hours 
subsequent to drug exposure. Pre-treatment or treatment at later times was ineffective. 
When exposure for shorter periods (10 hours) was assayed the enhanced toxic effect of N- 
1 was evident during each 10 hour period for the initial 20 hours following adriamycin
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exposure. However, while there was a consistent trend, the results were just outside the 
error values. To improve on these results, the clonogenic assay could be used instead of 
the growth assay used in this thesis. This assay may be more sensitive and thus could be 
used to quantify shorter time periods when exposure to a test compound may be 
important.
Since the active test compounds exerted their synergistic effect during the first 24 hours 
after drug removal, cycloheximide, a protein synthesis inhibitor, and actinomycin D, an 
inhibitor of transcription and translation, were used to try and block the synergistic effect. 
However, there was no inhibition of the enhanced toxic effect when they were used, 
separately, in combination with an active test compound after adriamycin exposure.
Further studies could be performed to investigate the effect of synchronising cells in 
specific phases of the cell cycle. If cells were synchronised in, for example, mitosis and 
pulse treated with a chemotherapeutic drug, followed by exposure to an active test 
compound, would there be an increase or decrease in sensitivity? In these experiments the 
cell cycle progression could be followed using flow cytometry and apoptotic events could 
be examined by time-lapse videomicroscopy.
In order to further investigate the role of these test compounds, flow cytometric analysis 
was used to determine the cell cycle distribution in DLKP-SQ, a human lung carcinoma 
clonal cell line, pulse treated with adriamycin, vincristine or 5-fluorouracil for 2 hours 
alone or with subsequent exposure to the test compounds for 24 hours. U-l (active in the 
combination assay) on its own was shown to induce a transient G^S arrest but there was 
no apparent effect on the cell cycle distribution using A -l (inactive) or N-l (active). U-l 
or N-l in combination with adriamycin caused an increased delay in the Gj phase and the 
S phase compared to adriamycin alone. This delay was not observed with adriamycin plus 
A -l treatment. U-l or N-l in combination with vincristine, showed an increased G2/M 
arrest compared to vincristine treated cells alone. This G2/M arrest was expected since 
vincristine is a mitotic inhibitor. Vincristine plus A -l in combination did show a slight cell 
cycle delay in Gt/S at 12 - 15 hours but this was not as striking as in U-l or N-l treated
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cells. DLKP-SQ treated with 5-fluorouracil alone and in combination with U-l showed no 
effect on the cell cycle distribution.
These pulse treatment experiments were repeated using increasing concentrations of 
adriamycin or vincristine. These results showed that there was an increased Gi/S phase 
arrest, a delay in S and a G2/M arrest, with increasing concentrations of adriamycin. 
Increasing concentrations of vincristine showed a decrease in the Gj peak and an increased 
G2/M peak representing an increased G2/M arrest as compared to untreated cells. These 
results suggest that the effect of U-l and N-l in combination with a chemotherapeutic drug 
(adriamycin and vincristine but not 5-fluorouracil), may mimic higher chemotherapeutic 
drug combinations. HPLC analysis of cells treated with drug could be used to assay the 
levels of a chemotherapeutic drug and the test compound. This would demonstrate if there 
was an increased accumulation of chemotherapeutic drug in samples treated with 
chemotherapic drug plus an active test compound as compared to chemotherapeutic 
treatment alone.
Time lapse videomicroscopic studies of the above combinations were also undertaken, and 
the rates of apoptosis and mitosis measured. Apoptosis occurred within 24 hours with 
vincristine and the rate of apoptosis was higher in the combination. Cells underwent 
apoptosis 24 hours after treatment with adriamycin but there was no significant difference 
between the apoptotic rate of the cells treated with adriamycin alone compared to the 
combination. This was surprising given the observed enhancement of toxicity in the 7 day 
toxicity assay.
Further investigations could be performed to try to determine at what stage of the cell 
cycle DLKP-SQ undergo apoptosis. These experiments would attempt to explain the 
observation that the active test compounds enhanced the toxicity of vincristine to a greater 
extent than adriamycin, and why there seemed to be no difference in the rate of apoptosis 
in adriamycin alone and adriamycin plus U-l treated samples. An observation that could 
be further investigated is the fact that apoptosis begins 24 hours following adriamycin 
exposure, however the test compounds only enhance adriamycin toxicity during the initial
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24 hours after adriamycin is removed. A possible explanation is that the active test 
compounds may enhance apoptosis at an early stage in the apoptotic pathway. This could 
be investigated by determining the expression of proteins involved in early stages of 
apoptosis e.g. members of the bcl-2 family.
To study if the combination effect was due to interference with proteins controlling cell 
cycle progress, cyclin E/CDK2 kinase activity was assayed and the levels of cyclin E and 
CDK2 were determined using western blotting. The levels of cyclin E were not elevated in 
U-l treated samples as compared to the control, while the kinase activity of the cyclin 
E/CDK2 did increase over time. In contrast, the levels of cyclin E in adriamycin alone 
and adriamycin plus U-l treated samples increased significantly compared to the control 
and U-l samples but the kinase activity of adriamycin and adriamycin plus U-l decreased. 
This increase in protein levels but decrease in kinase activity suggests that cyclin E/CDK2 
activity was inhibited. Inhibition of cyclin E/CDK2 activity would lead to an arrest in G1 
and a delay in the S phase transition. Future work investigating the role of cyclin E and 
CDK2 proteins in vincristine treated cells would be very interesting. Although cyclin E is 
one protein that controls the Gj/S transition (see Section 1.3.1), Gt arrest may also be due 
to the inhibition of Rb, cyclin D1-CDK4/6 and/or by the induction of p21, p27, pl6 and 
other CKIs which inhibit cyclin-CDK complexes. Some of these proteins may be involved 
in the Gl/S delay induced by adriamycin and would be interesting proteins to investigate.
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